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Summary
The research presented in this thesis focused on neural precursors derived from mouse ES cells 
(also called neural embryoid bodies, NEBs) in particular attempting to direct their differentiation 
towards specific telencephalic precursors, with a view to providing an alternative donor cell 
source to primary foetal tissue for the generation of DARPP-32 positive medium spiny neurons 
(MSNs) for neural transplantation in Huntington’s disease. Neural induction of mouse ES cells 
was addressed, with further directed differentiation by addition of factors known to be important 
in the neural tube for development of specific telencephalic precursors. Subsequent neuronal 
differentiation of precursors was assessed both in vitro and in vivo.
Chapter 3 characterised the neural and forebrain features of NEBs up to day 8 in neural induction 
medium, using a reporter cell line, in which LacZ was tagged to the early forebrain marker, Foxgl. 
Addition of FGF2 but not the Wnt inhibitor DKK-1, increased the forebrain population within the 
overall cell population. Day 8 NEBs, subjected to neuronal differentiation conditions, yielded p- 
II 1-tubulin positive neurons but no DARPP-32 expression.
In Chapter 4, NEBs cultured for either 8 or 16 days were compared for expression of neural 
markers and then transplanted into the QA lesioned rat striatum to assess their potential to 
generate mature phenotypes in vivo. Day 8 NEBs generated teratomas by 2 weeks post­
transplantation. At 6 weeks post-transplantation, day 16 NEBs generated heterogeneous grafts 
with graft-derived neurons and glia, but no graft-derived DARPP-32 expression.
Expression of dorso-ventral telencephalon markers in NEBs was investigated in Chapter 5, 
drawing comparisons to expression in the mouse (E l4) developing telencephalon. The effects of 
the SHH agonist, purmorphamine, and the SHH antagonist, cyclopamine, were used in an attempt 
to enrich the forebrain precursors generated in Chapter 3 for ventral telencephalic-like precursors. 
Although gene expression changes were demonstrated, no distinct dorso-ventral patterns were 
shown.
In vitro neuronal differentiation of day 16 NEBs was analysed in Chapter 6, in particular looking 
for expression of the MSN marker DARPP-32. Cultures of cells from the lateral ganglionic 
eminence (LGE) (the origin of MSNs) were used to determine if certain factors could increase the 
yield of DARPP-32 positive neurons. Addition of BDNF yielded the highest proportion of 
DARPP-32 from LGE. However, when this condition was applied to neuronal differentiation 
cultures of day 16 NEBs there was no effect on the expression of GABA, DARPP-32 or FoxPl, 
all markers of MSNs.
In Chapter 7, day 16 NEBs, with and without addition of purmorphamine, were transplanted into 
the QA lesioned mouse striatum. All resulting grafts were small, but analysis revealed densities of 
neuronal and striatal markers in day 16 NEB-derived grafts to be similar to E14-derived grafts.
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Chapter 1 Introduction
Chapter 1
Introduction
Neural transplantation in neurodegenerative diseases currently employs 
primary foetal striatal tissue for cell replacement and circuitry repair. In 
Huntington's disease cell loss occurs predominantly in the medium spiny neuron 
population o f the striatum. The specificity o f cell loss makes transplantation a viable 
therapeutic option. Ethical and logistical issues surrounding the use o f primary foetal 
tissue indicate the need fo r an alternative donor cell source. The requirement o f any 
alternative donor source is to have the capability to generate the mature phenotype 
that is lost in the disease process. Thus, cells need to be responsive to inductive 
developmental cues and the major challenge for the use o f any donor cell is the 
specificity o f the precise terminal phenotype. Here, Huntington’s disease is used as a 
model fo r striatal transplantation and this thesis attempts to identify the signals 
required for directing differentiation o f  embryonic stem cells in order to generate 
medium spiny striatal projection neurons.
1.1 Huntington’s disease
Huntington’s disease (HD) was first described by George Huntington in 1872, 
when he detailed a condition referred to as ‘hereditary chorea’ in The Medical and 
Surgical Reporter: A Weekly Journal (Philadelphia) (Huntington, 2003). Huntington 
was a physician in East Hampton, Long Island and observed that this condition was 
confined to ‘certain and few families’ and was passed on between generations, rarely 
skipping a generation, with a tendency to manifest itself only in adult life, gradually 
developing over a number of years and increasing in severity. The choreic movements 
may be described as ‘dance-like’ with a ‘continual jigger’ while the sufferer is awake, 
but not while asleep, and have the potential to affect all voluntary muscles. 
Huntington also reported that those diagnosed had a tendency towards insanity and
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suicide. At this early date little was known about the pathology of HD and the chorea 
was thought to be due to a ‘functional derangement’ of the cerebellum.
It was over 100 years later when the gene responsible for this hereditary 
condition was first mapped and found to reside on the short arm of chromosome 4 
(Gusella et al., 1983). A further decade on, in 1993, a new gene, IT-15 (interesting 
transcript 15), now known as ‘huntingtin’, was isolated and cloned by the 
Huntington’s Disease Collaborative Research Group, and a mutation of the 
huntingtin (HIT) gene was found on exon 1 of the short arm of chromosome 4 
(HDCRG, 1993). This mutation was found to be an unstable expansion of the tri­
nucleotide repeat CAG which codes for glutamine, and HD may also be referred to as 
a poly-glutamine repeat disorder. Tri-nucleotide repeats, as a ‘mechanism of 
mutation’, were first recognised in 1991 in Kennedy disease and fragile X syndrome, 
followed by myotonic dystrophy in 1992 and then HD in 1993 (Harper, 1997).
1.1.1 Clinical Huntington’s disease
Huntington’s disease affects one in 10,000 individuals in most European 
populations (Harper et al., 1991). Age of onset of the disease is usually within the 
third and fourth decades of life, however there have been juvenile as well as late-onset 
cases reported. Disease onset is progressive and death occurs within 15-30 years.
HD is an inherited autosomal dominant disorder which is characterised by 
neurodegeneration in the form of extensive atrophy of the striatal projection neurons. 
The loss of these cells leads to a variety of symptoms which can be put into three 
different categories: motor disturbances, cognitive impairment and psychiatric 
disorders. Motor symptoms include involuntary choreic movements, dystonia, 
dysphasia, dysarthria, bradykinesia, apraxia and eye movement abnormalities; 
cognitive symptoms include executive impairment, memory loss and progressive 
dementia; psychiatric symptoms include irritability, depression, anxiety, apathy, 
personality changes and, rarely, psychosis. HD is a progressive neurodegenerative 
disease and, as time goes on, the associated symptoms get progressively worse. 
Pneumonia is the leading cause of death in HD patients, and others include choking, 
nutritional deficiencies and suicide (Lanska et al., 1988; Harris and Barraclough,
1994).
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In normal individuals up to 35 repeats o f the CAG triplet code may be carried 
and when the number o f repeats is increased above 35 this is considered a ‘disease- 
causing allele’. However, CAG repeat lengths between 36 and 39 are regarded as 
‘variable penetrance’, with repeat lengths greater than 39 invariably leading to disease 
state within a normal life span (Rubinsztein et al., 1996). Longer repeat lengths, 
typically greater than 70, are associated with juvenile onset of the disease. There has 
been shown to be an inverse correlation between the number o f repeats and the age of 
onset o f the disease, suggesting that the greater the number of CAG repeats the 
younger the age of onset (Andrew et al., 1993). The number of repeats has also been 
shown to correlate with the severity and progression of the disease on a population 
basis, although it is not the only determinant o f these factors.
1.1.2 Pathology o f  H untington’s disease
The mechanism by which the genetic mutation causes HD is unknown. HD 
pathology affects widespread areas in the brain (Rosas et al., 2003), but it is 
predominantly the striatum that is affected. The characteristic pathology is the 
selective loss o f the medium-sized spiny neurons (MSNs) o f the caudate nucleus and 
putamen, collectively called the ‘neostriatum’, and there is also a degree o f cortical 
degeneration which may be primary or secondary to the striatal degeneration (Figure
1.1). The dysfunction and severe atrophy o f the striatum causes a disruption to the 
basal ganglia circuitry and this is largely responsible for the symptoms associated 
with the disease.
Figure 1.1. (A) Coronal section through a normal adult brain, showing the caudate nucleus 
(c) and the putamen (p). (B) Coronal section through an HD brain, showing the atrophy in the 
caudate nucleus and putamen as well as the cerebral cortex. (Bates et al., 2002).
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Vonsattel et al., graded HD brains according to striatal loss, with a link 
between extent of atrophy and stage of clinical impairment (Vonsattel et al., 1985). 
The post-mortem brain of an HD sufferer may be 10-20% lighter than that of an age- 
matched control (Gutekunst et al., 2002).
Another characteristic of the HD brain is the presence of insoluble neuronal 
intranuclear inclusions formed by the mutant Htt. These have been detected in post 
mortem brains of HD patients, in both the striatum and the cortex (Difiglia et al.,
1997). It is not yet known what role these aggregates play in the course of the disease, 
if any. One proposal is that they are causative of the cell death associated with HD 
(Yang et al., 2002). Introduction of mutant Htt to cultured striatal neurons induced 
cell death which could be protected by addition of neurotrophic factors such as brain- 
derived neurotrophic factor (BDNF) (Saudou et al., 1998). However, Saudou et al 
(1998) demonstrated that the presence of intranuclear inclusions did not correlate with 
cell death, and suggested that the aggregates might be acting to protect the cell from 
htt-induced death, which was further demonstrated by Arrasate et al (2004) who 
showed that cells with aggregate formation demonstrated improved cell survival. In 
addition, a mouse model of HD with widespread aggregation, displayed no neuronal 
degeneration or dysfunction, further indicating a protective mechanism (Slow et al., 
2005). It has also been proposed that aggregates might be toxic in one cell location 
but protective in another (Arrasate et al., 2004), and that the timing of aggregate 
formation might predict whether the subsequent effects are toxic or beneficial (Gong 
et al., 2008).
One leading suggestion concerning the development of the disease is that the 
HD mutation causes the subsequent damage via a gain-of function of the mutant htt 
protein. The insertion of exon 1 of the HD gene carrying an expanded CAG repeat, 
resulted in a mouse model with a reduction in the size of various brain structures 
including the striatum, and a progressive neurological phenotype including symptoms 
such as dyskinesia, tremor and involuntary stereotypic movements (Mangiarini et al.,
1996).
It is also suggested that loss-of-function of normal Htt may contribute to the 
HD phenotype. Mice homozygous for the targeted mutation of the Htt gene are 
embryo-lethal, while those that are heterozygous survive to term and adulthood (Nasir 
et al., 1995). Stereological analysis of the heterozygous mutant brains revealed a loss
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o f neurons in the globus pallidus (GP) and subthalamic nucleus (STN) with an 
increase in apoptosis in these areas (O'Kusky et al., 1999).
1.2 The normal adult striatum
The striatum is made up o f the caudate nucleus and the putamen (see Figure
1.1), and forms part o f the basal ganglia along with the STN, GP and substantia nigra 
(SN). It receives inputs from the cerebral cortex, SN, thalamus and brain stem, and 
sends outputs to the GP and SN.
The striatum is both anatomically and neurochemically heterogeneous (Prensa 
et al., 1999), and comprises a variety o f neurons which can be subdivided according to 
size, density o f spines, target destination o f axons and utility o f neurotransmitters and 
neuropeptides. The MSNs (Figure 1.2) constitute 95% o f the striatal neuronal 
population in the rodent, whilst the aspiny intemeurons o f the striatum make up most 
o f the remaining 5%, with non-MSN projection neurons representing a small 
percentage (Freeman et al., 1995).
Figure 1.2. A medium-sized spiny neuron, with branched, spiny dendrites.
Courtesy of Professor P. Harper (Institute of Medical Genetics, Cardiff University).
MSNs have a medium-sized cell body, branched dendrites that are densely 
spiny, and they are the projection neurons o f the striatum, which can be distinguished 
from the intemeurons by their expression o f the phosphoprotein dopamine and cyclic 
adenosine 3 ’, 5’- monophosphate-regulated phosphoprotein, 32kDa (DARPP-32). 
DARPP-32 is found in the majority o f striatal neurons projecting to the SN and those 
projecting to the GP, but it is absent from major types o f intemeuron. 
Morphologically MSNs are a homogeneous population; however they are 
biochemically heterogeneous (Graybiel, 1990).
5
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MSNs are the predominant projection neurons of the striatum and use gamma- 
amino butyric acid (GABA), which is an inhibitory transmitter, as their principal 
neurotransmitter (Kita and Kitai, 1988) along with one or more neuropeptides (Reiner 
and Anderson, 1990). These GABAergic neurons can project to the GP, internal (GPi) 
and external (GPe) segments (striatopallidal neurons) and the SN pars compacta and 
reticulata (striatonigral neurons). The neuropeptides involved are enkephalin, 
substance P and dynorphin, with the latter two largely co-existing in striatal projection 
neurons (Reiner and Anderson, 1990). The majority of striatal projection neurons 
expressing enkephalin project to the GP, while the majority of neurons that co-express 
substance P and dynorphin project to the SN (Gerfen and Young, III, 1988). The 
presence of these neuropeptides in addition to GABA has been shown to be important 
in communication between the striatal projection neurons and their target neurons.
Striatal inputs from the SN are dopaminergic and those from the cortex and 
thalamus are non-dopaminergic, primarily glutamatergic. The glutamatergic afferents 
provide excitatory inputs to the MSNs. The inputs and outputs of the striatum are 
shown in Figure 1.3. Dopaminergic projections from the SNc act on the D1 and D2 
dopamine receptors of the GABAergic MSNs. Projection to the D1 receptors results 
in activation of the direct pathway to the GPi via neurons expressing GABA and 
substance P. The indirect pathway is activated as a result of dopaminergic projections 
acting on the D2 receptors which causes inhibition of those striatal MSNs expressing 
GABA and enkephalin which project to the GPe.
The aspiny intemeurons, or ‘local circuit’ neurons, comprise medium and 
large cells with smooth dendrites. They may be split into three categories; i) those that 
use acetylcholine as a neurotransmitter, ii) those that contain the calcium-binding 
protein parvalbumin and also express glutamate decarboxylase (GAD) and use GABA 
as a neurotransmitter, and iii) those that contain somatostatin, neuropeptide Y and 
NADPH diaphorase (Kawaguchi, 1993).
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Cerebral cortex
Glutamate
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Figure 13. Inputs and outputs o f the striatum. Excitatory projections are represented with 
dashed lines and inhibitory projections with solid lines. Abbreviations: DA - dopamine; GPe - 
external segment o f globus pallidus; GPi - internal segment o f globus pallidus; SNc - 
substantia nigra pars compacta; SNr - substantia nigra pars reticula; STN - subthalamic 
nucleus; Sub P - substance P. (Adapted from (Bates et al., 2002) Bates G, Harper P, Jones L., 
Huntington’s Disease, Third Edition.).
One level of compartmentalisation in the striatum is the characteristic 
striosome (patch)-matrix organization which is based on the expression of 
neurochemical markers. Acetylcholinesterase (AChE) positive neurons are distributed 
throughout the striosome-matrix compartments, with AChE-poor areas comprising the 
striosomes and AChE-rich areas comprising the matrix. The matrix compartment also 
contains neurons expressing the 28kD calcium-binding protein calbindin as well as 
somatostatin-positive fibres. Calbindin and parvalbumin have been shown to label 
striatonigral projection neurons. Calbindin labels the striatonigral matrix neurons 
whereas parvalbumin labels the striatonigral striosome neurons (Gerfen et al., 1985).
1.2.1 DARPP-32 expression in the striatum
DARPP-32 is a phenotypic marker of the MSNs of the adult striatum that 
distinguishes them from the other striatal cells. It is the most commonly used MSN 
marker and in the rodent brain it has been demonstrated that more than 90% of all 
MSNs express DARPP-32 (Ouimet et al., 1998; Anderson and Reiner, 1991). 
However, it is important to note that expression of DARPP-32 is not absolute in
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defining a MSN, but is currently one of the only measures available in distinguishing 
mature MSNs from other striatal neurons.
Further markers of MSNs are continuously being sought, including those 
expressed in MSN precursors. The transcription factor COUP TF1-interacting protein 
2 (CTIP2) has been shown to be expressed exclusively in striatal MSNs (Arlotta et al.,
2008). In the adult mouse striatum, all DARPP-32 positive cells were shown to co­
express CTIP2 (Arlotta et al., 2008). Conversely however, in neurons derived from 
human ES cells, CTIP2 has been shown to co-label with the dorsal telencephalic 
markers TBR1 and vesicular glutamate transporter 1 (VGLUT1) (Li et al., 2009). 
Another potential candidate is FoxPl, which has also been shown to co-label with 
CTIP2 (Arlotta et al., 2008), and was shown to be upregulated during development in 
the striatum between the ages embryonic day (E) 12 and E16 (Kelly et al., in 
preparation). FoxPl expression has been detected by in situ hybridization from E l3.5 
in the developing mouse brain, and its expression persists into adulthood, with 
expression in the projection neurons but not intemeurons of the adult striatum 
(Ferland et al., 2003; Tamura et al., 2004).
In the embryonic rat caudate nucleus it has been demonstrated by 
immunohistochemistry, that DARPP-32 immuno-reactive cells are first detectable at 
E14 (Foster et al., 1987). At this age only very few DARPP-32 positive cells are 
present, although both the number of DARPP-32 positive cells and the intensity of 
immuno-fluorescent labelling increase rapidly and by postnatal day 0 (P0) the pattern 
of DARPP-32 immuno-reactivity is nearly that seen in the adult striatum.
In the mouse brain DARPP-32 mRNA is undetectable at E14 and at P0 both 
DARPP-32 mRNA and protein are present in very small amounts (Ehrlich et al., 
1990). Levels of both then increase dramatically throughout the first 3-4 postnatal 
weeks, with the mRNA reaching adult levels before the protein. Ehrlich et al (1990) 
propose that induction of DARPP-32 gene transcription occurs primarily during the 
last week of gestation, since DARPP-32 cells are largely present at birth, and MSN 
production peaks at E15 and is almost complete by PI-2 in both the mouse and rat 
(Marchand and Lajoie, 1986; Sturrock, 1980).
Immunohistochemical analysis reveals that there is an overlap of DARPP-32 
immuno-reactive neurons and dopaminoceptive neurons containing dopamine D1 
receptors (Walaas and Greengard, 1984), which coincides with the observation that 
DARPP-32 phosphorylation is regulated by dopamine D1 receptor activation (Ouimet
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et al., 1998). Further, the ontogeny of DARPP-32 and pre- and post-synaptic 
components of the dopamine D1 synapse follow a similar time course which further 
suggests a role for DARPP-32 in regulating dopamine D1 receptor mediated signal 
transduction (Ehrlich et al., 1990).
The HD paradigm, in which degeneration in the striatum is a focal point at 
which to aim to replace the cells lost, offers a disease model suitable for striatal 
transplantation. Since it is the DARPP-32 positive MSNs that are predominantly lost 
in HD, it is these cells that we endeavour to replace.
1.3 Development o f research models for Huntington’s disease
Models of HD are required to further our understanding of the progression of 
the disease, and to give an insight into the potential of therapeutic strategies for repair, 
including transplantation. Excitotoxic lesions are widely used to generate models of 
HD. They are useful for studying behavioural aspects, as well as investigating cell- 
based therapies of the disease, reviewed in (Dunnett and Rosser, 2004). This method 
has been shown to reproduce many of the histological, neurochemical and behavioural 
features of the disease. One such toxin is quinolinic acid (QA) which, when 
administered directly to the striatum, causes striatal atrophy with predominant loss of 
MSNs (Schwarcz et al., 1983; Schwarcz and Kohler, 1983). QA is toxic to the 
GABAergic MSNs and spares the cholinergic intemeurons and the aspiny 
intemeurons containing somatostatin, neuropeptide Y and NADPH diaphorase (Beal 
et al., 1986). The selective striatal cell loss observed with the QA lesion resembles 
that seen in the human condition and this model is currently the most widely used for 
transplantation studies in HD. Another toxin is 3-nitropropionic acid (NPA), which is 
administered systemically in low doses and over a period of weeks causes striatal cell 
loss (Borlongan et al., 1997). It functions to disrupt mitochondrial energy metabolism, 
which causes the striatal damage and induces functional impairments. For 
transplantation studies it is a less useful model than the QA lesion because it results in 
a less stable lesion, which is bilateral and therefore leaves no control side, and there is 
more variability in lesions within experiments.
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The identification of the mutation of the gene causing HD has led to the 
generation of genetic models of the disease for research. Genetically modified models 
of HD have been generated in Drosophila melanogaster (Warrick et al., 1998), 
Caenorhabditis elegans (Faber et al., 2002), zebrafish (Schiffer et al., 2007) and non­
human primates (Yang et al., 2008), as well as rodents. In terms of cell-replacement 
strategies for repair of function and circuitry, rodents offer the most attractive model 
due to both ease of use in transplantation and behavioural studies, and their complex 
brain organisation.
Models of HD differ phenotypically according to behaviour and 
neuropathology and can therefore be used to look at different aspects of the disease. 
There are both knock-in and transgenic rodent models of HD. The knock-in models of 
HD are those in which an expanded CAG repeat is introduced into the endogenous 
mouse Htt gene. They include the poly-Q (polyglutamine) models which differ 
according to the number of CAG repeats, such as the Q92 and Q111 models (Wheeler 
et al., 1999). The knock-in models show few behavioural deficits and no cell loss but 
there is the presence of neuronal intranuclear inclusions.
Transgenic models are those in which either a portion of the human HD gene 
or the full length gene is inserted randomly into the genome. These include the R6/2 
model which contains the HD promoter, exon 1, and about 155 polyglutamine repeats 
(Mangiarini et al., 1996). R6/2 mice show reduced numbers of striatal neurons and 
overall brain atrophy (Stack et al., 2005), as well as learning impairments and 
progressive motor deterioration. Polyglutamine aggregates in the form of neuronal 
intranuclear inclusions and cytoplasmic aggregates have been reported in the R6 
models (Davies et al., 1997), and as with most of the transgenic mouse models, there 
is a rapid progression of the HD phenotype which largely resembles juvenile onset. 
Transplantation into the R6/2 striatum resulted in graft survival with a degree of 
integration, although improvements in the behavioural phenotype were only marginal 
(Dunnett et al., 1998). Other transgenic mouse models include the YAC (yeast 
artificial chromosome) mouse models, YAC72 and YAC 128, which contain the entire 
human HD gene, its regulatory elements and 72 or 128 polyglutamines, respectively 
(Hodgson et al., 1999; Slow et al., 2003). The BACHD model (bacterial artificial 
chromosome) contains the human Htt locus with a modified exon 1, and displays 
progressive striatal and cortical atrophy with expression of neuronal intranuclear 
inclusions (Gray et al., 2008).
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The majority of transgenic models of HD are mouse models although a rat 
model of HD has recently been generated (von Horsten et al., 2003). This model has a 
truncated htt cDNA fragment with 51 CAG repeats under the control of the native rat 
htt promoter. The homozygous transgenic rat has been shown to exhibit phenotypes 
which appear to represent the late-onset and slow progression of adult HD. Neuronal 
intranuclear inclusions have been reported from 12 months of age (von Horsten et al., 
2003) and a decrease in striatal neuronal numbers is observed at 12 months (Kantor et 
al., 2006).
In vitro models of HD have been developed to investigate the intracellular 
pathology associated with the disease and can be useful for screening potential drug 
candidates. Cell culture models of HD provide the opportunity to study the 
distribution of Htt within cells and the role it plays in different cellular compartments. 
These models have been used to investigate the aggregation of both wild-type and 
mutant Htt. Various cell culture models of HD have been generated by transfection of 
full-length Htt with normal or expanded polyglutamine repeats, resulting in both 
transient expression (Trottier et al., 1995; Cooper et al., 1998) and stable, long-term 
expression (Lunkes and Mandel, 1998). Following transient transfection with full- 
length Htty the protein was found to be localized diffusely in the cytoplasm, whereas 
with N-terminal fragments of htt, aggregates were found in both the cytoplasm and 
the nucleus (Cooper et al., 1998). With the stable cell model, it was found that mutant 
Htt expression leads to formation of inclusions in both the cytoplasm and the nucleus, 
and this was dependent on time and the length of polyglutamine repeats (Lunkes and 
Mandel, 1998). It is suggested here that it is a truncated N-terminal fragment of Htt 
which is involved in inclusions in the cytoplasm at early time points and in the 
nucleus at later time points. A truncated Htt fragment has also been implicated in HD 
pathogenesis (Difiglia et al., 1997).
Cell lines have been established from mouse embryos of knock-in models of 
HD. Trettel et al (2000) generated striatal cells from HdhQl 11 mice, compared these 
with wild-type cells and found that the mutant protein causes toxicity and disrupts 
striatal cell homeostasis (Trettel et al., 2000). An alternative approach, for generation 
of human embryonic stem (ES) cell lines, involves donation of blastocysts following 
in vitro fertilisation (IVF) and pre-implantation genetic diagnosis (PGD). PGD allows 
detection of embryonic genetic defects and can result in availability of embryos for 
derivation of ES cell lines. A blastocyst donated for research, in which the paternal
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donor was affected with HD, was used to derive a human ES cell line which carries 44 
CAG repeats (Mateizel et al., 2006). This cell line expressed markers of 
undifferentiated human ES cells, formed embryoid bodies when subjected to 
suspension culture, and was able to differentiate into cells of the three germ layers, 
ectoderm, endoderm and mesoderm (Mateizel et al., 2006). More recently, two human 
ES cell lines carrying CAG repeats of 37 and 51 have been derived following PGD, 
and have been shown to undergo neural differentiation with formation of 
neurospheres and subsequent generation of neurons and astrocytes (Niclis et al.,
2009).
The recent discovery of induced pluripotent stem (iPS) cells, where 
pluripotency-linked factors are introduced to fibroblasts to reprogram them so they 
express pluripotency markers and behave like ES cells, offers a novel cell source 
(Takahashi and Yamanaka, 2006; Lowry et al., 2008; Yu et al., 2007; Takahashi et al., 
2007; Park et al., 2008). iPS cells do not exhibit chromosomal abnormalities and can 
differentiate to produce cells of the three embryonic germ layers. Disease-specific iPS 
cells have been generated, including a human iPS cell line for HD that has 72 CAG 
repeats (Park et al., 2008).
Models of HD have proved useful for the study of pathogenesis of the disease, 
symptomatic aspects and therapeutic strategies. Cell culture models of HD allow 
analysis and characterisation of cells affected by the disease and allows specific cells 
to be targeted for therapeutic strategies. In terms of neurodegeneration, HD offers a 
model with a focal point of cell loss (predominantly the striatum) making 
transplantation an attractive therapeutic approach.
1.4 Transplantation in Huntington’s disease
There is currently no known cure for HD and only limited symptomatic 
treatments are available. Various therapeutic strategies are being explored targeting 
the cellular pathology, including neuronal protection, knock-down of mRNA and cell 
replacement by transplantation of foetal neural precursors. Transplantation aims to 
replace the neurons that are lost and reconstruct the circuitry that is affected by the
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disease. Primary foetal striatal tissue offers a source of MSN precursors and is 
currently the ‘gold standard’ for transplantation in HD.
Preclinical studies have investigated the optimum parameters for 
transplantation into the HD brain, such as age of the developing embryo, region of the 
developing brain for dissection and tissue preparation (Olsson et al., 1995; Flicker et 
al., 1997; Watts et al., 1997). It has been reported that whole ganglionic eminence 
(WGE) grafts into the lesioned striatum in rat generate a higher proportion of striatal- 
like tissue, as determined by AChE and DARPP-32 immunohistochemistry, when 
derived from gestational ages E14 and E l6, and not older donor ages (Flicker et al.,
1997), but functional recovery of animal recipients of these grafts was only improved 
when the donor tissue was younger (E l4) rather than older (E l6) (Watts et al., 1997). 
Xenotransplantation studies of human foetal neural precursors into rodent models of 
HD have provided information which suggests that human foetal tissue between 8-10 
weeks of gestational age is optimal for harvesting striatum for transplantation (Rosser 
and Dunnett, 2003; Freeman et al., 1995). However, to date, no systematic studies 
looking at donor age of human foetal tissue have been carried out.
Comparison of grafting the WGE versus the lateral ganglionic eminence 
(LGE) or medial ganglionic eminence (MGE) indicate that the LGE grafts contain a 
greater proportion of striatal-like cells, confirmed by staining with DARPP-32 
(Pakzaban et al., 1993), and a much higher proportion of AChE-positive tissue is seen. 
The LGE represents the major source of striatal projection neurons (Olsson et al.,
1998) and the striatal intemeurons appear to come predominantly from the MGE with 
a smaller proportion originating in the LGE (Olsson et al., 1998; Marin et al., 2000). 
Fate mapping studies revealed that cells originating in the LGE migrate both 
anteriorly and ventrally, giving rise to projection neurons of the striatum, nucleus 
accumbens and olfactory tubercle, whilst the majority of cells originating in the MGE 
migrate dorsally and generate intemeurons expressing GABA, parvalbumin and 
somatostain (Wichterle et al., 2001). Grafts comprising both LGE and MGE have 
been shown to be heterogeneous with respect to striatal phenotype (Olsson et al.,
1995). In these grafts, there are regions with striatum-like tissue, called ‘P regions’ 
which express DARPP-32 and AChE. There are also ‘NP regions’ which contain 
neurons usually found in adjacent forebrain regions such as the cortex and GP (Olsson 
et al., 1995; Graybiel et al., 1989).
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Human foetal neural precursor cells for replacement are currently obtained 
from collection of foetuses following elected termination of pregnancy under full 
ethical consent of the maternal donors (Polkinghome, 1989; Boer, 1994). Upon 
retrieval of foetal tissue, the developing striatum is dissected out and tissue may be 
‘hibernated’ for up to a week before transplantation, without a reduction in viability 
(Hurelbrink et al., 2000).
Clinical trials for cell-replacement therapy in HD using foetal tissue are on­
going and have demonstrated proof-of-principle, but consistent efficacy has not yet 
been achieved. Bilateral human foetal striatal grafts in symptomatic HD patients have 
been shown to survive and show typical morphology of developing striatal grafts, as 
seen in post mortem evaluation of one patient (Hauser et al., 2002). Assessments of 
safety reveal that human foetal striatal grafts do not accelerate disease progression 
(Rosser et al., 2002), and patients exhibiting no graft benefits appear to decline 
similarly to non-grafted patients (Bachoud-Levi et al., 2006). Hauser et al (2002) 
reported a decrease in the unified HD rating scale (UHDRS) score at 12 months post­
transplantation, indicating an improvement in neurological assessment. More 
convincing evidence of efficacy was demonstrated by a group in Creteil, France, who 
reported on five patients at six years post-transplantation, who received foetal neural 
transplants (Bachoud-Levi et al., 2006). They used UHDRS, neuropsychological tests 
and MRJ and determined that there are benefits both clinically and in terms of brain 
activity, which provide a short term improvement and stability for the patient.
A recent post mortem study, ten years post-transplantation, demonstrates graft 
survival but also suggests degeneration of grafted neurons (Cicchetti et al., 2009) 
compared with a patient from the same cohort who died 18 months post­
transplantation (Freeman et al., 2000). In the more recent report, the authors 
demonstrate survival of tissue with expression of striatal projection neurons and 
striatal intemeurons as well as synaptic connections between transplanted neurons and 
host-derived dopaminergic and glutamatergic neurons, although there is also evidence 
of some graft damage (Cicchetti et al., 2009).
Another recent post-mortem analysis study, at six months post-transplantation, 
reported graft-derived DARPP-32, NeuN, calretinin, somatostatin and astrocytes, as 
well as innervation of host-derived TH fibers (Capetian et al., 2009). There was also 
the presence of more immature precursors including doublecortin (DCX), Sox2 and 
Ki67 (Capetian et al., 2009). This study gives an indication of graft morphology at an
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early time point post-transplantation. However, we are unable to draw any direct 
comparisons between data from the various studies because there are different 
protocols being applied at different centres, and this therefore reinforces the need for 
controlled multi-centre trials.
Foetal tissue as a source for cell replacement is limited and brings about both 
practical and ethical constraints. For transplantation in Parkinson’s disease (PD) it has 
been shown that there is a requirement for several foetuses per transplant. It is likely 
that this is also the case for clinical transplantation in HD and if so, would pose 
logistical and quality control issues in terms of retrieving several foetuses of the same 
gestational age, as well as manipulation and storage of tissue under new Good 
Manufacturing Practice (GMP) guidelines (EU Directive).
There is an urgent need for an alternative supply of tissue. Possible 
alternatives include stem cells, such as ES cells, neural stem cells and mesenchymal 
stem cells, xenogenic tissue (for example, porcine), genetically engineered cells and 
most recently iPS cells (Takahashi and Yamanaka, 2006). The emergence of iPS cells 
might prove useful for both research and clinical applications, since they bypass the 
use of embryos and would enable generation of patient-specific cell lines therefore 
avoiding administration of immuno-suppression. Potential alternative cell sources 
have been investigated, although the majority of research has focussed on neural stem 
cells and ES cells. Neural stem cells are attractive because they are already lineage 
restricted, but they do have limited capacity for proliferation (Zietlow et al., 2005). ES 
cells have a greater proliferation potential, are more plastic, and can be directed down 
the various different lineages. There is now over a decade of work on ES cells for the 
purpose of achieving an alternative cell supply and it is likely that outcomes found for 
ES cells will be pertinent for the differentiation of other alternative cell sources, 
making ES cells a good area on which to focus.
1.5 Embryonic stem cells
ES cells offer an alternative source of cells for transplantation in 
neurodegenerative disorders such as HD. The characteristic features of these cells are 
their capacity for unlimited self-renewal and proliferation and their pluripotency
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which gives them the potential to generate any cell type (Evans and Kaufman, 1981; 
Martin, 1981). ES cells are derived from the inner cell mass (ICM) of the developing 
blastocyst and have the potential to generate cells from any of the three primary germ 
layers of the embryo; ectoderm, endoderm and mesoderm. This makes them an 
attractive source of cells for therapeutic strategies in a range of diseases. In HD, since 
it is the MSNs of the striatum that are predominantly lost, and the optimum ‘cell-type 
mix’ that will ultimately be necessary for restoration of function is not yet known, the 
MSNs are likely to be the cells we wish to generate for replacement and this, 
therefore, is the current focus.
Mouse ES cell lines have been derived, including those with insertion of 
reporter genes, to investigate effects on gene expression within neural induction 
culture systems and determine effects of addition of factors. More recently human ES 
cell lines have also been derived (Thomson et al., 1998). Studies have shown 
similarities and differences between mouse and human ES cell lines in terms of ES 
cell culture conditions and subsequent neural induction protocols, reviewed in (Wobus 
and Boheler, 2005).
1.5.1 ES cells fo r  transplantation in Huntington’s disease
ES cells offer a potentially inexhaustible supply of cells with the potential for 
use in cell replacement strategies. One of the main caveats is obtaining the specific 
phenotype required, which in the case of HD is MSNs. Even foetal neural precursors, 
taken from the developing striatum, which have been exposed to the temporal and 
spatial cues necessary for induction of the desired phenotype, do not go on to generate 
the full complement of striatal projection neurons and intemeurons when transplanted 
into the adult striatum. Long-term in vitro expansion of both mouse and human foetal 
neural progenitors prior to transplantation resulted in reduced survival following a 
long-term post-transplantation period (Zietlow et al., 2005). It has been reported that 
there are changes in gene expression between early (8 weeks) and late (20 weeks) in 
vitro expansion times of human foetal neural progenitors, with upregulation of genes 
associated with apoptosis after prolonged time in culture (Anderson et al., 2007). 
Further, the long-term expanded progenitors showed reduced transplant size as well as 
reduced neurogenic potential (Anderson et al., 2007). For ES cells, the predominant
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requirement is to direct the differentiation both in the initial in vitro stage, and then in 
the subsequent maturation stage following transplantation into the adult striatum.
There has been some degree of success in generating specific neuronal 
phenotypes from ES cells for replacement in neurodegenerative disease, for example 
PD. Transplantation of ES cell-derived neural precursors has predominantly focused 
on obtaining dopaminergic neurons and the general principles of directing 
differentiation of these cells applies for cell types throughout the developing brain. 
Dopaminergic neurons have been reported in vivo in graft-derived cells post­
transplantation (Wemig et al., 2004; Ferrari et al., 2006; Lee et al., 2007), with one 
case demonstrating long-term survival and function of these neurons (Rodriguez- 
Gomez et al., 2007). Table 1.1 outlines transplantation studies that have employed 
neural induction of ES cell-derived precursors. Few studies have been carried out 
involving transplantation of ES cell-derived neural precursors into HD models and of 
those that have been reported only the QA-lesioned striatum model has been 
employed.
Mouse ES cell-derived precursors subjected to RA-induced suspension culture 
and then transplanted into the QA-lesioned striatum rat model generated GABA and 
AChE immuno-positive neurons following 6 weeks survival (Dinsmore et al., 1996). 
A study looking at the proportion of neural precursors, dividing cells and neurons 
prior to transplantation revealed that the greater the proportion of neural precursors 
(as determined by nestin immuno-reactivity) and dividing cells (using BrdU), the 
greater the potential to generate tumours (Dihne et al., 2006). When the proportion of 
dividing precursor cells was lower and that of mature neurons was greater, grafts 
generated neurons, astrocytes and oligodendrocytes, and there were no teratomas 
formed. Transplantation of cell populations greater than 95% nestin and 42% BrdU 
positive resulted in 70% tumours; 42% nestin, 16% BrdU and 13% p-tubulin resulted 
in 17% tumours; and 14% nestin, 5.9% BrdU and 76% P-tubulin resulted in no 
teratoma formation (Dihne et al., 2006).
Human ES cell-derived neural precursors induced in defined neural induction 
medium generated DCX immuno-positive neuroblasts, neurons and astrocytes, but no 
DARPP-32 immuno-positive neurons and no tumours at six weeks post­
transplantation in a QA-lesioned rat striatum (Joannides et al., 2007b). A similar study 
looked at neural induction of human ES cell-derived precursors with addition of Sonic 
Hedgehog (SHH) and Dickkopf-1 (DKK-1) and after six weeks survival no DARPP-
17
Chapter 1 Introduction
32 was found but there were teratomas (Aubry et al., 2008). Increased neural 
induction time with addition of BDNF, dbcAMP and valproic acid prior to 
transplantation, resulted in generation of some DARPP-32 immuno-positive neurons 
and no teratomas (Aubry et al., 2008). Longer-term survival up to 21 weeks post­
transplantation of these latter neurally induced precursors revealed regions of 
DARPP-32 immuno-positive cells but there was also the observation of large, 
overgrown grafts that compressed the host brain (Aubry et al., 2008).
A recent study of human ES cell-derived precursors generated in neurobasal 
medium with bFGF and the BMP inhibitor noggin, cultured for more than four weeks 
expressed 80% nestin-positive cells at transplantation (Nasonkin et al., 2009). 
Relatively low numbers of cells were transplanted into the non-lesioned rat striatum 
and differentiation was analysed at 1.5, 3 and 6 months. Nestin and DCX decreased 
over time post-transplantation (44% reduced to 1% for nestin expression; 52% 
reduced to 5% for DCX expression), while p-III-tubulin expression increased over 
time (20% increased to 86%), and although there was no DARPP-32 expression at 
three months, nearly a third of grafted cells were DARPP-32 positive at six months, 
demonstrating the need for long-term differentiation to achieve DARPP-32 expression 
(Nasonkin et al., 2009).
Thus far in HD research, transplantation of ES cell-derived neural precursors 
has resulted in good survival in the QA-lesioned host brain, with good integration and 
neuronal generation in some instances even into DARPP-32 immuno-positive 
neurons. However, the teratoma formation reported is a concern that needs to be 
addressed as urgently as directing the differentiation towards the desired phenotype.
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Tablet.1. Transplantation studies o f neurally induced ES cell-derived precursors
Study Experimental Paradigms Notes Results
Cells Host Protocols
Dinsmore et al., 
1996
Mouse ES cells 
(lines E14& D3)
QA lesioned 
striatum, rat, 
CsA
Free-floating, 
RA-induced neuronal 
differentiation
3x105-106 cells 
transplanted. 
Survival: 6 weeks.
Neurons expressing GAB A, AChE, NSE & 
neuron specific tubulin, but no in vivo cell 
numbers reported.
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Dihne et al., 
2006
Mouse ES cells
(i)eGFP line 
derived from 
transgenic 
C57L/6J mice 
expressing eGFP 
under influence 
of chicken p- 
actin promoter
(ii)Rl line
QA lesioned
striatum,
mouse
EB formation in 
absence of LIF; neural 
induction in insulin/ 
transferrin/selenium 
chloride/fibronectin, 
then expanded in B27 
&FGF2
~100,000cells/pl 
transplanted. 
Survival: 1, 4 & 16 
weeks.
The higher the proportion of neural precursors 
(nestin) and dividing cells (BrdU), the greater 
the risk of tumours.
56.9% NF-200 neurons. Grafted cells 
expressing P-tubulin and GAD65/67, also 
astrocytes & oligodendrocytes.
W
T 3a>o3"O
Joannides et al., 
2007
Human ES cells
(i)H9
(ii)HUES9
QA lesioned 
striatum, rat, 
CsA
Defined neuralizing 
medium
100,000-250,000 
cells transplanted. 
Survival: 6 weeks.
Grafted cells expressing DCX, NeuN, GFAP, 
but no DARPP-32.
CUl-H
3
<L>
Song et al., 
2007
Human ES cells 
Miz-hES 1
QA lesioned 
striatum, rat, 
CsA
Co-culture on PA6 
stromal cells (generate 
high proportion of 
nestin-positive cells)
20,000 cells in 2pl 
transplanted. 
Survival: 3 weeks.
Improved apomorphine rotations at 1, 2 & 3 
weeks compared with sham group.
Grafted cells expressing nestin, Tuj 1, DCX & 
GAD. No NeuN, MAP2 or DARPP-32.
No tumours.
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Study ____________ Experimental Paradigms____________  Notes Results
Cells Host Protocols
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Aubry et al., 
2008
Human ES cells
(i) SA-01
(ii) H9
QA lesioned 
striatum, 
immuno­
competent rat
Rosettes in N2 & 
BDNF; addition of 
SHH/DKK-1; 
differentiation in 
BDNF/dbcAMP/ 
valproic acid
50,000-200,000 
cells transplanted. 
Survival: 4-6 
weeks.
Transplantation in early stages of neural 
induction resulted in teratomas & no DARPP- 
32.
Transplantation of later stage cells resulted in 
no teratomas, and grafts contained clusters of 
DARPP-32 & calbindin neurons.
G
CO
<3
a
QA lesioned 
striatum, 
immuno­
competent rat
Neural induction as 
above. Cells at the 
stage which gave best 
in vivo outcome at 4-6 
weeks.
50,000 cells 
transplanted. 
Survival: 13-21 
weeks.
Large overgrown grafts that compressed the 
host brain. Regions of graft-derived DARPP- 
32 cells throughout the graft, often calbindin- 
negative, unlike short-term grafts. Very few 
TH neurons, no AChE & few GFAP cells.
U
nl
es
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ne
d
Nasonkin et al., 
2009
Human ES cells 
BG01
Unlesioned 
striatum, 
nude rats
Neurobasal with 7.5% 
KSR/bFGF/noggin for 
3 days. Then colonies 
picked from MEFs 
onto gelatin in 
neurobasal with bFGF/ 
noggin for 4 weeks
15000 cells 
transplanted. 
Survival 1.5, 3 and 
6 months.
High nestin expression prior to grafting 
(80%). Nestin and DCX expression decreased 
overtime in vivo, J3-tubulin expression 
increased overtime. No GAD at 6 months; no 
DARPP-32 at 3 months but 30% DARPP-32 
at 6 months; Some calretinin & parvalbumin 
at 6 months.
No teratomas or graft overgrowth.
Ot
he
r 
ce
lls
 i
nto
 
Q
A Bosch et al., 
2004
Immortalised 
striatal neural 
stem cell line 
ST14A
QA lesioned 
striatum rat
Sequential RA then 
KC1 treatment, pre­
differentiated to 
GABAergic phenotype
9000 cells per 
striatum (6 graft 
sites).
Survival: various 
time points.
Maintained GABAergic phenotype 3 days 
post-transplantation.
At 1 & 5 weeks after grafting, reduction in 
apomorphine rotations, compared with 
ungrafted rats.
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Study Experimental Paradigms Notes Results
Cells Host Protocols
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Brustle et al., 
1997
Mouse ES cells 
(line J 1), 
DIG-labeled
Intrauterine 
transplant 
(E16-18), 
telencephalic 
vesicle, rat
Embryoid body 
formation, insulin- 
transferrin 
medium
0.1 -1 x 106 cells injected. 
Survival: 0-15 days after 
birth.
Grafted cells migrated & integrated into 
various brain regions including striatum, 
cortex & thalamus. Neurons, astrocytes & 
oligodendrocytes detected.
Undifferentiated ES cells & non-neural tissue. 
Used M2 & M6 antibodies.
Deacon et al., 
1998
Mouse ES cells
(i) D3
(ii) E14TG2a
Rat 6-OHDA 
unilateral 
nigrostriatal 
lesion, CsA; 
Mice
unlesioned
1.5xl0() cells in 
5ml DMEM 
+/- RA (0.5mM), 
no LIF
Rats: 100,000-300,000 
cells;
Mice: 60,000 cells. 
Survival : 2-4wceks.
RA+ grafts: rats 2/5 grafts survived, mice 4/4 
grafts survived.
RA- grafts: rat 17/26 grafts survived, mice 3/3 
grafts survived.
In rat host, no migration of donor cells away 
from graft site. TH & 5-HT neurons & GFAP. 
Weak AChE in RA+ but none in RA- grafts. 
Variability between graft size & appearance. 
Heterogeneous tissue types, with significant 
volume negative for neuronal markers.
D
iff
er
en
t 
m
od
el
s; 
in 
1
Kim et al., 2002 Mouse ES cells 
(stable Nurrl 
line, pCMV 
driving 
expression of 
Nurrl)
6-OHDA 
lesioned rat, 
immuno- 
suppressed
Neural induction, 
includes addition 
ofSHH, FGF8& 
FGF2/FGF4.
480,000 cells 
transplanted.
Survival: 4 & 8 weeks.
Grafted cells expressed TH, serotonin & 
GAD67, at 4 & 8 weeks. No Ki67 cells. 
Grafted neurons developed functional 
synapses & electro-physiological properties 
like mesencephalic neurons. Improvement in 
rotations, cylinder & paw-reaching.
No teratomas detected.
Used M2 to detect grafted cells.
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Study Experimental Paradigms 
Cells Host Protocols
Notes Results
Wemig et al., TauEGFP ES Embryonic EB formation 5-7 Transplanted 2-4x 105 Cells migrated to various brain regions incl.
2004 cells (neuron- (E l6.5) rat, days cells. hippocampus, thalamus, neocortex, &IT) 
rt 1 specific enhanced cerebral Survival: 1 & 14 days striatum. Immature neural cells; bipolar,O
r f \
GFP) ventricles after birth. multipolar & pyramidal neurons; GAD65/67,
W & TH. Synaptic integration of donor & host.
T3<D Ectopic expression of region-specific markers
T3 Bfl, Dlx, Enl & Pax6.fl TauEGFP didn’t allow analysis of non­
neuronal cell types.
nJ
£ Teratomas but no undifferentiated ES cells.<L> Ferarri et al., Cynol primate 6-OHDA rat, SHH/FGF8, then 100,000 cells over 2 No sig difference in TH positive cells betweent+HO 2006 parthoenogenetic immuno- BDNF/AA, sites. pES & dES grafts; 80% improvement in D-d_o ES cell line suppressed differentiation in Survival: 12 weeks. amphetamine rotations with dES; 50% with
.22 BDNF/GDNF/ pES. Patches of very dense TH axons, with
d dbcAMP/AA. NeuN, NF70 & Foxgl. Expression ofUh
£<+* Progenitors day28 DARPP-32 & calbindin.
(pES); different­ Heterogeneous graft morphology with non-
o.> iated neurons neural cells.
day42 (dES).,K Lee et al., 2007 Human ES cells In ovo: stage Rosettes exposed Rat; 40,000 cells per In vitro: FGF8/SHH resulted in forebrain but
1 3 (i)Hl; (ii)H9; 16-17 chick to FGF8/SHH, side, bilateral. not hindbrain markers. RA/SHH reduced
”0O
e (iii)RUESleGFP spinal cord; then RA/SHH. Survival: 1 day, 2 and 6 forebrain & increased hindbrain.d
-*-* Non-human In vivo: adult Differentiation in weeks. In ovo: survival of graft-derived motoneurons.d
<D
l - primate ES cells rat spinal GDNF, BDNF & In vivo: Graft survival up to 6 weeks.
<& (i)Cynol cord AA. Expression of motoneuron precursors at 1 day,s then decrease at 2 & 6 weeks. Increase in
mature neurons over time eg ChAT.
22
Chapter 1
1.6 Neural Development
Introduction
Currently there is no protocol for robust, efficient and reproducible 
differentiation of MSNs either in vitro or in vivo. Central to the development of new 
protocols for directing the differentiation of cells to specific phenotypes is the 
understanding of signals that are important in their development in the brain. In this 
section neural development is reviewed, with the focus being on the developing 
telencephalon, the origin of the putative striatum.
In early mouse embryonic development, following fertilization, the ICM and 
primitive endoderm are formed within the trophectoderm. Just prior to gastrulation, at 
E5.5 to E6, the anterior-posterior axis is formed as the distal visceral endoderm 
(DVE) migrates towards the anterior pole and gives rise to the anterior visceral 
endoderm (AVE). The AVE primarily functions to repress posterior gene expression 
involved in induction of mesoderm, which is as a result of expression of the genes 
DKK-l and Lefty7, which act to antagonise Wnt and TGF-P signalling in the epiblast. 
During gastrulation the three germ layers of the gastrula are formed; endoderm, 
mesoderm and ectoderm. It is at this stage of development that generation of the 
nervous system begins. Endogenous signals are released from the underlying 
mesoderm along the midline of the developing brain, and in response to these signals 
the ectoderm thickens and forms the neural plate. The neural plate folds inwards to 
generate the neural groove (E7.5), and eventually the folds meet and give rise to the 
neural tube, a process known as neurulation (E8.5). Patterning of the neural tube at 
this stage is regulated, in part, by the anterior neural ridge (ANR). As the neural tube 
develops it bends, resulting in flexures and this gives rise to vesicles along the tube: 
the telencephalon and diencephalon make up the forebrain, the mesencephalon the 
midbrain and the rhombencepalon the hindbrain (Figure 1.4; A) (Rubenstein et al., 
1998; Lu et al., 2001; Wilson and Houart, 2004; Takaoka et al., 2007).
The developing telencephalon, at the most rostral point of the neural tube, can 
be divided into the pallium (the dorsal-most region), which gives rise to the cerebral 
cortex, and the subpallium (the ventral-most region), which forms the striatum and is 
also the origin of cells that go on to populate the olfactory bulb, GP and cortex. The 
subpallium comprises the LGE and MGE (Figure 1.4; B). In the human striatum, the 
MGE starts to appear a day before the LGE, at Carnegie stages 14 and 15 respectively
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(Freeman et al., 1995). The MGE gives rise to the amygdaloid body and also the GP 
and ventral pallidum, whilst the LGE is the foetal primordium which gives rise to the 
caudate and putamen (Deacon et al., 1994; Sturrock, 1980). Striatal projection 
neurons originate in the LGE and make up nearly 90% of LGE neurons. The majority 
o f telencephalic intemeurons are generated in the ventral telencephalon and then 
migrate to the region that they populate in the adult brain. Those from the LGE go on 
to populate the cortex, olfactory bulb and striatum, while those from the MGE will 
migrate to the cortex, GP and also the striatum (Wilson and Rubenstein, 2000; 
Anderson et al., 1997b; Anderson et al., 1997a; Marin et al., 2000).
Mesenc-Dienc
Telencephalon Rhombenc-
Figure 1.4. The distinct regions of the developing mouse brain. The folding of the neural 
plate and then the neural groove results in the formation of the neural tube, which 
comprises the four regions of the developing brain: telencephalon, diencephalon, 
mesencephalon and rhombencephalon (A). Coronal brain section of mouse embryonic day 
(E) 12.5, showing the dorsal/pallial (CTX) and ventral/subpallial (LGE and MGE) regions 
of the developing telencephalon. Expression of the Dlx2 gene showing the position of cells 
in the LGE and MGE (B). Abbreviations: CTX - cortex; LGE - lateral ganglionic 
eminence; MGE - medial ganglionic eminence.
During telencephalic development, positioning o f progenitor cells within the 
neural tube accounts for the distinct regionalization seen in the adult brain. The 
molecular mechanisms involved in forebrain development are complicated and not yet 
fully elucidated. Signalling centres produce secreted molecules and morphogens 
which generate transcription factors at various levels, which in turn induce patterning 
within the neural tube according to their graded levels o f expression. It is the 
expression o f combinations o f transcription factors at certain times and in specific 
regions that is responsible for this organisation within the developing neural tube
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(Lupo et al., 2006). Dorsal and ventral regions differ with respect to the secreted 
molecules present in that region and the level at which cells are exposed to these 
molecules, imposing a degree of regional identity on the cells.
1.6.1 Factors involved in telencephalon development
There are various groups of factors involved in the patterning of the 
telencephalon. Members of the fibroblast growth factor (FGF) family are one such 
group. FGF8 is expressed in the ANR and as well as being involved in cell 
proliferation and cell survival it has been shown to have a role in rostro-caudal 
patterning and regulates expression of the rostral forebrain marker Foxgl (Shimamura 
and Rubenstein, 1997; Ye et al., 1998; Storm et al., 2006). Interestingly, FGF8 beads 
inhibit expression of caudal forebrain markers Otx2 and Emx2 (Crossley et al., 2001). 
Expression of FGF8 is not the only factor involved in rostral forebrain formation since 
in FGF8 null mutant mice the telencephalon is still present although it is small and 
has patterning abnormalities (Storm et al., 2006; Wilson and Rubenstein, 2000; 
Shanmugalingam et al., 2000). Loss-of-function studies reveal a role in ventralisation 
of the telencephalon as there is a loss of the MGE and LGE structures in the absence 
of FGF8, which coincides with a reduction of ventral gene expression including 
Nkx2.1 and Dlx2, and an expansion of dorsal gene expression including Pax6 (Storm 
et al., 2006). Expression of Dlx2, but not Nkx2.1 has been shown to increase with 
increased FGF8 (Crossley et al., 2001).
One factor required for maintaining FGF8 expression is the signalling protein 
sonic hedgehog (SHH) (Ohkubo et al., 2002). SHH is a morphogen secreted from the 
notochord, which underlies the posterior structures of the brain and is thought to 
extend anteriorly as far as the posterior diencephalon, and the prechordal plate, which 
underlies the telencephalon (Rubenstein et al., 1998). It is important in embryonic 
development and patterning, as well as cancer progression and stem cell renewal, and 
is required for the generation and development of the mammalian telencephalon, 
giving rise to distinct neural progenitor subtypes in the ventral neural tube (Jessell,
2000). SHH has been shown to elicit its effect in a concentration-dependent gradient, 
for example in the patterning of the spinal cord the generation of motoneurons and
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intemeurons arise in distinct dorso-ventral progenitor domains according to the levels 
of expression of this morphogen (Jessell, 2000; Altaba et al., 2003). Both the level 
and duration of SHH expression are important for specification of ventral cell fates 
(Stamataki et al., 2005).
Expression of SHH is observed in the ventral telencephalon from El 1.5 in the 
developing brain (Kohtz et al., 1998). It plays an essential role in patterning of the 
forebrain in particular ventralising activity (Kohtz et al., 1998; Ericson et al., 1995; 
Chiang et al., 1996) and is both necessary and sufficient to induce expression of 
ventral forebrain markers (Chiang et al., 1996). In mice lacking SHH expression there 
is a complete absence of ventral forebrain structures, accompanied by an ectopic 
expression of dorsal forebrain markers in the ventral telencehalon (Chiang et al., 
1996), whereas over-expression of SHH results in the dorsal expansion of ventral- 
specific genes (Goodrich et al., 1997). Culture of telencephalon explants treated with 
SHH express ventral forebrain markers such as Nkx2A (Ericson et al., 1995), and 
misexpression of SHH in the cortex results in ectopic expression of Dlx2 and Nkx2.1 
(Kohtz et al., 1998).
SHH expression initiates a pathway involving patched and smoothened such 
that when hedgehog binds patched, patched is blocked and smoothened is de­
repressed. This activates Gli (glioma-associated oncogene homolog 3) which induces 
the target gene expression of the SHH pathway (Figure 1.5).
GliR
SHH | Patched | Smoothened — ► ^
GliA ___ ^  Target gene
expression
Figure 1.5. The SHH induction pathway for target gene expression. When SHH binds 
Patched, Patched is blocked and Smoothened is freed. The Gli repressor (GliR) becomes 
activated to the Gli activator (GliA) and this induces target gene expression of Hedgehog. 
Abbreviations: SHH -  sonic hedgehog; Gli -  glioma-associated oncogene homolog.
There are three members of the Gli family of zinc finger-containing 
transcription factors, which are homologues of the drosophila cubitus interruptus (Ci), 
namely Glil, Gli2 and Gli3. Gli transcription factors have been shown to regulate 
SHH-dependent gene expression. Stamataki et al (2005) showed that incremental
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changes in SHH concentration result in a gradient of Gli activity (Stamataki et al.,
2005). Glil and Gli2 proteins generally promote ventral patterning in response to 
SHH signalling. At low levels of SHH signalling, the Gli3 protein is cleaved from an 
activator into a repressor form that results in promotion of dorsal patterning. 
Inhibition of the GH3 repressor formation appears to be the primary role of SHH in 
telencephalic patterning, and in SHHl~\Gli3~l~ double mutants there is substantial 
rescue of ventral telencephalic patterning (including expression of Nkx2.1) (Gulacsi 
and Anderson, 2006).
Retinoic acid (RA) is the biologically active form of vitamin A. It has been 
implicated in survival, proliferation, specification and differentiation during forebrain 
development (Haskell and LaMantia, 2005; Marklund et al., 2004). RA is generated 
by members of the retinaldehyde dehydrogenase family, it elicits its effects through 
retinoic acid receptors (RAR) and retinoid X receptors (RXR), and subtypes (a, P, and 
y) of both receptor groups can be found in the developing striatum. RARp is 
selectively expressed in the LGE and RXRy is primarily expressed in the LGE with 
low levels in the MGE and no expression in the CGE. RXRy I"1' mutant mice exhibit 
specific reduction of choline acetyltransferase (ChAT) expression in the striatum, with 
no change in expression in GABA and TH (Saga et al., 1999). Loss of RARp in 
RARp1' mice results in reduction of striatal-enriched tyrosine phosphatase mRNA, a 
gene found to be regulated by RA, in the striatum (Liao et al., 2005), and loss of the 
compartmental structure of the rostral striatum, with a reduction in DARPP-32 
positive neurons as well as dynorphin, p-opioid receptor (MORI) and TH, compared 
with wild-type mice (Liao et al., 2008).
RA is required for forebrain development (Schneider et al., 2001; Ribes et al.,
2006), and its expression is maintained in forebrain regions throughout adult life 
(Haskell and LaMantia, 2005). Retinoid signalling has been shown to maintain FGF8 
and SHH expression in the forebrain (Schneider et al., 2001; Haskell and LaMantia, 
2005), and in the absence of retinoid signalling, expression of FGF8 and SHH is lost 
(Schneider et al., 2001).
The LGE appears to be a source of retinoid signalling, and retinoids from the 
glia of this region have been implicated in striatal neuronal differentiation (Toresson 
et al., 1999). In the developing chick telencephalon, RA has been shown to specify 
intermediate character. Blocking RA in chick embryos blocks expression of Meis2,
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which is expressed in progenitor cells in the intermediate zones of the telencephalon 
(Marklund et al., 2004). In Gsx2 mutant mice, where development of the 
telencephalon is perturbed and DARPP-32-expressing neurons are reduced, addition 
of exogenous RA results in an increase in the number of DARPP-32 positive neurons 
(Waclaw et al., 2004), thus RA is implicated in the regulation of DARPP-32 in the 
developing brain.
In vitro LGE cultures have been shown to be responsive to both RAR and 
RXR signalling, showing up-regulation of striatal neuron differentiation (Toresson et 
al., 1999). Supplementation of RA to LGE cultures induces an increase in DARPP-32 
expression (Toresson et al., 1999). This was observed at different RA concentrations 
(10‘7M and 10*8M) and was specific to the LGE, with no increase in DARPP-32 
expression detected in MGE or cortical cultures.
Wingless (Wnt) protein family of ligands are a class of secreted glycoproteins 
that regulate P-catenin activity and therefore gene transcription and have been shown 
to be important during development. Intracellular Wnt signalling can be divided into 
three pathways; the canonical pathway which involves the activation of p-catenin; the 
planar cell polarity pathway which involves jun N-terminal kinase (JNK); and the 
calcium pathway which involves calcineurin. The latter two are non-canonical 
pathways which are p-catenin-independent reviewed in (Huelsken and Behrens,
2002). It is the canonical pathway that is involved in telencephalon development.
In the canonical Wnt signalling pathway (Figure 1.6), Wnt binds to the 
membrane-bound receptor Frizzled which activates the intracellular component 
Dishevelled (Dsh). This destabilizes the complex formation between axin and 
glycogen synthase kinase 3p (GSK-3p) which in turn decreases the phosphorylation 
of p-catenin and prevents its degradation. P-catenin accumulates in the cytoplasm and 
is then translocated to the nucleus where it binds and activates target transcription 
factors of Wnt signalling such as T-cell factors (TCF). This regulates the expression 
of a variety of Wnt target genes such as c-myc and cyclin Dl. In the absence of Wnt 
the cytoplasmic P-catenin joins the axin and GSK-3P complex where it becomes 
phosphorylated and subsequently degraded, preventing its accumulation and 
translocation into the nucleus for gene activation.
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W nt
GSK30
APC A PC
D e g ra d a tio n
TCF TCF
Figure 1.6. The canonical Wnt signalling pathway for target gene expression. When Wnt 
binds Frizzled, Dsh is activated and inhibits formation of the axin-GSK-3p complex. This 
prevents the break-down of p-catenin and permits its translocation to the nucleus where it 
induces target gene expression. Abbreviations: APC - adenomatous polyposis coli; Dsh - 
Dishevelled; GSK3P - glycogen synthase kinase 3P; TCF - T-cell factor. (Taken from 
Frontiers in Bioscience 9 (Hsieh, 2004).
Using a reporter line where a LacZ  gene is under the control o f P-catenin/TCF 
responsive elements, the canonical W nt signalling pathway has been shown to be 
active in the pallium but not the subpallium o f the mouse telencephalon at El 1.5 and 
E l6.5 (Maretto et al., 2003; Backman et al., 2005). More recently, a reporter line 
using LacZ  tagged to Axin2 (a negative feedback regulator o f the Wnt pathway which 
is expressed in response to Wnt signalling) revealed Wnt signalling activity in the 
cortex and up to 5% o f cells in the subventricular zone, at E14.5 in the mouse brain 
(Kalani et al., 2008). Inhibition o f Wnt signalling has been reported to be necessary 
for telencephalic generation (Houart et al., 2002). In order to look at the effects o f 
canonical Wnt signalling in the telencephalon before neurogenesis, Backman et al 
(2005) generated a mouse line with a conditional Cre/loxP system to inactivate or 
activate p-catenin before or after neurogenesis in the telencephalon. The loss of p- 
catenin in the mouse telencephalon prior to the onset of neurogenesis leads to down- 
regulation o f the dorsal markers Em xl, Emx2 and Ngn2 (Backman et al., 2005). 
Interestingly, expression o f the dorsal telencephalic marker Pax6 was not down- 
regulated in this model at this time. Analysis o f the subpallial markers Dlx2, M ashl 
and Gsx2 pre-neurogenesis revealed their ectopic expression in the pallium of the 
inactivated-P-catenin mutant. The expression o f the MGE marker Nkx2.1 remained 
the same in both wild-type and mutant animals.
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In chick embryos sequential signalling of Wnt and FGF results in the 
specification of dorsal telencephalic cells (Gunhaga et al., 2003). During embryonic 
mouse development Wnt signalling is evident from E6.5, in the posterior region of the 
embryo (ten Berge et al., 2008). In the mouse telencephalon, activation of p-catenin in 
the subpallium results in reduced expression of the ventral markers Nkx2.1, Dlx2, 
Gsx2 and Mashl, along with expanded expression of the dorsal markers Pax6 and 
Ngn2 (Backman et al., 2005). This data implicates a role for canonical Wnt signalling 
in the specification of telencephalic cells by repressing induction of ventral character. 
Analysis of the expression of dorsal and ventral markers in the inactivated-P-catenin 
mutant following onset of neurogenesis revealed that there was no shift in the dorsal- 
ventral specification of cells of the telencephalon, as was observed pre-neurogenesis 
(Backman et al., 2005).
Loss of P-catenin in the ventral telencephalon caused reduced growth of the 
MGE with reduced proliferation of cells in this region but, although neuronal numbers 
were reduced, the differentiated fate of cortical intemeurons and subcortical 
cholinergic neurons from this region was largely unaltered (Gulacsi and Anderson,
2008).
Bone morphogenetic proteins (BMPs) belong to the TGF-P family of secreted 
growth factors. They are secreted by the roof plate, spread ventrally and influence the 
induction of dorsal neural cell types in a concentration-dependent manner. Signalling 
of FGF appears to be necessary for inhibition of BMP expression and the subsequent 
neural induction in the neural tube (Wilson and Rubenstein, 2000). Increased BMP4 
expression by implantation of BMP4-soaked beads results in a reduction of both 
FGF8 and SHH expression in the telencephalon (Ohkubo et al., 2002), and in the 
absence of RA there is a reduction in BMP4 expression (Wilson and Houart, 2004). 
Forebrain specification was repressed in telencephalic explant cultures treated with 
BMPs as shown by inhibition of Foxgl expression, as well as Nkx2.1 and DIx2 
(Furuta et al., 1997).
For normal neural development it is essential to have the right levels of the 
right molecules in the right region so that the appropriate levels of transcription 
factors are generated and subsequently cells are correctly specified according to their
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location, which then ensures the correct balance of mature phenotypes following 
differentiation.
1.6.2 Foxgl expression in the developing telencephalon
The earliest known marker of the telencephalon is Foxgl (forkhead box Gl), 
formerly known as Brain factor 1 (BF-1) (Tao and Lai, 1992). Foxgl is a member of 
the winged helix family of transcription factors and in mammals was first identified in 
the developing rat brain with an expression pattern restricted to the telencephalon of 
the forebrain (Tao and Lai, 1992). This initial study revealed high levels of Foxgl, 
detected by in situ hybridization, from E10 in the developing rat telencephalon and 
reported the absence of expression in the neighbouring diencephalon (Tao and Lai, 
1992). From this it was suggested that Foxgl might have a role in telencephalon 
development including establishing boundaries between the forebrain subdivisions.
Xuan et al (1995) generated mice with a null mutation in the Foxgl gene. By 
replacing most of the Foxgl coding sequence with a LacZ and neomycin cassette, the 
expression of the (3-galactosidase enzyme is under the control of the Foxgl promoter. 
X-Gal histochemistry revealed Foxgl expression in the neural tube from as early as 
E8.5 and E9.0, and at this stage there was no difference in Foxgl expression between 
wild-type and Foxgl'1' mice. From E l0.5 the size of the telenecephalon was greatly 
reduced compared with the wild-type and this was further exacerbated by E l2.5 
(Xuan et al., 1995; Martynoga et al., 2005).
In the Foxgl'1' mutant telencephalon there is a significant reduction in the 
expression of FGF8 at E l0.5, as compared with wild-type (Martynoga et al., 2005). 
This reduction is not due to an increase in apoptosis in this region, since apoptosis 
was shown to decrease in the Foxgl'1' mutant telencephalon at this age (Martynoga et 
al., 2005). BMP expression is increased (indicated by immunohistochemistry for the 
tyrosine-phosphorylated forms of Smad-1, 5 and 8; direct effectors of BMP 
signalling) at El 1.5 in the Foxgl'1' mutant telencephalon, but not at the earlier time 
point of E l0.5 where the reduction of FGF8 was observed and Wnt signalling does 
not appear to be affected (Martynoga et al., 2005).
Furthermore, Xuan et al., (1995) showed that it is the ventral telencephalon 
that is more severely affected than its dorsal counterpart, and at E l2.5 the ganglionic
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eminences were not present in the Foxgl'1' mutants. In addition they reported the 
presence of the dorsal telencephalic markers Emx2 and Pax6, but not the ventral 
telencephalic markers Dlxl and Dlx2. Analysis of region-specific markers of the 
ventral telencephalon, comparing wild-type and Foxgl'1' mutant telencephalon, 
reveals the absence of Nkx2.1 and Mashl from the ventral region at E9.5, and Gsx2 at 
E l0.5 (Martynoga et al., 2005). This is consistent with earlier findings that report the 
absence of expression of the ventral markers Nkx2.1, Dlxl/2 and Gsx2 throughout the 
telencephalon at E l2.5 (Xuan et al., 1995; Dou et al., 1999). In addition, there is an 
increase in expression of dorsal markers, such as Pax3, whose expression reveals an 
expanded dorsal region in the Foxgl'1' mutant, and Pax6, whose expression expands 
throughout the telencephalon rather than being restricted to only the dorsal-most 
region (Martynoga et al., 2005). Studies in the developing cortex have reported that 
Foxgl suppresses the production of the earliest bom neurons and in Foxgl'1' mutants 
these neurons are over-generated (Hanashima et al., 2004).
Analysis of cell proliferation by labelling with bromodeoxyuridine (BrdU) 
revealed that only cells of the dorsal telencephalon, and not the ventral telencephalon, 
are actively proliferating which suggests that it is the lack of proliferating precursor 
cells in the ventral telenecephalon that is responsible for the absence of this region. A 
more recent study (Martynoga et al., 2005) introduced a BrdU and iododeoxyuridine 
(IddU) double-labelling protocol to determine total cell cycle time and the length of S- 
phase in the cell cycle. They reveal an increase in cell cycle time in the Foxgl'1' 
mutant telencephalon however they did not observe this increase in ventral regions 
(Martynoga et al., 2005) as reported previously (Xuan et al., 1995).
Recently Foxgl has been shown to co-ordinate the signalling pathways of 
SHH and Wnt/p-catenin, which are independently required for development of the 
subpallial and pallial telencephalon, respectively (Danesin et al., 2009). Danesin et al 
(2009) demonstrate that Foxgl inhibits dorsal identity via the inhibition of the Wnt/p- 
catenin pathway, and confirm the requirement of Foxgl for ventral telencephalic 
identity, but reveal that Foxgl and SHH act independently in their induction of ventral 
fates.
The studies mentioned here support Foxgl as an integral part of forebrain 
development and reveal its requirement for the expression of ventral telencephalic 
markers.
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1.6.3 Dorso-ventral organisation in the developing telencephalon
As mentioned earlier, the developing telencephalon can be divided into the 
dorsal/pallial portion which is the developing cortex, and the ventral/subpallial portion 
which is made up o f the MGE and LGE. There are distinct boundaries between the 
dorsal and ventral regions, and between the two ventral subdivisions, the LGE and 
MGE, in terms o f gene expression (Figure 1.7). In the dorsal telencephalon Pax6, 
Ngnl/2 and Emxl/2 genes are expressed; in the ventral telencephalon Gsx2, Mashl, 
Dlxl/2 and Nkx2.1 are expressed. Nkx2.1 is specific to the MGE; Gsx2, Mashl and 
Dlxl/2 genes are expressed predominantly in the LGE although they are not 
necessarily specific to this domain.
Figure 1.7. Coronal schematic section through the telencephalon showing the dorsal and 
ventral domains defined by distinct gene expression patterns. Dorsal telencephalic markers 
include Emxl/2 , Ngnl/2  and Pax6, and ventral telencephalic markers include Mashl, Dlxl/2, 
Gshl/2 (now Gsxl/2) and Nkx2.1. Figure adapted from (Schuurmans and Guillemot, 2002).
Pax6 is a paired homeodomain gene essential for the proper development o f 
cortical progenitors and its expression is restricted to proliferating precursors in the 
developing cortex (Toresson et al., 2000). Emxl is a marker o f the dorsal 
telencephalon and its expression domain is further limited to the dorsal region o f the 
cortex, with no expression in the ventral portion o f the cortex. Neurogenin 1 (Ngnl) 
and neurogenin 2 (Ngn2) genes encode basic helix-loop-helix (bHLH) transcription
Obtl/2
33
Chapter 1 Introduction
factors that are necessary for determining dorsal telencephalic phenotype. Ngnl/2 are 
expressed throughout the cortex along with Pax6.
Pax6 expression is first observed in the developing forebrain at E8.0 
(Stoykova and Gruss, 1994). Pax6 mutant mice, also known as the Small eye (Sey) 
mutation, have patterning defects in the forebrain with abnormal development 
involving a shift in the cortical-striatal boundary (Stoykova et al., 1997) and 
expression of other dorsal markers such as Ngnl/2 and Emxl are down-regulated in 
the cortical region (Toresson et al., 2000; Stoykova et al., 2000). Ventral markers of 
the LGE, Dlxl/2 (Stoykova et al., 1996; Stoykova et al., 2000; Toresson et al., 2000), 
Mashl (Toresson et al., 2000; Stoykova et al., 2000) and Gsx2 (Toresson et al., 2000) 
show ectopic expression across this boundary into more dorsal regions of the Pax6 
mutant telencephalon, and expression of the MGE marker Nkx2.1 expands dorsally 
into the LGE and shifts the LGE-MGE border (Stoykova et al., 2000).
The neurogenins Ngnl and Ngn2 are expressed exclusively in the dorsal 
telencephalon and loss-of-function analysis reveals their requirement for the 
maintenance of the dorsal-ventral boundary in the developing telencephalon (Fode et 
al., 2000). In the absence of Ngn expression the ventral marker Mashl is ectopically 
expressed in the dorsal telencephalon, resulting in dorsal cells acquiring a ventral fate. 
This subsequently alters the specification of a subset of cortical neurons to express the 
ventral markers Dlxly Dlx2 and GAD 65/67, which is expressed by ventral 
telencephalic neurons and encodes the enzyme required for biosynthesis of the 
neurotransmitter GAB A.
In the wild-type developing forebrain, expression patterns of the ventral gene 
Gsx2 and the dorsal gene Pax6 are complementary. Further, these two genes have 
been shown to cross-repress each other in order to generate the cortical-striatal 
(pallial-subpallial) boundary and correct regional expression of each is dependent on 
the other. The regions of the pallium and subpallium that are immediately proximal to 
this boundary have been termed the ventral pallium and the dorsal LGE (dLGE), and 
in the dLGE expression of Pax6 and Gsx2 overlaps at E l0.5 in the mouse (Yun et al.,
2001). The pallial-subpallial boundary (PSB), a source of a subgroup of Cajal-Retzius 
cortical neurons and olfactory bulb intemeurons, requires both Pax6 and Gsx2 for 
correct expression of PSB-specific genes (Carney et al., 2009).
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Gsx2 (formerly Gsh2) is a homeobox gene (Hsieh-Li et al., 1995) with 
expression first detected in the developing forebrain between E9 and E10 and during 
early telencephalic development it is restricted to the prospective LGE. It is essential 
for the early expression of a number of genes that mark various aspects of 
specification and differentiation of the LGE (Corbin et al., 2000). Gsx2 is also 
essential for specification of distinct cell populations and the establishment of the 
molecularly defined boundary between the developing cortex and the LGE.
Loss of Gsx2 in Gsx2~' mutants results in loss of Mashl and Dlx2 (Szucsik et 
al., 1997; Corbin et al., 2000; Toresson et al., 2000), accompanied by expansion of 
dorsal markers Pax6 and Ngn2 into the LGE (Corbin et al., 2000; Toresson et al., 
2000). Overall there is a reduction in LGE size from E12 (Szucsik et al., 1997), 
reduction in striatum size at E l8.5 (Wang et al., 2009) and reduced expression of 
striatal projection neurons which originate in the LGE (Deacon et al., 1994; Olsson et 
al., 1998). Interestingly the decreased Dlx2 is more pronounced in LGE than MGE, 
and expression of the MGE specific marker Nkx2.1 is not affected by the loss of Gsx2 
(Szucsik et al., 1997). From these loss-of-fimction studies it has been established that 
Gsx2 is required for the early expression of Mashl, Dlxl and Dlx2 in the ventral 
telencephalon, and promotes expression of these ventral genes while repressing dorsal 
character via cross-repression with Pax6. In the Gsx2 l',Pax6’l~ double mutant there is 
rescue of the telencephalic defects reported in the single mutants of these genes 
(Corbin et al., 2003).
Gain-of-function studies with Gsx2 revealed no ectopic expression of Dlx2 or 
Mashl, nor inhibition of the dorsal markers Pax6 and Ngn2, but it did cause ectopic 
expression of the retinol binding protein (RBP) normally expressed in LGE radial 
glial cells, which is not lost in the Gsx2~' mutant (Corbin et al., 2000). In SHH 
knockout mice the striatum is lost (Chiang et al., 1996) along with loss of Gsx2 and 
RBP in the forebrain (Corbin et al., 2000). In addition, mis-expression of SHH by 
injection of a SHH-expressing retrovirus in vivo resulted in ectopic expression of 
Gsx2. Taken together this indicates that Gsx2 is a downstream target of SHH 
signalling (Corbin et al., 2000).
Mashl, also called Ascll (Mouse Genome Informatics) is a basic helix-loop- 
helix (bHLH) gene which has been shown to be essential for proper development of 
the ventral telencephalon (Casarosa et al., 1999). In contrast to the dorsal bHLH genes
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Ngnl/2 which are expressed only in the dorsal telencephalon, Mashl expression is 
seen throughout the ventral telencephalon in a complementary pattern to Ngnl/2 
(Fode et al., 2000). Analysis of mutant mice that lack Mashl {Mashl'1') reveals 
defects in the developing telencephalon including a reduction in size of the MGE and 
loss of early bom striatal neurons (Casarosa et al., 1999). Expression of Gsx2 in the 
M ashl1' mutant is similar to that in the wild-type at E12.5, but by E l8.5 there is an 
increase in Gsx2-expressing cells indicating a potential repressive function of Mashl 
on Gsx2 at a later developmental time point (Wang et al., 2009).
Expression of the dorsal marker Ngn2 in the Mashl'1' mutant is similar to that 
in the wild-type (Wang et al., 2009), whereas in the Gsx2~,~ mutant, dorsal character 
expands ventrally with expression of Ngn2 (Corbin et al., 2000; Wang et al., 2009) 
and Pax6 (Corbin et al., 2000) observed in the LGE.
Gsxl, a gene closely related to Gsx2, is also expressed in the ventral 
telencephalon and has been implicated in partially compensating ventral 
telencephalon patterning in Gsx2'/' mutants (Wang et al., 2009). In the Gsx2''' mutant, 
expression of Gsxl and Mashl is similar in the LGE. DARPP-32 expression is absent 
and calbindin expression is maintained in both Gsx2'l'\Mashl~1' and Gsx2'l';Gsxl'/' 
double mutants. The similarities in mutant phenotypes suggest that Mashl is 
necessary for the role of Gsxl in striatal compensation in GSX2'1' mutants (Wang et al.,
2009).
Analysis of the striatal neuronal marker FoxPl at E l8.5 reveals a slight 
reduction of expression in the Mashl'1' mutant, a more marked reduction of 
expression in the G sxl1' mutant and a severe reduction in the Gsx2' '\Mashl' ' double 
mutant (Wang et al., 2009). A similar pattern is seen with DARPP-32, the striatal 
projection MSN marker, with the Gsx2'l'\MashV1' double mutant exhibiting a 
complete loss of DARPP-32 expression in the striatum (Corbin et al., 2000; Wang et 
al., 2009). Interestingly expression of the striatal-matrix marker calbindin is reduced 
in the Mashl'1' striatum and slightly increased in both the Gsx2' ' and Gsx2'l'\Mashl'1' 
striatum (Corbin et al., 2000; Wang et al., 2009).
Distal-less homeobox (Dlx) 1 and 2 genes have almost identical expression 
patterns in the developing brain (Bulfone et al., 1993). Bulfone et al looked at the 
expression at E l2.5 and observed that in the telencephalon, both Dlxl and Dlx2 were
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found to be expressed in the MGE, the LGE and the septum, and the only difference 
in expression in these areas was the intensity of the hybridization signal, which was 
always greater for Dlxl. Dlxl/2 expression patterns suggest a role in striatal 
development and evidence supports a role in differentiation of the basal ganglia and 
migration of cells from the subcortical telencephalon to the neocortex (Anderson et 
al., 1997a; Anderson et al., 1997b). Single mutants of Dlxl and Dlx2 have almost no 
forebrain defects, but double Dlxl/2 mutants reveal marked abnormalities in the 
development of the striatum, specifically LGE (Nery et al., 2003; Anderson et al., 
1997b).
Expression of these genes begins when progenitors move from the ventricular 
zone (VZ) into the sub-ventricular zone (SVZ) and later these DZx-expressing cells 
migrate away from this proliferative zone to various regions of the brain and Dlx 
expression is switched off when the cells differentiate (Nery et al., 2003). Dlx2- 
expressing cells are highly migratory, following which they differentiate into 
intemeurons (Anderson et al., 1997a). Overexpression of Dlx2 can induce 
telencephalic progenitors to express GAD65/67 (Stuhmer et al., 2002a). Analysis of 
mice with the tauLacZ reporter gene inserted into the Dlx2 locus shows migration of 
D/jc2-expressing cells firstly to the cortex from E13.5 onwards and later to the 
olfactory bulb and hippocampus (Nery et al., 2003). Another fate-mapping study 
supports the presence of Dlx cells expressing GABA in the cortex (Stuhmer et al., 
2002b). Further Dlxl/2 double mutants display a reduction in cortical GABAergic 
intemeurons (Anderson et al., 1997a) and a loss of later bom striatal matrix neurons 
that are believed to be derived from the SVZ (Anderson et al., 1997b).
Nkx2.1, also known as thyroid transcription factor 1 (TTF1) (Mouse Genome 
Informatics) is another homeodomain-containing transcription factor. It is expressed 
in the medial subdivision of the WGE, is required for the development of this region 
and functions to repress LGE character in the MGE. Expression of Nkx2.1 is induced 
by SHH (Ericson et al., 1995). Inhibition of SHH results in reduced expression of 
Nk2.1 in the MGE (Gulacsi and Anderson, 2006) with dorsalisation of the ventral 
telencephlaon (Chiang et al., 1996) and overactivation of SHH signalling results in the 
dorsal expansion of Nkx2.1 (Goodrich et al., 1997). Loss of GH3 however does not 
cause dorsalisation of the MGE suggesting that the SHH-induced Nkx2.1 expression is 
independent of GH3.
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In the absence of Nkx2.1, in Nkx2.1'1' mice, the MGE fate converts to that of 
the LGE, with some MGE-like cells expressing DARPP-32 (Sussel et al., 1999). 
Generation of Nkx2.1~/' mutants with the Dlx2 tauLacZ reporter gene revealed loss of 
Dlx2 early in development but not later (Nery et al., 2003). The Nkx2A''' mutant 
results in loss of GABA and calbindin positive neurons from the cortex, and also loss 
of striatal cholinergic cells (Sussel et al., 1999). In Nkx2.rl';Gsx2~1' double mutant 
mice the combined loss of these medial and lateral ventral telencephalon genes results 
in more profound effects on regional patterning of the MGE and LGE (Corbin et al.,
2003).
In the knockouts of Dlxl/2 , Mashl and Nkx2.1 a reduction in cortical 
intemeurons is observed (Anderson et al., 1997a; Anderson et al., 1997b; Casarosa et 
al., 1999; Sussel et al., 1999; Marin et al., 2000). The cortical intemeurons of Gsx2 
mutants are unaffected and it is the olfactory bulb intemeurons that are altered in this 
case (Corbin et al., 2000). This suggests a role for Gsx2 in olfactory bulb intemeuron 
differentiation and migration. These factors are essential for establishment of regional 
specification during development and also the subsequent identity of mature neurons 
that originate in the specified regions. The window of expression and balance between 
these dorsal-ventral transcription factors are important in ensuring the identity of cells 
in the correct region.
1.7 Directed differentiation o f ES cells
Mouse ES cells in vitro are maintained in their self-renewing, pluripotent state 
in the presence of leukaemia inhibitory factor (LIF) and upon withdrawal of this 
cytokine ES cells lose this undifferentiated state and begin to differentiate. For in vitro 
differentiation of ES cells, different induction conditions are applied depending on the 
cell type of interest. Mouse ES cells can be induced to differentiate into a neural 
lineage (Bain et al., 1995; Okabe et al., 1996). The original approach towards 
promoting neural cell populations involved culture of mouse ES cells in 
bacteriological dishes where they grow as free-floating multicellular aggregates 
termed embryoid bodies (EB) (Bain et al., 1995). In this study EBs were cultured for
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4 days without RA followed by 4 days with RA in medium without LIF or P- 
mercaptoethanol, and the initial cell-seeding density was arbitrarily determined as a 
‘quarter of a confluent flask’. When these aggregates were dissociated and plated as a 
monolayer, cells developed a neuronal appearance and 38% were immuno-reactive for 
the neuronal marker p-III-tubulin, whereas untreated aggregates generated no p-III 
tubulin positive neurons.
Suspension culture of EBs for 4 days followed by attachment to substrate and 
change of culture medium to DMEM/F12 supplemented with insulin, transferrin, 
selenium and fibronectin (ITSF medium) for 6 days resulted in 84% cells showing 
immuno-reactivity for the neural precursor marker nestin (Okabe et al., 1996). These 
factors have a role in cell survival with insulin in particular shown to be specific for 
survival of nestin-positive cells. Addition of basic FGF to the culture medium resulted 
in increased proliferation of nestin-positive cells and subsequent differentiation in the 
absence of basic FGF revealed a threefold decrease in nestin-positive cells and three- 
to four-fold increase to 60% in MAP2-positive neurons (Okabe et al., 1996).
It has been shown that mouse ES cells will survive, proliferate and 
differentiate in serum-free medium (Johansson and Wiles, 1995), and can yield 
neuroectodermal cells under these conditions (Ying et al., 2003). This indicates that 
the intermediate step of EB generation prior to neural precursor cell (neural lineage) 
induction can be by-passed. Direct transfer of mouse ES cells to suspension culture 
with no serum, but bovine serum albumin (BSA), synthetic lipids, LIF, transferrin and 
insulin, collectively termed chemically defined medium (CDM), results in 
differentiation as neural embryoid bodies (NEB) with up-regulation of neuroectoderm 
and telencephalic precursor marker Pax6 (Wiles and Johansson, 1999). This study 
showed that with addition of activin the aggregates generate both mesoderm and Pax6 
in parallel, but a dose response of BMP4 reveals that Pax6 expression is inversely 
related to BMP4 concentration.
Continued investigations into the serum-free (CDM) suspension culture 
system have shown the importance of an optimal cell-seeding density for suspension 
cultures from ES cell colony dissociation (Bouhon et al., 2005; Watanabe et al., 
2005). The neurogenic potential of the suspension cultures has been reported 
following immunocytochemistry identifying nestin, soxl and RC2 immuno-positive 
cells following 8 days in CDM and when these cells are dissociated and plated onto 
substrate they are seen to express p-III tubulin (Bouhon et al., 2005). Fluorescence
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activated cell sorting (FACS) analysis reveals 83% nestin positive cells at day 2 and a 
decrease to 67% by day 8 in CDM suspension culture. With addition of FGF2 to the 
medium the percentage of nestin positive cells at day 8 is more similar to that seen at 
day 2 in CDM alone. Cultures beyond day 8 are dependent on FGF2 for maintenance 
(Bouhon et al., 2005). Markers of the developing neural tube were seen to up-regulate 
between day 4 and day 8 in CDM culture, including Pax6 (dorsal telencephalon 
marker) and Gsx2 (ventral telencephalon marker) (Bouhon et al., 2005).
Wnt signals have been shown to inhibit neural differentiation of EBs in vitro 
(Aubert et al., 2002). Within EBs, activation of the Wnt pathway is necessary for 
establishing the anterior-posterior axis (ten Berge et al., 2008). Addition of exogenous 
Wnt induces posterior character with mesendodermal differentiation, while inhibiting 
Wnt signals induces anterior character with neuroectodermal differentiation (ten 
Berge et al., 2008).
In the serum-free suspension culture system expression of Wnt3a is not 
detected at day 2 but is detectable from day 4 through to day 8 (Bouhon et al., 2005). 
Supplementing CDM with BMP, LiCl (to mimic Wnt signalling), an FGF receptor 
anatagonist and a Hedgehog antagonist reduced the percentage of neural precursors as 
shown by immunocytochemistry with Soxl (Bouhon et al., 2005). Using an ES cell 
line where the reporter GFP is tagged to Soxl, separate addition of Wnt3a, Nodal (a 
member of the TGF-p ligand superfamily) and BMP each causes a decrease in Soxl- 
positive cells (Watanabe et al., 2005). The anti-Nodal agent, LeftyA, and the anti-Wnt 
reagent DKK-1, together caused an increase in Soxl positive cells, but individually 
there was only a small non-significant increase and anti-BMP reagents did not have an 
effect on the Soxl population (Bouhon et al., 2005). Interestingly, a study looking at 
the effect of Soxl on telencephalic neural progenitor cells (from El 2-El 6 mouse 
ganglionic eminences) reported that neurosphere formation was not compromised 
with reduced or absent Sox 1 expression, however subsequent differentiation resulted 
in a significant reduction of p-III-tubulin positive neurons, compared to wild-type 
derived cultures (Kan et al., 2007).
Addition of DKK-1 during days 0-5 of NEB culture caused an increase in the 
percentage of Foxgl positive cells (from 15% to 30%), and this increase was 
counteracted by addition of Wnt3a (Watanabe et al., 2005). DKK-1 did not affect the 
percentage of cells positive for TH, 5-HT and Tujl. With addition of both DKK-1 and 
LeftyA, Foxgl positive cells increased to 35%. Late addition of Wnt to serum-free
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suspension cultures did not significantly alter the Foxgl population, but within the 
Foxgl population there was a reduction of ventral telencephalic markers Nkx2.1 and 
Gsx2, and an increase in the percentage of the dorsal telencephalic marker Pax6 
(Watanabe et al., 2005).
Analysis of rostral markers revealed that SHH addition to serum-free 
suspension culture increased Nkx2.1 positive cells and decreased Pax6 and Emxl 
positive cells, and did not have a significant effect on Gsx2 and Mashl, without 
affecting the Foxgl population (Watanabe et al., 2005). This indicates that SHH does 
not have an affect on anterior-posterior patterning but does alter dorsal-ventral 
patterning within the forebrain population. Inhibition of SHH in defined serum-free 
medium with the SHH antagonist cyclopamine resulted in increased expression of the 
dorsal markers Emxl and Pax6, and decreased expression of the ventral markers Dlxl, 
Gsx2 and Nk2.1, without altering the nestin neural precursor population (Gaspard et 
al., 2008).
Exposing ES cell cultures to signals indicative of regionalisation and 
specification can direct their differentiation towards a specific phenotype. Addition of 
SHH and RA, which induced ES cells to differentiate into motoneurons (Wichterle et 
al., 2002) has provided proof-of-principle for this strategy of applying knowledge of 
developmental biology to ES cell differentiation. Further, Soundarajan et al (2006) 
found that treatment with a SHH agonist and RA (both at lO^M), induced ES cells to 
differentiate into functional motoneurons specific to the medial motor column 
(Soundararajan et al., 2006). Functional GABAergic and glutamatergic neurons have 
been generated in defined serum-free culture conditions with a greater proportion of 
glutamatergic neurons generated in the presence of cyclopmine (Gaspard et al., 2008). 
Together, this demonstrates the potential to direct ES cells to functional mature 
neuronal phenotypes.
Time and length of exposure have also been implicated as important factors 
when treating cultures to direct neural differentiation. Early exposure of EBs to high 
RA concentrations (5xl0'7M) has been shown to promote neural differentiation of ES 
cells (Bain et al., 1995), but also results in ablation of the forebrain markers Foxgl 
and Otx2 and induction of caudal markers (Irioka et al., 2005; Watanabe et al., 2005). 
Later addition results in only suppression of forebrain markers alongside induction of 
caudal markers (Watanabe et al., 2005). This supports the theory of specific time 
windows for addition of factors in influencing the fate of neural precursor cells.
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When added to cultures of mouse ES cells, RA induces concentration 
dependent effects on neural differentiation. Ngn2 expression is enhanced by high RA
n
concentrations (>10‘ M), whilst at lower concentrations, mesodermal (Brachyury) and 
endodermal (Pdxl) markers are detected. It has also been demonstrated that higher 
RA concentrations induce a dorsal phenotype, while lower RA concentrations induce 
a more ventral phenotype, as indicated by expression of ventral genes such as Nkx2.2 
(Okada et al., 2004). This induction of ventral neural progenitors with low RA 
concentrations occurred as a result of increased expression of the N-terminus of SHH 
protein, and the effect was abolished upon addition of the SHH antagonist 
cyclopamine (Okada et al., 2004).
Notably, expression of the ES cell specific marker Oct-3/4 is shown to persist 
following four days in CDM, albeit to a lesser degree than the same time in the 
presence of serum, as shown by the use of an ES cell line where LacZ expression is 
under the control of the Oct-3/4 promoter (Bouhon et al., 2005). Oct-3/4 expression in 
serum-free suspension culture down-regulates over time as shown by RT-PCR 
(Bouhon et al., 2005) and immunocytochemistry (Watanabe et al., 2005), however 
RT-PCR does still reveal evidence of a faint band at day 8, and 
immumocytochemistry indicates that a very low percentage of cells are still 
expressing Oct-3/4 (Bouhon et al., 2005; Watanabe et al., 2005).
The mouse ES cell culture system offers a robust model that is easy to 
manipulate, enabling integration of reporter systems for analysis of genes of interest 
in response to signalling cues. Although there are some differences in the maintenance 
of mouse ES cells compared to human ES cells, their fundamental properties are 
transferable, including the capacity to respond to developmental cues. Mouse ES cells 
require LIF in order to maintain their self-renewal and pluripotency characteristics, 
and in the presence of LIF and serum or serum-replacement, can be maintained in 
vitro indefinitely. Human ES cells are insensitive to LIF and until recently were 
reliant upon the presence of feeder layers for maintenance (Thomson et al., 1998). 
Some of the shared characteristics of mouse and human ES cells include expression of 
the ES cell marker Oct-3/4, telomerase activity and the capacity to form teratomas 
containing derivatives of the three germ layers (Thomson et al., 1998; and reviewed in 
Wobus and Boheler, 2005). Human ES cells exhibit a slower growth rate than mouse 
ES cells and are more susceptible to cell death upon dissociation. One study looked at
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addition of a Rho-associated kinase (ROCK) inhibitor, an inhibitor of apoptosis, to 
attempt to overcome this problem of cell death, and demonstrated that dissociation- 
induced apoptosis was significantly reduced compared to untreated human ES cells 
(Watanabe et al., 2007). Further, when they applied the ROCK inhibitor to serum-free 
suspension culture for neural induction, they were able to generate 30% Foxgl 
positive cells, 95% of which expressed the dorsal telencephalic marker Pax6 
(Watanabe et al., 2007).
Various methods have been utilised for neural lineage derivation from human 
ES cells, including co-culture on stromal cells, which induces formation of neural 
rosettes, with subsequent culture of cells attached to substrate (Perrier et al., 2004; 
Aubry et al., 2008); stromal cell co-culture followed by suspension culture and then 
further differentiation on substrate (Park et al., 2005); and direct transfer of ES cells to 
defined neuralizing medium under substrate and feeder-free conditions (Joannides et 
al., 2006; Joannides et al., 2007a). Stromal-feeder induction of neural precursors from 
human ES cells yields a decrease in expression of ES cell markers, such as Oct-3/4, 
with an increase in both Pax6 and MAP2 expression over time (Perrier et al., 2004). 
Neural rosettes following sequential application of SHH, FGF8, BDNF, ascorbic acid, 
GDNF, dibutyryl cAMP and TGF|33, resulted in 30-50% p-III-tubulin positive 
neurons, with 64-79% of these expressing TH and 1-2% expressing GAB A (Perrier et 
al., 2004). Application of a similar protocol of sequential addition of factors, but with 
the notable inclusion of DKK-1 and exclusion of FGF8 and GDNF, resulted in 22% 
MAP2 positive neurons, of which 36% expressed GABA, 53% expressed DARPP-32, 
10% expressed calbindin and less than 2% expressed TH (Aubry et al., 2008).
Culture of human ES cells in suspension with defined human neuralizing 
medium which included human serum albumin, transferrin, insulin, as well as amino 
acids and lipids, resulted in expression of immature neural markers including Soxl 
and Pax6 (Joannides et al., 2007b; Joannides et al., 2007a). Following 14 days 
terminal neuronal differentiation of these cells at day 25, 95% of the population 
expressed P-III-tubulin, and at day 70, 60% expressed p-III-tubulin (Joannides et al., 
2007b). Further analysis of the day 70 derived neurons revealed that 55% expressed 
GABA and 34% expressed glutamate (Joannides et al., 2007b).
A novel method for neural induction of human ES cells uses two inhibitors of 
SMAD signalling (activated in the BMP signalling pathway), noggin and SB431542, 
which have previously been shown to enhance neural induction (Lee et al., 2007;
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Elkabetz et al., 2008; Smith et al., 2008), in order to avoid the use of stromal feeder 
layers (Chambers et al., 2009). Addition of both inhibitors resulted in an increase in 
Pax6 expression to 80% of the total population by day 7 in culture. There was also an 
increase in other neural markers Otx2, Foxgl and Soxl, with a decrease in Oct-3/4 
expression. The generation of such protocols helps to lead the way for more specific 
induction of ES cells to lineages whilst concomitantly avoiding potential 
contamination from feeder cells and associated medium components.
One issue regarding the neural induction protocols with ES cells is that 
differentiation is not exclusively neural and the resulting population is often 
heterogeneous containing multiple cell types. The continued presence of 
undifferentiated ES cells in the culture system makes this cell source less attractive as 
a prospect for transplantation due to their potential to form teratomas. To reduce the 
risk of teratoma formation cell populations could be subjected to purification using 
techniques such as FACS, or magnetic activated cell sorting (MACS), or integration 
of DNA plasmids with antibiotic resistance linked to a specific gene, into an ES cell 
line, which would enable selection of cells expressing the gene of interest. Another 
strategy involves increased differentiation of ES cell-derived precursors in culture 
prior to transplantation in order to encourage down-regulation of pluripotency 
markers, and with addition of the patterning factors known to be required for correct 
neural developmental, specifically directing cells towards the desired phenotype.
However, this is not the only issue that needs to be overcome prior to clinical 
translation, and of equal importance is the reliable and reproducible production of a 
defined phenotype that not only has the capacity to survive, but also to function 
following transplantation into the brain. Since primary foetal tissue has provided the 
proof-of-principle for cell replacement studies and is the current ‘standard’, it is 
important, when assessing alternative cell sources, to refer to this ‘standard’ and be 
able to draw comparisons.
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1.8 Aims o f this thesis
Introduction
It is evident from the research outlined above that transplantation into the 
neurodegenerative HD brain is a viable strategy for repairing circuitry and function, 
and although it is unlikely to be the sole therapy responsible for a cure, it has the 
potential to alleviate some of the symptoms associated with the disease. The 
experiments in this thesis will explore ES cell-derived neural precursors as an 
alternative cell source for transplantation in HD. Information obtained from 
developmental biology which gives an insight into the development of the cell type of 
interest will be applied in order to attempt to direct ES cell differentiation and 
generate specified neural precursors, which have the capacity to differentiate into the 
desired mature MSN phenotype that is lost in HD.
Chapter 3 addresses forebrain characterisation and specification of NEBs 
including addition of factors known to be important in the developing neural tube. In 
Chapter 4 NEBs following different times in neural induction culture are transplanted 
into the QA-lesioned rat striatum model of HD in order to assess survival and 
differentiation in vivo. NEBs are then further treated with both a SHH agonist and 
antagonist in Chapter 5 in order to determine the effects of this morphogen on the 
dorsal-ventral patterning of these cells. Following this, in Chapters 6 and 7, the 
mature phenotypes of the NEBs after differentiation in vitro and in vivo (in the mouse 
QA-lesion model) are investigated to confirm or deny the presence of the MSN 
marker DARPP-32 as well as other neuronal markers.
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Chapter 2
Materials and Methods
2.1 In vitro methods
2.1.1 Mouse ES cell culture
ES cells were maintained in ES cell culture medium which consisted of 
Iscove’s modified Dulbecco’s medium (IMDM) (Gibco, Invitrogen, Paisley, 
Scotland, UK), supplemented with 15% ‘knock-out’ serum replacement (KSR) 
{Gibco), 1% penicillin/streptomycin (PS) {Gibco), non-essential amino acids (MEM) 
(ImM) {Gibco), L-glutamine (2mM) {Gibco), p-mercaptoethanol (0.1 mM) {Sigma, 
Gillingham, Dorset, UK) and leukaemia inhibitory factor (LIF) (produced ‘in-house’ 
as described in Appendix 5).
ES cells were maintained on 10cm tissue culture treated petri-dishes {Nunc, 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK) coated with 0.1% 
gelatin in Ultrapure water {Chemicon International, Chandlers Ford, Southampton, 
UK). Medium was changed daily and cultures were passaged when sub-confluent 
(every 2-3 days) using 0.1% trypsin/EDTA {Gibco). For passaging, ES cell culture 
medium was aspirated off and cells were washed with phosphate buffered saline 
(PBS) pH 7.4 {Gibco), then lifted off culture dishes using 0.1% trypsin/EDTA, 
incubated at 37°C for 2-3 minutes and this enzymatic reaction was stopped by 
addition of ES cell culture medium. Cells were harvested from the culture dishes and 
collected by centrifugation at lOOOrpm for 3 minutes. The resulting pellet was 
resuspended in ES cell culture medium followed by re-plating according to the 
desired ratio for the split, usually 2 x 106 cells per 10cm plate.
2.1.2 Freezing and thawing mouse ES cells
For freezing ES cells were washed with PBS, incubated at 37°C for 2-3 
minutes in 0.1% trypsin/EDTA at 37°C, harvested from the culture dishes following 
addition of ES cell culture medium and centrifuged at lOOOrpm for 3 minutes. Frozen
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stocks were made by freezing cells at the desired density, usually 2 x 106 cells/ml, in 
10% dimethyl sulfoxide (DMSO) (Sigma) in ES cell culture medium, in cryovials 
using a cryochamber with isopropanol, at -80°C.
Frozen ES cells were removed from -80°C, thawed rapidly in a water-bath at 
37°C for 2-3 minutes and transferred to a tube containing ES cell culture medium 
before being centrifuged at lOOOrpm for 3 minutes. The pellet was re-suspended in 
fresh ES cell culture medium and the cells were plated on gelatin-treated petri-dishes 
for culture.
2.1.3 Formation and maintenance o f  NEBs
ES cells were harvested using trypsin-EDTA (as described above) and a 
single-cell suspension was made. To remove any serum and LIF, cells were washed in 
10ml of PBS and then a cell count was performed. For the cell count lOpl of cell 
suspension was taken, transferred to a haemocytometer with a glass cover-slip and 
viewed under the microscope. Cells in the centre square of the haemocytometer were 
counted and the number of cells per pi was calculated as well as total cell number.
Cells were re-suspended in a chemically defined medium (CDM), ADF+, 
which consisted of Advanced DMEM/F-12 (ADF) (Gibco), 1 x lipid concentrate 
(Gibco), PS, glutamine (2mM), 12.5mg/ml transferrin (final concentration 150pg/ml) 
(Sigma), lOmg/ml insulin (final concentration 14pg/ml) (Sigma), and p- 
mercaptoethanol (0.1 mM). Cells were plated on untreated bacteriological grade 
culture dishes (Sterilin, Caerphilly, UK) at a density of 5 x 104 cells/ml and this was 
referred to as day 0. ADF+ was changed every 2 days by collecting NEBs into falcon 
tubes (Sterilin), harvesting a pellet of cells by centrifugation at 500rpm for 3 minutes, 
followed by resuspending cells in ADF+ and plating onto fresh bacteriological dishes.
For some of the studies the ADF+ medium was supplemented with factors to 
analyse their effects on the NEB cultures. FGF2 (R&D Systems, Abingdon, 
Oxfordshire, UK) was resuspended in PBS and used at 1, 5, 10 and 20 ng/ml. DKK-1 
(R&D Systems) was resuspended in PBS and used at 10, 100 and 1000 ng/ml. 
Purmorphamine (Calbiochem, Merck, Hull, UK) was resuspended in DMSO and used 
at 0.5, 1, 2 and 5pM. Cyclopamine (Calbiochem) was resuspended in methanol and 
used at 0.1, 0.5, 1 and 2pM.
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Figure 2.1. Schematic representation of NEB differentiation.
ES cells are transferred into ADF+ chemically defined medium, termed ‘day O’. Medium is 
replaced every two days and addition of different factors in the different studies was at day 0, 
day 2 or day 4. Following initiation of growth factor addition, this factor addition was 
maintained through to day 8 or day 16, when cells were plated onto substrate for 
differentiation and analysis.
2.1.4 Differentiation o f  NEBs
Glass cover-slips were first coated with poly-L-lysine (PLL) (0.1 mg/ml in 
distilled H2O) (Sigma) overnight at 4°C in 24-well plates (Iwaki, Sterilin) and then 
washed with distilled H2 O and allowed to dry. Then a 30pl drop of laminin (Sigma) 
(0.1 mg/ml in distilled H2 O) was added to each cover-slip and left for 45 minutes at 
37°C. Immediately prior to plating down the cells, the laminin was removed, but the 
cover-slips were not allowed to dry.
Cells were harvested, washed in PBS and incubated with accutase (PAA 
Laboratories, Farnborough, Hampshire, UK) at 37°C for 15 minutes. A single-cell 
suspension was generated by gently triturating the cells and neuronal differentiation 
medium was added to stop the enzymatic reaction. The cell suspension was 
centrifuged at lOOOrpm for 3 minutes, the pellet was resuspended in neuronal 
differentiation medium (DMEM/F-12, 1% PS, 2% B-27 and 1% FCS) and cells were 
counted as described previously.
Cells were plated onto the PLL/laminin cover-slips or onto LGE glial cultures 
(preparation described in section 2.1.2 & 2.1.3), at a known density, usually 25,000 
cells/cm2, in 30pl of neuronal differentiation medium. (The seeding density is lower
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for the differentiating NEBs than the LGE neuronal differentiation cultures because 
the NEBs continue to proliferate for the first few days following plating and it 
becomes difficult to visualise individual cells for subsequent counts and analysis.) 
Cells were allowed to adhere for 2-3 hours at 37°C and then 500pl o f neuronal 
differentiation medium was added to each well before returning the plate to 37°C. 
Cells were left to differentiate for 7-14 days and medium was discarded and replaced 
with fresh neuronal differentiation medium every 2-3 days.
2.1.5 Dissection and preparation o f  primary mouse cells
Mouse embryos at embryonic day (E) 14 were collected in Hank’s Balanced 
Salt Solution (HBSS) (Gibco), the brains were removed and the striatal eminences 
were dissected out, as shown in figure 2.2. Dissections were carried out using a 
dissecting microscope in a laminar flow hood.
WGE
r
LGE
Figure 2.2 Dissection of the striatal eminences.
Following removal of the brain, a longitudinal cut is made along the cortex, close to the 
midline, which is opened up to reveal the striatal primordium. To remove the WGE a 
superficial cut is made, removing the heart-shaped structure. To remove the LGE a vertical 
cut is made down the midline of the WGE to divide the LGE and the MGE, and the lateral 
side is collected by a superficial cut underneath (arrow). (Figure adapted from (Dunnett and 
Bjorklund, 1992).
The dissected tissue pieces were washed in HBSS, then transferred to a 
solution o f 0.1% trypsin ( Worthington, Lakewood, New Jersey, USA) in 0.5% DNAse 
(Sigma) in HBSS for 20 minutes at 37°C. Trypsin inhibitor (Sigma) and DNAse were
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added and the tissue was incubated for a further 5 minutes at 37°C. The tissue was 
then washed in DMEM/F-12 {Gibco), centrifuged at lOOOrpm for 3 minutes and the 
remaining pellet was resuspended in 200 pi DMEM/F-12 and triturated 10-15 times 
with a 200 pi Gilson pipette to generate a single cell suspension. Cells were counted 
using a haemocytometer and trypan blue (0.4% trypan blue solution) (Sigma) 
exclusion, in order to assess cell viability. lOpl of cell suspension was taken, diluted 
with DMEM/F-12 and trypan blue, and transferred to a haemocytometer with a glass 
cover-slip and viewed under the microscope. Cells in the centre square of the 
haemocytometer were counted and the number of cells per pi was calculated as well 
as total cell number, taking the dilution factor into account:
cells counted/squares counted x dilution factor x 1 0  = cells/pl
2.1.6 LGE glia expansion cultures
For generation of LGE glial cultures, cells were resuspended at a density of 
200cells/pl in T25 tissue-culture treated flasks (Iwaki, Sterilin) with 10ml glial 
expansion medium, which consisted of; DMEM/F-12, 1% PS, 10% fetal calf serum 
(FCS), glutamine (2mM) and epidermal growth factor (EGF) (20ng/ml), and the 
medium was changed every 2-3 days, depending on cell density. When 80-90% 
confluency was reached, glial cultures were passaged. Cells were washed with PBS, 
followed by incubation with 0.1% trypsin-EDTA at 37°C for 2-3 minutes. Glial 
expansion medium was added to inhibit the enzymatic reaction and the cells were 
harvested by centrifugation at lOOOrpm for 3 minutes. Cells were resuspended in glial 
expansion medium at the required density, and re-seeded in tissue-culture flasks for 
further expansion.
When glial cultures reached passage 4, stocks were made by harvesting cells 
and freezing at the required density in 10% DMSO in glial expansion medium, in 
cryovials using the cryo-chamber.
2.1.7 LGE glia co-cultures
Glial cells were plated onto coverslips 2-3 days prior to the beginning of co­
culture with neuronal plate-downs. Frozen glial cells were removed from the -80°C 
storage box, thawed rapidly in a water-bath at 37°C, for 2-3 minutes and transferred to 
a tube containing glial expansion medium before being centrifuged at lOOOrpm for 3
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minutes. The pellet was re-suspended in fresh glial expansion medium and cells were 
plated at a density of 40,000 cells/cm2 onto 13mm diameter glass cover-slips, which 
had been coated with PLL. Cells were plated in 30pl drops onto the cover-slips and 
allowed to adhere for several hours before each well was flooded with 500pi glial 
expansion medium.
24 hours before co-culture, the medium in the wells was replaced with 500pl 
glial differentiation medium, which was DMEM/F-12 with 1% PS, 10% FCS and 
glutamine (2mM).
2.1.8 LGE neuronal differentiation cultures
For generation of LGE neuronal differentiation cultures, cells were 
resuspended in neuronal differentiation medium and seeded onto either PLL-coated 
glass cover-slips or LGE glia co-cultures. When plated onto PLL-coated cover-slips, 
cells were seeded at 100,000 cells/cm2 in 30pl drops and were allowed to adhere for 
2-3 hours before the wells were flooded with 500pl neuronal differentiation medium. 
When plated onto LGE glia co-cultures on cover-slips, cells were seeded at 100,000 
cells/cm in 500pl suspension, to prevent the glia cultures from drying out.
Cultures were maintained at 37°C in humidified 5% CO2 and 95% 
atmospheric air, and differentiation medium was replaced with fresh medium every 2 - 
3 days.
In Chapter 6  differentiation medium was supplemented with factors to 
determine their effects on the survival and yield of DARPP-32 positive neurons. 
Brain-derived neurotrophic factor (BDNF) (Peprotech, New Jersey, USA) was 
resuspended in PBS and used at 50 and 100 ng/ml. RA {Sigma) was resuspended in 
DMSO and used at 10, 100 and 1000 nm.
2.1.9 Immunocytochemistry
Following differentiation of cells for the required time period, differentiation 
medium was removed, cells were washed in PBS and fixative solutions were added. 
Cells were fixed in either 4% formaldehyde in PBS for 20 minutes, 0.2% 
gluteraldehyde in 4% formaldehyde in PBS for 15 minutes, or methanol at -20°C for 
1 0  minutes, depending on the antibodies to be used, and were subsequently washed 3  
times in PBS.
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Appendix 3 lists the antibodies used and details the appropriate blocking sera, 
optimal concentrations and secondary antibodies to be applied.
Cells were first permeabilised with 100% ethanol for 2 minutes, followed by 3 
washes in PBS. To prevent non-specific antibody binding, a blocking serum was 
applied for 2 hours (3% normal serum in a 3% bovine serum albumin (BSA) in PBS 
solution). Primary antibody was then added at the appropriate dilution, in 3% normal 
serum in 3% BSA in PBS, and cells were incubated overnight at 4°C. Where double­
labelling was performed, both primary antibodies were added at the same time, 
ensuring they were raised in different species. The primary antibody was then 
removed, cells were washed 3 times with PBS and secondary antibody was added, in 
3% normal serum in 3% BSA in PBS, and incubated for 2 hours at room temperature 
and in the dark. The secondary antibody was washed off with PBS and Hoechst 
nuclear stain was added for 10 minutes. Cover-slips were rinsed in PBS, mounted 
onto glass microscope slides using PBS:glycerol (1:1), sealed with clear nail varnish 
and stored at 4°C in the dark.
2.1.10 X-gal assay
Incubation of Foxgl-lacZ ES cell-derived NEB cultures with 5-Bromo-4- 
chloro-3-indolyl galactopyranoside (X-gal) yields a blue product, allowing 
visualisation of Foxgl-lacZ positive cells within the population. Cells were harvested, 
plated onto PLL/laminin substrate and partially fixed in 1% formalin for 5-10 
minutes. Following PBS wash X-gal staining solution (see Appendix 2b) was added 
and cultures were incubated at 37°C for 2-4 hours and then overnight at 4°C. X-gal 
staining solution was discarded, cells were fixed in 4% formalin for 15 minutes and 
washed 3x in PBS. Cells were counterstained with eosin solution, which was diluted 
1 : 1 0  in distilled water, for 1 0  minutes.
2.1.11 Microscopy
Cells were visualised under UV fluorescence using a Leitz microscope. UV 
was used to detect the Hoechst positive nuclei and obtain a total cell count within a 
grid placed randomly on the coverslip with a magnification of 40X. Cells were then 
checked for counterstaining with antibodies under fluorescence using different UV 
wavelengths (560nm-red; 494nm-green; 346nm-blue). The grid was placed randomly
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over 5 different fields per cover-slip in order for cell counts to be performed, and 
replicates of 3-4 coverslips were counted per condition. Images were processed using 
Optronics MagnaFire Software and Adobe Photoshop.
53
Chapter 2 Materials and Methods
2.2 Molecular methods
2.2.1 RNA extraction and quality check
Cells were harvested (as described previously), washed in PBS and RNA was 
extracted using the Qiagen RNeasy Mini kit, RNase-free DNase set and QiaShredder 
(all Qiagen, West Sussex, UK). Following extraction, the amount of RNA was 
determined using NanoDrop and 500ng RNA was run on a formaldehyde gel.
Formaldehyde gel was made as a 1.7% agarose gel with addition of 
formaldehyde from 39% stock solution and 10X 3-(N-Morpholino)-propane sulfonic 
acid (MOPS) buffer, which consisted of 200mM MOPS pH7.0, 80mM sodium acetate 
and lOmM ethylene diamine tetra acetic acid (EDTA) pH8.0.
The extracted RNA was mixed with RNA loading buffer heated to 65°C for 
10-15 minutes, cooled on ice and then loaded onto the gel. The gel was run at 100V 
for 40 minutes in IX MOPS solution, and visualized using ethidium bromide and 
Alphalmager 2200 Multi-image Light Cabinet.
2.2.2 cDNA synthesis
For first strand synthesis, DNase-treated RNA was incubated with random 
primers (.Invitrogen) and lOmM dNTP mix for 5 minutes at 65°C. Following a brief 
chill on ice, 5X first strand buffer, 0.1M DTT and RNase Out RNase Inhibitor (all 
Invitrogen) were added and incubated for 2 minutes at 25°C. Finally, Superscript II 
(Invitrogen) was added and incubated at 25°C for 10 minutes, then 42°C for 50 
minutes and then 70°C for 15 minutes. cDNA was used for PCR reactions.
2.2.3 RT-PCR: Reverse Transcription -  Polymerase Chain Reaction
For PCR amplifications, the basic PCR mix used was: cDNA from first strand 
synthesis, 10X Bioline NH4  Reaction Buffer (Bioline, London UK), 50mM MgCb, 
lOmM dNTP, BioTaq DNA polymerase (Bioline), oligo pair at lOpmol each and 
water (Sigma), to make it a 25pl reaction. The reaction conditions used were initial 
denaturation step at 95°C for 1 minute, with a cycle of denaturing at 95°C for 45 
seconds, annealing at 60°C for 1 minute and extension at 72°C for 1 minute. The final 
extension was at 72°C for 10 minutes. PCR products were analysed by electrophoresis 
on a 1 % agarose gel and visualised with ethidium bromide.
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2.2.4 QPCR
For QPCR reactions the fluorescent probe SYBR Green (Bioline) was used. 
For each cDNA sample to be analysed 3 replicate wells were prepared with 1 pi cDNA 
(diluted with water at 1:20), lOpmol of each of the oligo pairs of interest, lOpl SYBR 
Green mastermix and water (Sigma) to give a 20pl reaction mix. Opticon Monitor 3 
software was used for QPCR analysis. Amplification conditions used were 95°C for 
15 minutes followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 
72°C for 30 seconds. Melt curves were generated from readings every 0.5°C between 
53°C and 95°C. Amplification of the target transcript sequence was quantified using 
relative quantification, where the ratio between the Ct value of the target transcript 
and that of p-actin was determined.
2.2.5 Primer sequences
Primer pairs were generated using Mouse Genome Informatics and Ensembl 
for sequence information, and Primer 3 Input for primer design. All QPCR primers 
were designed to; melt at 60°C, be a sequence of 18-22 base pairs in length and 
generate a transcript of 80-120 base pairs. Primer pair sequences are listed in 
Appendix 4.
2.2.6 Transformation and inoculation o f  plasmid DNA
Plasmid DNA was added to TOP 10 E. coli chemically competent cells 
(Invitrogen) and left on ice for 20 minutes. This underwent a heat shock at 42°C for 1 
minute and was then transferred to ice for a further 2  minutes before 1 ml cultivation 
medium (Invitrogen) was added. The bacterial suspension was then transferred to a 
bacteriological tube (Falcon, Becton Dickinson Labware, New Jersey, USA) and left 
to shake at 37°C for 30 minutes. Subsequently, 100 pi bacterial suspension was 
streaked onto a plate of selective agar (ampicillin resistant) and left at 37°C overnight.
An individual colony was picked using an inoculation loop, and transferred to 
a bacteriological tube with 5ml Luria-Bertani (LB) media (DIFCO; Becton 
Dickinson) and ampicillin (150pg/ml) (Sigma), and left to shake at 37°C overnight.
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2.2.7 Midi prep
A colony from the ‘master plate’ was picked and inoculated in LB media plus 
ampicillin (150pg/ml) and left to shake at 37°C overnight. From this bacterial 
suspension, a glycerol stock was made by combining 600pl bacterial suspension with 
400pl LB media:glycerol (1:1). The remainder of the bacterial suspension was 
centrifuged and a Midi prep was performed on the resulting pellet using the Qiagen 
Midi prep kit, according to manufacturer’s instructions. A sample of the resulting 
DNA was run on a 0.8% agarose gel and visualized with ethidium bromide. The DNA 
was stored at -20°C in Tris-EDTA (TE) at lpg/pl.
2.2.8 DNA digest
DNA was digested for an analytical check by incubation with the appropriate 
restriction enzyme, 10X BSA and 10X Buffer (New England Biolabs, Ipswich, MA, 
USA\ at 37°C overnight. At this stage, a sample of the DNA was run on a 1% agarose 
gel against undigested DNA, and visualized with ethidium bromide.
2.2.9 Transfection
For transfection, COS (monkey renal epithielial) cells were used. Cells were 
maintained on T25 tissue culture treated flasks in DMEM supplemented with 10% 
FCS, L-Glutamine (2mM) and 1% PS. Medium was changed every 2-3 days and cells 
were passaged at 70-80% confluence. Briefly, medium was aspirated off, cells were 
washed in PBS, trypsin-EDTA was added and cells were incubated at 37°C for 2-3 
minutes. Cells were harvested, resuspended in COS culture medium and centrifuged 
at lOOOrpm for 3 minutes. The pellet was resuspended in COS culture medium and 
cells were re-seeded according to desired ratio for split, usually 2 x 106 cells per T25 
flask. Cells were transfected at 70% confluency and 2-4 hours before transfection, 
culture medium was changed to that containing no PS.
Transfection reagent FuGENE 6  (Roche, West Sussex, UK) was used 
according to instructions in the kit. FuGENE 6  was added to Opti-MEM (Gibco) and 
left at room temperature for 5 minutes. Then plasmid DNA was added and left for a 
further 15 minutes at room temperature and then more Opti-MEM was added. The 
media was aspirated off the cells and ‘transfection mix’ was added and left at 37°C 
for 2-3 hours. Following this incubation period, Opti-MEM was added and the cells
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were left at 37°C overnight. After 24 hours, the transfection mix was discarded and 
replaced with COS cell culture medium.
Chapter 2
2 3  In vivo methods
Materials and Methods
2.3.1 Animal care, anaesthesia and immunosuppression
All animal experiments were performed in compliance with local ethical 
guidelines and approved animal care according to the UK Animals (Scientific 
Procedures) Act 1986 and it subsequent amendments. Adult female Sprague-Dawley 
rats (.Harlan, UK) weighing 200-250g at the start of the experiment were used, and 
were housed in cages of up to four in a natural light-dark cycle with access to food 
and water ad libitum.
All surgery was performed under gaseous isoflurane anaesthesia. Anaesthesia 
was induced in an induction chamber with isoflurane and oxygen, and maintained by 
passive inhalation of isoflurane ( 1 -2 1 /min) and a mixture of oxygen (0.81/min) and 
nitrous oxide (0.41/min). Animals were recovered in a warmed recovery cage and 
received analgesia by paracetemol dissolved in drinking water (2mg/ml) for 3 days 
following surgery.
In experiments involving xeno-transplantation into adults, animals were 
immunosuppressed with daily intraperitoneal injections of Cyclosporin A (CsA, 
Sandimmun, lOmg/kg) (.Novartis, Hampshire, UK) commencing the day prior to 
transplantation and continuing for the duration of the experiment.
2.3.2. Quinolinic acid lesion
Quinolinic acid (QA) was dissolved in 0.1M phosphate-buffer to make a 
90mM solution. Animals received a unilateral injection of 45nmol QA into the right 
striatum.
For QA lesions in rats, a Hamilton syringe attached to a pump and cannula 
was used to infuse 0.75pl of QA solution at two sites for 3 minutes per site and 1.5 
minutes each at two heights. The stereotaxic coordinates from bregma were +0.4/+1.4 
mm anterior-posterior (AP) and -3.2/-2.4 mm lateral (L). The heights (H) below dura 
were -5.0 mm and -4.0 mm. Following QA infusion, the needle was left at the lesion 
site for a further 3 minutes before being withdrawn. The incision was sutured and the 
animals were administered a subcutaneous injection of 5ml saline glucose into the 
scruff and an intramuscular injection of 0.15ml diazepam into the upper leg.
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For QA lesions in mice 0.5 pi QA was infused at one site for 4 minutes. The 
stereotaxic coordinates from bregma were +0.9mm AP, -1.8mm L and -2.7mm below 
dura. The needle was left at the lesion site for a further 4 minutes before being 
withdrawn, the incision was sutured and animals were administered a subcutaneous 
injection of 0.5ml saline glucose into the scruff and an intramuscular injection of 
0.03ml diazepam into the upper leg.
2.3.3 Unilateral striatal grafts
For transplants into adult rat brain 2pl of cell suspension (250,000cells/pl) 
were delivered at a rate of 1 pl/minute with 1 minute each at two heights, using a 
Hamilton syringe. Grafts were placed ipsilateral to the side of the lesion using the 
stereotaxic coordinates +0.6 mm AP and -2.8 mm L from bregma, at two heights -5.0 
mm and -4.0 mm below dura. Following grafting, the needle was left at the graft site 
for a further 2 minutes before being withdrawn. The incision was sutured and the 
animals were administered a subcutaneous injection of 5ml saline glucose into the 
scruff.
For transplants into adult mouse brain 2pi of cell suspension (125,000cells/pl) 
were delivered at a rate of 1 pl/minute with 1 minute each at two heights, using a 
Hamilton syringe. Grafts were placed ipsilateral to the side of the lesion using the 
stereotaxic coordinates +0.9 mm AP and -1.8 mm L from bregma, at two heights -2.7 
mm and -2.4 mm below dura. Following grafting, the needle was left at the graft site 
for a further 2 minutes before being withdrawn. The incision was sutured and the 
animals were administered a subcutaneous injection of 0.5ml saline glucose into the 
scruff
2.3.4 Perfusions and sectioning
Animals were terminally anaesthetised by intraperitoneal administration of 
0.5ml sodium pentobarbital (Euthatal) and transcardially perfused with a prewash 
solution, pH 7.3 for 2 minutes followed by 1.5% paraformaldehyde solution, pH 7.3 
(PFA) for 3 minutes. The brains were removed, post-fixed in 1.5% PFA overnight and 
transferred to 25% sucrose in prewash solution until they sank.
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Brains were sectioned coronally at 40 pm thickness using a freezing-stage 
microtome. Sections were stored in 0.2% sodium azide in Tris-buffered saline (TBS), 
in 24-well plates at 4°C.
2.3.5 Cresyl violet staining
Brain sections (1 in 12 series) were mounted onto glass microscope slides, 
previously double-subbed with 1% gelatin, and allowed to dry. Sections were 
subjected to 10 minutes in increasing levels of alcohol from 70%, to 95% and then 
1 0 0 %, followed by xylene for 1 hour and then decreasing alcohols for 1 0  minutes 
from 100% to 95% to 70% and then distilled water, before incubation in the cresyl 
violet stain for 10 minutes. Stained sections were rinsed in water, dehydrated in 70% 
and 95% alcohol, then decolourised in 2.5% acetic acid in 95% alcohol for 2-5 
minutes, until the desired colour was achieved, further dehydrated in 95% and 100% 
alcohol and then cleared in xylene before coverslips were mounted using DPX 
mountant.
2.3.6 Acetylcholinesterase (AChE) histochemical staining
Brain sections (1 in 12 series) were mounted onto glass microscope slides, 
previously double-subbed with 1% gelatin, and allowed to dry at 37°C overnight. 
Sections were transferred to glass koplin jars with incubation solution for 3 hours at 
37°C. The incubation solution comprised acetylthiocholine iodide and ethopropazine 
in a stock solution of copper sulphate, glycine and sodium acetate in distilled water. 
Following the incubation sections were thoroughly washed 4 x 3  minutes in distilled 
water and then transferred to sodium sulphide solution for 30 seconds to 2 minutes for 
the brown colour to develop. Sections were then allowed to dry overnight, and were 
then dehydrated in 70%, 95% and 100% alcohol, cleared in xylene and coverslips 
were mounted with DPX mountant.
2.3.7 Immunohistochemistry on free-floating tissue sections
1 in 12 series of brain sections were washed in TBS and then quenched with 
10% hydrogen peroxide and 10% methanol in distilled water for 5 minutes followed 
by three 5 minute washes in TBS, pH 7.4. Blocking solution of 3% appropriate serum 
in 0.2% Triton X-100 in TBS (TXTBS) was added for 1 hour, and then, without
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washing, block was discarded and primary antibody was added at the appropriate 
concentration (see Appendix 3) in 1% serum in TXTBS and incubated overnight at 
room temperature. Negative controls were performed in parallel, where the primary 
antibody was not added and sections remained in blocking solution. Sections were 
washed 3 times in TBS before addition of a biotinylated secondary antibody at 1:200 
dilution in 1% serum in TBS for 2 hours. The secondary antibody solution was 
washed off by 3 washes in TBS and streptavidin ABC (A and B both at 1:200 dilution 
in 1% serum in TBS; prepared 30 minutes before addition) was added for a further 2 
hours. The sections were washed 3 times in TBS followed by twice more in 0.05M 
tris non saline (TNS) pH 7.4 and positive staining was visualised using either 
diaminobenzidine (DAB) at 0.5mg/ml in TNS with 12pl hydrogen peroxide, which 
reveals the cells as brown colour, or the vector SG kit (Dako, Glostrup, Denmark) 
made up in TNS, which reveals the cells as a grey colour. Following the appropriate 
colour change, sections were washed twice in TNS before being mounted on 
gelatinised glass microscope slides, allowed to dry and then dehydrated in increasing 
levels of alcohol, cleared in xylene and coverslips were mounted using DPX 
mountant.
2.3.8 Photomicroscopy and analysis o f  grafts
Cells expressing markers of interest were counted using a Leitz light 
microscope and Olympus CASTgrid stereology software. Images were processed 
using Optronics MagnaFire Software and Adobe Photoshop.
Estimate of graft volume was calculated using the formula: (£a*M)/f 
where: a = area (mm2), M = section thickness and f  = frequency of sampled 
sections ( 1 :1 2 ).
Estimate of total number of cells per animal was calculated using the formula: 
Ic*[Ia/(Ln*a)]*f
where: c = cells counted, a = area, n = total number of grids counted within the 
area and f  = frequency of samples sections.
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2.4 Statistical analysis
Statistical analyses were performed using Minitab 15 statistical software. 
Parametric data were analysed using two-sample t-tests, or one- or two-factor analysis 
of variance (ANOVA) with Tukey-Kramer post-hoc comparisons when appropriate, 
to compare differences between pairs of mean values.
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Chapter 3
The forebrain character of NEBs
3.1 Summary
This chapter looks at characterising in vitro differentiation of mouse ES cells 
under defined neural induction conditions that are currently used as ‘standard’ in our 
lab. Mouse ES cells have been shown to generate neural precursors in vitro when 
cultured in CDM and default to a forebrain character without addition of further 
exogenous factors. This study utilised the mouse ES cell line FoxglZ, in which the 
expression of the reporter gene LacZ is under the control of the Foxgl promoter; 
Foxgl is the earliest known marker of the forebrain. This enables detection of Foxgl- 
expressing cells using X-gal or antibodies against P-galactosidase. Neural induction of 
FoxglZ ES cells using standard neuralising conditions yielded an increase in 
percentage of Foxgl positive cells over days in culture up to day 8 . Addition of FGF2 
resulted in a further increase in Foxgl positive cells, with 20ng/ml FGF2 added at day 
4 yielding the highest Foxgl population, but Wnt inhibition with DKK-1 did not alter 
the proportion of Foxgl positive cells. Interestingly, FGF2 addition did not 
significantly increase nestin or Otx2 expression in neural induction cultures. When 
cultures were differentiated for 7 days p-III-tubulin immuno-positive neurons were 
generated, including GABAergic neurons but not DARPP-32 positive neurons, and 
there were no GFAP immuno-positive astrocytes. Addition of FGF2 resulted in 
increased p-III-tubulin yield following 7 days neuronal differentiation. In summary, 
neural induction cultures of mouse ES cells resulted in a proportion of Foxgl positive 
cells, which could be increased by addition of FGF2, and these precursors went on to 
generate neurons. These results are at odds with some previous studies in the literature 
and there are a number of possible explanations for this including discrepancies in 
culture conditions, which may have differing effects on subsequent gene expression.
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3.2 Introduction
Forebrain character ofNEBs
ES cells have become a widely researched cell source due to their potential to 
generate any cell from the three germ layers, namely ectoderm, mesoderm and 
endoderm. With regards to neurodegenerative diseases, such as HD, and cell- 
replacement strategies, ES cells offer an alternative source of cells to primary foetal 
neural tissue which is currently used as standard. In addition, mouse ES cells offer a 
robust culture system that is easily employed in conjunction with genetic 
manipulation including incorporation of reporter systems to aid analysis of genes of 
interest.
Foxgl expression is restricted to the telencephalic neuroepithelium and the 
nasal half of the retina and optic stalk, and has been implicated in defining the 
compartmental boundary between the telencephalon and diencephalon (Tao and Lai, 
1992). The FoxglZ mouse ES cell line (used in this study, a gift from J. Quinn and D. 
Price), was derived from FoxglZ mice and offers a useful tool for the analysis of 
Foxgl expressing cells. Foxgl Z mice were generated by replacing most of the coding 
sequence of Foxgl, which is contained in a single exon, with a LacZ and neomycin 
cassette. The LacZ sequence, with a nuclear localization signal was fused in-frame to 
the first 13 amino acids of Foxgl, so that expression of the p-galactosidase enzyme is 
under the control of the Foxgl promoter (Xuan et al., 1995). This enables 
visualisation of Foxgl positive cells using the X-gal assay or antibodies against p- 
galactosidase. Foxgl -LacZ knock-in reporter ES cells have previously been used to 
show induction of Foxgl expression in neural induction protocols of mouse ES cells 
using stromal feeder layers with serum replacement medium followed by culture in 
N2 and bFGF with later addition of SHH, FGF8  and BDNF (Barberi et al., 2003). 
Further, GABAergic neurons generated using this method were demonstrated to be of 
forebrain identity by assessment of p-galactosidase histochemistry (Barberi et al., 
2003).
During embryonic development the presence of certain endogenous factors in 
the neural tube are important for the generation of the telencephalon. Members of the 
FGF family are involved in cell proliferation and cell survival, and have a role in 
patterning within the telencephalon including regulation of Foxgl (Shimamura and 
Rubenstein, 1997; Storm et al., 2006). Wnt proteins have been shown to be involved
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in the regulation of neural development, reviewed in (Michaelidis and Lie, 2008) and 
Wnt signalling inhibition is reported to be necessary for telencephalic generation 
(Houart et a l, 2002; Backman et al., 2005; Gulacsi and Anderson, 2008).
Mouse ES cells cultured in defined serum-free suspension without the addition 
of exogenous factors yield neural precursor cells, although different proportions of 
various markers are reported, including nestin positive cells ranging from 67-90% and 
Soxl positive cells ranging between 60-70% (Ying et al., 2003; Bouhon et al., 2005; 
Watanabe et al., 2005; Smukler et al., 2006; Okabe et al., 1996). Addition of FGF2 to 
neural induction cultures has been reported to result in a greater proportion of neural 
precursors following 8  days in culture, with an increase in nestin-positive cells (Okabe 
et al., 1996; Bouhon et al., 2005), Soxl-positive cells (Ying et al., 2003) and an 
upregulation of Foxgl expression (Bouhon et al., 2006).
The Wnt inhibitor DKK-1 causes an increase in Foxgl positive cells when 
added early (days 0-5) to mouse ES cell-derived neural induction cultures (Watanabe 
et al., 2005). This increase in Foxgl can be counteracted by the concurrent addition of 
the Wnt3a protein with DKK-1. Late addition (days 6-10) of Wnt3a does not 
significantly alter the Foxgl population, although it does result in an increase in 
expression of the dorsal telencephalic marker Pax6  and a decrease in expression of the 
ventral telencephalic markers Nkx2.1 and Gsx2 within the Foxgl population 
(Watanabe et al., 2005). Therefore specific time points for addition of factors to the 
neural induction suspension culture system are important for the induction of neural 
precursor cells expressing appropriate markers.
In this chapter neural induction of FoxglZ ES cells is analysed following 8  
days in serum-free suspension culture. Neural character is assessed within culture 
populations, in particular the proportion of Foxgl expression, via the LacZ reporter 
assay. Following addition of factors to the culture system, including the mitogen 
FGF2 and the Wnt inhibitor DKK-1, expression of Foxgl was analysed in the 
precursor population. Expression of other neural precursor markers such as nestin and 
Otx2 was also assessed. Cultures at day 8  were transferred to neuronal differentiation 
medium for 7 days and subsequently analysed for expression of neuronal and 
astrocyte markers.
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Cell culture
The mouse ES cell line Foxgl-LacZ (FoxglZ) (a gift from J. Quinn and D. 
Price, University of Edinburgh, Edinburgh, UK) was used in this study. NEBs were 
derived from the FoxglZ mouse ES cell line as described in Chapter 2. Briefly, ES 
cells were transferred from ES cell culture medium to CDM (ADF+ medium) at a 
density of 50,000 cells per ml and medium was replaced every 2 days. To determine 
the effects of addition of factors, FGF2 was added at 1, 5, 10 and 20 ng/ml. DKK-1 
was added at 1 0 , 1 0 0  and 1 0 0 0  ng/ml.
X-Gal assay
Cells were plated onto PLL/laminin treated cover-slips at a density of 50,000 
cells per 30pl drop on each cover-slip. Cells were fixed 2-4 hours after plating, on 
adhering to the substrate, in 1% formalin for 5-10 minutes, followed by washing in 
PBS and incubation in X-gal staining solution (see Appendix) at 37°C for 2-4 hours 
and then overnight at 4°C. Following the overnight incubation, X-gal was removed 
and cells were fixed in 4% formalin for 15 minutes, washed in PBS and 
counterstained with eosin for 1 0  minutes.
Immunocytochemistry
Cells were fixed 2-4 hours after plating, on adhering to the substrate, or after 7 
days in neuronal differentiation medium. Fluorescent immunocytochemistry was 
performed according to the protocol detailed in Chapter 2. Primary antibodies used 
were anti-p-galactosidase (1:1000), anti-nestin (1:400), anti-Otx2 (1:500), anti-p-III- 
tubulin (1:1000); anti-GFAP (1:100), anti-GABA (1:500) and anti-DARPP-32 
(1:20,000). (For antibody details see Appendix 3).
Gene expression analysis
Cells were harvested, RNA extracted and cDNA was generated. QPCR 
analysis of axin expression was performed using cDNA dilutions and the SYBR green 
assay. (For primer sequences see Appendix 4).
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Quantification
Cells expressing markers of interest were visualised and counted under UV 
fluorescence using a Leitz microscope. Hoechst positive nuclei were detected and 
cells immuno-labelled with the marker of interest were counted, as described in 
Chapter 2. Images were processed using Optronics MagnaFire Software and Adobe 
Photoshop.
Statistical analyses were performed by two-sample t-tests, and one-factor 
ANOVA with Tukey-Kramer post-hoc comparisons when appropriate, using Minitab 
15 software.
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Foxgl expression in NEBs
To determine the proportion of FoxglZ positive cells in the culture and to 
assay the effects of factors on the proportion of Foxgl-positive cells, incubation with 
5-Bromo-4-chloro-3-indolyl galactopyranoside (X-gal) which yields a blue product 
was employed. FoxglZ ES cell-derived NEBs (FoxglZ NEBs) were cultured in 
ADF+ neural induction medium for up to 8  days and were analysed at different time 
points within this time window. Within cultures there were clusters of cells that were 
negative (Figure 3.1; A) along side both individual cells and clusters of cells that were 
positive (Figure 3.1; B) for X-gal. Undifferentiated FoxglZ ES cells were negative for 
X-gal (Figure 3.1; C), as were CGR8 . 8  NEBs (a mouse ES cell line without the LacZ 
reporter) following the 8  days in ADF+ (Figure 3.1; D).
The proportion of X-gal positive cells present in cultures at different days 
following neural induction was expressed as a percentage of the total cell number as 
determined by eosin counterstaining (Figure 3.2). Analysis was performed on NEBs 
from day 0 through to day 8  of neural induction. There was a highly significant 
difference in the proportion of X-gal positive cells with increasing time in neural 
induction culture (time, ¥4 ^ 5  = 117.31, p<0.001), with no positive cells identified at 
day 0 and the greatest proportion of X-gal positive cells evident at day 8 . The 
percentage of positive cells at day 2 (0.68 ± 0.60%) (mean ± SEM) was not 
significantly different from that at day 0 (0.00). The percentage of positive cells at day 
4 (19.89 ± 1.43%) was statistically significant from that at day 0, day 2 and also day 8  
(25.91 ± 1.78%). At day 6  (21.75 ± 0.90%) the percentage was not statistically 
significant from that at either day 4 or 8 , but was significantly different from that at 
day 0  and day 2 .
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Figure 3.1. FoxglZ NEBs were harvested, dissociated and plated onto substrate. After 2-4 
hours cells had adhered to the substrate and were partially fixed, followed by incubation in X- 
gal staining solution (blue) and subsequent counterstaining with eosin (pink). Within cultures 
there were NEBs present with very few or no X-gal positive cells (A), interspersed with 
regions exhibiting patches of X-gal positive cells (B). Photomicrographs A and B are different 
areas of the same culture plate-down. Undifferentiated FoxglZ ES cells (C) and CGR8.8 
NEBs (D) exhibited no X-gal positive cells. Scale bars = 50pm.
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Figure 3.2. FoxglZ NEBs were harvested, dissociated and plated onto substrate for analysis 
at days 0, 2, 4, 6 and 8 following neural induction. After adhering to the substrate cells were 
partially fixed and then incubated in X-gal staining solution followed by counterstaining with 
eosin. X-gal positive cells were counted and are represented as a percentage of total eosin 
stained cells. Each bar on the graph represents a mean of 3 different neural induction cultures 
and error bars represent SEM. There was a significant difference in X-gal positive cells with 
varying days in culture. Significant post-hoc differences are indicated with brackets.
(***p<0.001).
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Effect o f FGF on Foxgl expression
Addition of increasing concentrations of FGF2 to neural induction cultures on 
day 4 resulted in an increase in the percentage of X-gal positive cells in the cultures 
(Figure 3.3). The increase was statistically significant overall (concentration, F^is = 
5.57, p<0.05). The percentage of X-gal positive cells in untreated cultures (25.73 ± 
2.71%) was not significantly lower than those treated with lng/ml (34.17 ± 7.34%), 
5ng/ml (35.61 ± 8.05%) and lOng/ml (44.39 ± 8.92%) FGF2, but was significantly 
lower than those treated with 20ng/ml FGF2 (70.67 ± 8.51%). There was no 
significant difference between those cultures treated with lOng/ml and 20ng/ml FGF2.
20ng/ml FGF2 was added to neural induction cultures on either day 0, 2 or 4 
and was maintained in cultures until day 8  when cells were analysed. The percentage 
of X-gal positive cells was significantly increased the later the initial addition of 
FGF2 (day, F3 ,i2 = 33.89, p<0.05) (Figure 3.4). Untreated cultures (26.56 ± 2.49%) 
were not significantly different from cultures treated with FGF2 from day 0 (35.24 ± 
4.92%), but were significantly different from those cultures treated from day 2 (55.01 
± 3.88%) and day 4 (74.10 ± 2.78%). There was also a significant difference in the 
percentage of X-gal positive cells between cultures where FGF2 was added from day 
2 and those where it was added from day 4.
Addition of 20ng/ml FGF2 at day 4 of neural induction resulted in the greatest 
proportion of X-gal-positive cells when analysed at day 8 , compared to untreated 
cultures (Figure 3.5).
FGF8  is the member of the FGF family known to be involved in telencephalon 
development, and FGF 2 is a synthetic equivalent of FGF8 . Addition of increasing 
concentrations of FGF8  to neural induction cultures on day 4 resulted in an increase in 
the percentage of X-gal positive cells, which was statistically significant overall 
(concentration, F3 ;i2 = 7.46, p<0.05) (Figure 3.6). The percentage of X-gal positive 
cells in untreated cultures (23.11 ± 0.86%) and those treated with 25ng/ml FGF8  
(23.28 ± 2.57%) was significantly lower than those treated with 50ng/ml FGF8  (52.85 
± 6.74%), but there was no significant difference between those cultures treated with 
50ng/ml and lOOng/ml FGF8  (36.44 ± 7.43%).
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X-gal expression In foxgl Z NEBs at various 
concentrations of FGF2
90
80
70
60
50
40
30
20
10
0
1 5 10
Concentration (ng/ml)
Figure 3.3 FGF2 (1, 5, 10 and 20 ng/ml) was added to FoxglZ NEBs at day 4 and cells were 
harvested, dissociated and plated onto substrate for analysis at day 8. X-gal positive cells were 
counted and are represented as a percentage of total eosin stained cells. Each bar on the graph 
represents a mean of 3 different neural induction cultures and error bars represent SEM. There 
was a significant increase in X-gal positive cells with increasing FGF2 concentration. 
Significant post-hoc differences are indicated with brackets. (*p<0.05).
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Figure 3.4. FoxglZ NEBs were cultured in neural induction medium and addition of 20ng/ml 
FGF2 was initiated on either day 0, 2 or 4, and maintained through to analysis at day 8. X-gal 
positive cells were counted and are represented as a percentage of total eosin stained cells. 
Each bar on the graph represents a mean of 3 different neural induction cultures and error bars 
represent SEM. There was a significant difference in the percentage of X-gal positive cells, 
depending on the initial day o f FGF2 addition. Significant post-hoc differences are indicated 
with brackets. (*p<0.05).
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Figure 3.5. FoxglZ NEBs were cultured in the absence or presence of 20ng/ml FGF2 from 
day 4 and at day 8 were harvested, dissociated and plated onto substrate. After 2-4 hours cells 
had adhered to the substrate; they were partially fixed, followed by incubation with X-gal 
(blue) and subsequent eosin counterstaining (pink). FoxglZ NEB cultures in the absence of 
FGF2 are shown to express few X-gal-positive cells (A and B). Cultures treated with 20ng/ml 
FGF2 reveal a greater proportion of X-gal-positive cells (C and D). Photomicrographs A and 
B are different magnifications of the same culture, and photomicrographs C and D are 
different magnifications of the same culture. Scale bars = 200pm (A and C); 100pm (B and 
D).
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Figure 3.6. FGF8 (25, 50 and 100 ng/ml) was added to FoxglZ NEBs at day 4 and cells were 
harvested, dissociated and plated onto substrate for analysis at day 8. X-gal positive cells were 
counted and are represented as a percentage of total eosin stained cells. Each bar on the graph 
represents a mean of 3 different neural induction cultures and error bars represent SEM. There 
was a significant increase in X-gal positive cells with increasing FGF8 concentration. 
Significant post-hoc differences are indicated with brackets. (*p<0.05).
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Effect o f DKK-1 on Foxgl expression
The W nt inhibitor DKK-1 was added to neural induction cultures to determine 
its effects on the forebrain population. Addition o f DKK-1 did not result in a 
statistically significant difference in the percentage o f X-gal positive cells 
(concentration, F3j 2 = 3.45, p = n.s) (Figure 3.7; A); (untreated 24.89 ± 2.13%; 
lOng/ml DKK-1 21.21 ± 1.35%; lOOng/ml DKK-1 23.45 ± 0.91%; lOOOng/ml DKK-1 
28.84 ± 2.19%). Earlier addition o f  lOOOng/ml DKK-1 did not result in a significant 
difference in X-gal positive cells (day, F3,n = 2.19, p = n.s) (Figure 3.7; B); (untreated 
24.89 ± 2.13%; from day 0 19.51 ± 1.86%; from day 2 19.30 ± 2.66%; from day 4 
24.03 ± 0.97%). DKK-1 addition from day 4 did alter the expression o f the W nt 
signalling pathway component, axin, com pared to untreated cultures (Figure 3.7; C) 
(concentration, t2 = 19.54, p<0.01).
addition of DKK-1
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Figure 3.7. DKK-1 (10, 100, 1000 ng/ml) was added to FoxglZ NEBs at day 4, and cells 
were harvested, dissociated and plated onto substrate for analysis at day 8 (A); addition of 
lOOOng/ml DKK-1 was initiated on either day 0, 2 or 4 and maintained through to analysis at 
day 8 (B). X-gal positive cells were counted and are represented as a percentage of total eosin 
stained cells (A and B). FoxglZ NEBs were untreated or treated with lOOOng/ml DKK-1 from 
day 4 to day 8 and expression of the Wnt signalling pathway component axin was analysed 
using semi-quantitative RT-PCR (C). Each bar on the graph represents a mean of 3 different 
neural induction cultures and error bars represent SEM. (**p<0.01).
The effect o f DKK-1 dose response on X-gal positive cells in NEB cultures was 
initially analysed in the absence o f  FGF2. To determine if  there was an additive effect 
o f these two factors lOOng/ml DKK-1 was added in conjunction with 20ng/ml FGF2 
at day 4 o f neural induction and cells were plated for analysis at day 8 (Figure 3.8). 
Statistical analysis confirmed a highly significant difference between the percentage 
o f X-gal positive cells yielded from untreated and treated cultures (treatment, F3j 2 =
114.60, p<0.001). Cultures treated with 20ng/m l FGF2 and lOOng/ml DKK-1 (67.44 ±
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3.53%) expressed significantly more X-gal than untreated cultures (24.89 ± 2.13%) 
and DKK-1 treated cultures (23.45 ± 0.91%), but did not differ significantly from 
those cultures treated with FGF2 alone (74.09 ± 2.78%).
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Figure 3.8. FoxglZ NEBs were maintained in neural induction medium with no additional 
factors (A), 20ng/ml FGF2 at day 4 (B), lOOng/ml DKK-1 at day 4 (C) or 20ng/ml FGF2 and 
lOOng/ml DKK-1 at day 4 (D), and were plated onto PLL-coated coverslips at day 8 for 
analysis with the X-gal assay (blue) and eosin counterstain (pink). Scale bar = lOOpm. 
Cultures treated with FGF2 alone or both FGF2 and DKK-1 have significantly more X-gal 
positive cells than untreated cultures and there is no significant difference between untreated 
cultures and those treated with DKK-1 alone (E). Each bar on the graph represents a mean of 
3 different neural induction cultures and error bars represent SEM. (***p<0.001).
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Further neural analysis o f  F o xg lZ  NEBs
Neural specification o f FoxglZ  NEBs following 8 days in neural induction 
medium was further characterised by analysis o f the neural precursor markers nestin, 
and Otx2, with or without the addition o f FGF2. Immunocytochemistry using 
antibodies against nestin and Otx2 was performed on day 8 NEBs that had been plated 
for 4 hours and fixed as precursors (Figure 3.9; A and B). Counts were performed and 
represented as a percentage o f Hoechst positive cells (Figure 3.9; C and D). NEB 
cultures with no FGF2 treatment were 54.53 ± 4.02% nestin positive at day 8, which 
was not significantly different from FGF2 treated cultures which were 63.46 ± 8.45% 
nestin positive (concentration, ts = 1.62, p = n.s) (Figure 3.9; A and C). Analysis o f 
Otx2 expression revealed no significant difference between untreated cultures (33.34 
± 6.79%) and FGF2 treated cultures (39.84 ± 9.52%) (concentration, t* = 0.56, p= n.s) 
(Figure 3.9; B and D).
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Figure 3.9. FoxglZ NEBs were maintained in neural induction medium either untreated or 
with addition of 20ng/ml FGF2 from day 4, harvested and dissociated at day 8 and plated onto 
PLL-coated coverslips for 4 hours before fixation. Cultures were immuno-labelled for nestin 
(red) (A and C) or Otx2 (green) (B and D) and counterstained with Hoechst nuclear stain 
(blue in A and B). Graphs represent immuno-positive cells as a percentage of total Hoechst 
cells counted. Each bar on the graph represents a mean of 4 (C) and 3 (D) different neural 
induction cultures and error bars represent SEM. Scale bars = 50pm.
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Neuronal differentiation o f  F o x g lZ  NEBs
To look at the neuronal differentiation o f ES cell-derived NEBs, Foxg lZ  
NEBs were harvested, dissociated, plated onto substrate and allowed to differentiate 
for 7 days in the presence o f 2% B27 growth supplement and 1% FCS, and in the 
absence o f  any additional growth factors (such as FGF2). F oxglZ  NEBs continue to 
express p-galactosidase following differentiation (Figure 3.10; A and E; Figure 3.13; 
A) and are shown to co-express the neuronal marker P-III tubulin (Figure 3.10; B, D, 
F and H; Figure 3.13; A). There were significantly more p-galactosidase/p-III-tubulin 
double-labelled cells in cultures with addition o f 20ng/ml FGF2 to ADF+ at day 4 
(34.42 ± 4.19%) com pared with untreated cultures (17.49 ± 4.34%) (concentration, t5 
= 2.81, p<0.05).
F oxg lZ  NEBs cultured for 8 days in ADF+ m edium without the addition o f 
FGF2 generated 31.66 ± 2.33% p-III-tubulin immuno-positive neurons whilst those 
cultured in the presence o f 20 ng/ml FGF2 yielded 37.80 ± 1.29% p-III-tubulin 
immuno-positive neurons, following subsequent neuronal differentiation for 7 days, 
which was a significant difference (concentration, ti2 = 2.31, p<0.05) (Figure 3.13; B).
The presence o f  GFAP positive astrocytes (Figure 3.11; B, D, F and H) was 
very rare both without FGF2 addition (0.05 ± 0.04%) and with FGF2 addition in 
ADF+ medium (0,14 ±  0.13%), and the difference in the 2 conditions was not 
statistically significant (concentration, t3 = 1.09, p = n.s) (Figure 3.13; B).
To assess the types o f neurons generated following neuronal differentiation, 
cultures were further immuno-labelled for GABA (Figure 3.12;A-D) and DARPP-32 
(Figure 3.12; E-H). Untreated neural induction cultures yielded 12.84 ± 1.74% GABA 
positive neurons, as a percentage o f total Hoechst positive nuclei, which was not 
significantly different to 15.52 ± 3.16% yielded from FGF2 treated cultures, 
(concentration, t3 = 0.74, p = n.s) (Figure 3.12; B). DARPP-32 was never detected in 
the cultures either with or without FGF2 addition to ADF+ medium (Figure 3.13; B).
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Figure 3.10. FoxglZ NEBs were harvested, dissociated and plated at day 8 following neural 
induction in either untreated medium (A-D) or FGF2 treated medium (E-H) and were 
differentiated for 7 days in B27 and FCS with no additional growth factors. Cultures were 
triple-labelled for 0-galactosidase (red) (A and E), 0-111 tubulin (green) (B and F) and Hoechst 
nuclear stain (blue) (C and G). Photomicrograph D is a merged image of A, B and C; and 
photomicrograph H is a merged image of E, F and G. Scale bars = 100pm.
Figure 3.11. FoxglZ NEBs were harvested, dissociated and plated at day 8 following neural 
induction in either untreated medium (A-D) or FGF2 treated medium (E-H) and were 
differentiated for 7 days in B27 and FCS with no additional growth factors. Cultures were 
triple-labelled for (3-III-tubulin (red) (A and E), GFAP (green) (B and F) and Hoechst nuclear 
stain (blue) (C and G). Photomicrograph D is a merged image of A, B and C; and 
photomicrograph H is a merged image of E, F and G. Scale bars = 100pm.
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Figure 3.12. FoxglZ NEBs were harvested, dissociated and plated at day 8 following neural 
induction with addition of FGF2 from day 4, and were plated for neuronal differentiation for 7 
days in B27 and FCS with no additional growth factors. Cultures were triple-labelled for P- 
III-tubulin (red) (A), GABA (green) (B) and Hoechst nuclear stain (blue) (C); or (3-III-tubulin 
(green) (E), DARPP-32 (red) (F) and Hoechst nuclear stain (blue) (G). Photomicrograph D is 
a merged image of A, B and C; and photomicrograph H is a merged image of E, F and G. 
Scale bars = 100pm.
N E B s d o u b le -lab e lled  w ith B -gal a n d  B-
tubu lin
45 £
40 T
35
30
25 < < < < > > >
20 > > > > > >
15 ;<;4> « \ V «10 j v X > > > >
5 -I 
0
vX» > > > 
> > >
0 20 
C oncen tra tion  (ng/m l)
Phenotype of differentiated foxgIZ NEBs with and without 
FGF2 addition
0 20 
C oncen tra tion  (ng/m l)
■  B-tubulin 
E3GFAP 
Q GABA 
□  D ARPP-32
Figure 3.13. FoxglZ NEBs were maintained in ADF+ neural induction medium with or 
without the addition of 20ng/ml FGF2 at day 4. On day 8 NEBs were harvested, dissociated 
and plated onto substrate and were allowed to differentiate for 7 days in neuronal 
differentiation medium. p-galactosidase and p-III-tubulin double-labelled cells are represented 
as a percentage of total Hoechst-positive nuclei (A). p-III-tubulin, GFAP, GABA and 
DARPP-32 immuno-positive cells were counted and are represented as a percentage of total 
Hoechst-positive nuclei. Each bar on the graphs represent a mean of at least 3 different neural 
induction cultures and error bars represent SEM. (*p<0.05).
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Expression o f X-gal in FoxglZ NEBs
Serum-free neural induction suspension culture of mouse ES cells results in 
generation of neural precursor cells (Wiles and Johansson, 1999; Ying et al., 2003; 
Bouhon et al., 2005; Watanabe et al., 2005). Over time in serum-free suspension 
culture there is an induction of neurogenicity, inluding upregulation of the 
neuroectodermal marker Soxl (Bouhon et al., 2006; Watanabe et al., 2005) and the 
neural precursor marker nestin (Bouhon et al., 2005), with a decrease in ES cell 
markers such as Oct-3/4 (Bouhon et al., 2005; Watanabe et al., 2005; Bouhon et al., 
2006).
The mouse ES cell line FoxglZ enables analysis of expression of the early 
forebrain marker Foxgl via use of the LacZ reporter gene and an X-gal assay or 
antibodies against the enzyme P-galactosidase (Xuan et al., 1995). FoxglZ ES cells 
cultured in the above conditions spontaneously form aggregates termed NEBs, and 
can be maintained in this state for a number of days without the addition of growth 
factors. When dissociated, plated onto substrate, fixed as precursors without 
differentiation, and stained with X-gal, blue cells can be visualised and counted as 
shown above. FoxglZ positive cells increased over time in culture as expected, up to 
25.91% at 8 days, which was a higher percentage than shown in a previous study 
(Watanabe et al., 2005). Feeder-dependent cultures maintained for 5 or 10 days 
resulted in less than 2% Foxgl positive cells. This was increased to 11% when 
cultures were feeder-free and in suspension for the initial 5 days, and further increased 
to 15% when all 10 days were feeder-free and in suspension (Watanabe et al., 2005).
Different studies looking at neural induction protocols of mouse ES cells apply 
different protocols as outlined in Table 3.1, which indicates the need for caution when 
drawing comparisons. Differences in composition of neural induction culture medium 
include the use of 5% knock-out serum replacement (KSR) in the ‘Watanabe’ 
medium, which contains lipids, insulin and transferrin, along with other components 
(Price et al., 1998), compared with the additional supplementation of these 3 
components to the ADF+ medium used in this study. KSR, unlike FCS, does not 
contain any undefined growth factors and has a stable composition. The concentration
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of lipids in the ‘Watanabe’ medium is nearly a third lower than in ADF+ and the 
concentrations of insulin and transferrin are 28 and 187.5 times less, respectively, than 
supplemented in ADF+ medium. ‘Bouhon’ medium comprises insulin at half the 
concentration in ADF+ and transferrin is double that in ADF+. Insulin and transferrin 
are important for cell survival, with insulin in particular, showing specificity for 
survival of neural precursor cells (Okabe et al., 1996). The ADF+ serum-free 
suspension culture system used here appears to encourage induction of Foxgl 
precursors more than other protocols.
W atanabe (2005) Bouhon (2005) This study (ADF+)
Cell lines 46CSoxGFP E14 FoxglZ
(gene targeting E14 cell 
line (129/Ola derived))
(129/Ola derived) (C57B16/J derived)
Substrate for Gelatin Feeders (MEFs), then Gelatin
ES cell culture gelatin for 2 passages
Base GMEM 
5% KSR
IMDM:F12 (1:1) 
BSA
Advanced-DMEMF 12
1 Lipid 1 x lipid concentrate 1 x lipid concentrate
<L> Insulin } from KSR 7pg/ml 14pg/ml
^ 5 Transferrin 150pg/ml 75pg/ml
Other Thioglycerol Thioglycerol (3-mercaptoethanol
Table 3.1. Comparison of medium components in neural induction protocols.
Discrepancies between protocols regarding effects of addition of factors on 
gene expression may be attributed to use of different cell lines, differences in culture 
media or different culture conditions. ‘Baseline’ Foxgl expression is variable between 
this study and Watanabe et al; not only were there differences in culture conditions, 
namely medium recipes, but also the cell lines employed were different. For this study 
the FoxglZ line was used, while Watanabe used the 46CSoxGFP cell line (Ying et al., 
2003; Watanabe et al., 2005). When working with mouse ES cell lines, and drawing 
comparisons between different studies, it is important to keep in mind the differences 
that may arise due to background strains of the mice used when cell lines were 
derived from the ICM. Different ES cell culture media may contain a different 
complement of factors which include signals that affect ES cell pluripotency and 
growth curves, and may have effects on subsequent ES cell differentiation. Different 
culture medium recipes for differentiation of ES cells may contain varying levels of 
signalling factors. A consequence of this might be affects on ‘baseline’ gene 
expression and also the outcome of supplementing medium with additional factors of
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interest, which may only influence neural induction under specific conditions. The use 
of feeder layers in maintenance of ES cells may also add to the differences in the 
presence of various signalling factors in the culture medium which in turn might 
impose modifications on the fate of cells.
Effect o f FGF and DKK-1 in FoxglZ neural induction culture
FGF8 is necessary for normal telencephalic development and in vivo studies 
have shown a relationship between expression of FGF8 and Foxgl, where loss of 
Foxgl results in reduced FGF8 expression in the developing telencephalon 
(Martynoga et al., 2005). Neural plate explants incubated with FGF8-soaked beads 
were shown to extensively express Foxgl in the area surrounding the beads compared 
with the PBS-soaked beads where no Foxgl was expressed (Shimamura and 
Rubenstein, 1997). Loss-of-function studies with FGF8 mutant mice revealed that 
Foxgl expression was reduced in the neural plate (9-10 somite stage) and also at the 
later gestational stage E9.0 (Storm et al., 2006).
Increasing concentrations of FGF8 added to FoxglZ NEB cultures resulted in 
increased expression of Foxgl /X-gal positive cells after 8 days, with the highest yield 
following addition of 50ng/ml FGF8. A similar increase in Foxgl/X-gal positive cells 
was demonstrated with addition of FGF2, the synthetic equivalent of FGF8, and for 
subsequent studies FGF2 was used.
Increasing concentrations of FGF2 added to FoxglZ NEB cultures increased 
the expression of Foxgl fK-gal positive cells after 8 days from 26% to 71%, which is 
consistent with previous studies that showed via semi-quantitative analysis, using RT- 
PCR, that treatment at day 4 with 20ng/ml FGF2 induced expression of Foxgl at day 
8 (Bouhon et al., 2006). Supplementing culture medium with 20 ng/ml FGF2 at earlier 
culture days did not yield higher expression of Foxgl than when treated at day 4. 
Members of the FGF family elicit their effects via FGF receptors. FGFR1 expression 
is not observed in mouse ES cells but following initiation of neural induction it can be 
detected from day 2 with increasing expression through to day 8 (Bouhon et al., 
2005). The absence of FGF receptors in early neural induction cultures might explain 
the lack of response to early exogenous FGF signals in culture, since the appropriate 
receptors are not yet detectable.
Treatment of mouse ES cells with the FGF inhibitor PD184352, which inhibits 
the MEK component of the mitogen-activated protein kinase (MAPK) cascade, was
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shown to inhibit early neural differentiation (Gaulden and Reiter, 2008). Treatment of 
mouse ES cells with a different FGF inhibitor, SU5402, which inhibits tyrosine kinase 
activity of FGFR1, has been reported not to alter early neural differentiation (Gaulden 
and Reiter, 2008; Smukler et al., 2006). Together this suggests that MAPK activation 
may be important for ES cell neural induction, but via an FGFR1-independent 
mechanism. However other studies looking at inhibition of FGF signalling through 
FGFR1, using SU5402, contradict this finding and show a reduction in Soxl positive 
neural precursor cells in both adherent and suspension cultures (Ying et al., 2003; 
Bouhon et al., 2005), which highlights discrepancies between culture systems and 
responses to inductive or inhibitive supplements. Factors other than FGFs that activate 
the MAPK cascade include insulin-like growth factors (IGF) (Pera et al., 2001). IGFs 
and insulin are members of a family of cytokines that are structurally and functionally 
related and IGF signals have been shown to be necessary for neural induction in vivo 
(Pera et al., 2001).
Addition of FGF2 to the ADF+ culture system did not significantly alter the 
expression of the neural precursor marker nestin or Otx2. Otx2 is not only expressed 
in the developing telencephalon, but also the diencephalon and mesencephalon 
(Boncinelli et al., 1993). Previous findings report that FGF2 increases nestin positive 
cells at day 8, when added at day 4, but it causes a decrease in Otx2 expression at day 
8 (Bouhon et al., 2005). These differences might be attributable to differences in cell 
lines, culture medium and culture conditions, all of which are inconsistent between 
the study here and the Bouhon study (detailed in Table 3.1).
Analysis at day 8, following addition of FGF2 at day 4, revealed that there 
were fewer neural precursors, as determined by expression of nestin (63%), than 
Foxgl-expressing cells (74%). Nestin expression is restricted to the neural precursor 
population including those cells throughout the CNS which are pre-determined to 
generate neurons, astrocytes and oligodendrocytes. One explanation for the lower 
proportion of nestin-expressing cells than Foxgl -expressing cells is that some of the 
cells are beginning to differentiate further and therefore nestin is being switched off. 
Cells were only analysed at day 8 in this study and the peak expression of nestin 
might occur a few days prior to this. Although Foxgl is expressed in the forebrain 
progenitor cells, it is not restricted to the proliferating population and is found in post­
mitotic cells derived from the telencephalic neuroepithelium (Dou et al., 1999). Foxgl
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expression has been shown in differentiating and mature neurons of the cortex (Ariani 
et al., 2008).
During mouse development Wnt signalling is evident from E6.5 in the 
posterior region of the embryo and in embryoid body development it is required for 
the establishment of the anterior-posterior axis (ten Berge et al., 2008). Inhibition of 
Wnt signalling within embryoid bodies promotes anterior expression and induces 
neuroectodermal differentiation (ten Berge et al., 2008). Here, addition of the Wnt 
inhibitor DKK-1 did exhibit an effect on the Wnt signalling pathway, although there 
was no effect on the expression of Foxgl in the ADF+ neural induction system, both 
when added at day 4 at a range of concentrations, and when lOOOng/ml was added on 
different starting days and maintained through to day 8. This was contradictory to a 
previous study which showed a significant upregulation of Foxgl expression from 
15% to 35% in the presence of lOOOng/ml DKK-1 between days 0 to 5 (Watanabe et 
al., 2005). In untreated neural induction cultures Wnt3a has been shown to be 
expressed from day 4 and its expression is maintained, albeit at a lower level, through 
to day 8 (Bouhon et al., 2005). The same cultures express DKK-1 at day 4 and day 6 
at a similar intensity, but at day 8 expression is reduced dramatically (Bouhon et al.,
2005). Although the presence of endogenous Wnt in neural induction cultures might 
implicate supplementation with Wnt inhibitors to allow for direction towards a neural 
lineage, the concomitant presence of endogenous DKK-1 in these cultures might be 
enough to inhibit alternative cell fates.
Neuronal differentiation o f FoxglZ NEBs
Allowing NEBs to adhere to substrate and differentiate for 7 days in the 
presence of B-27 growth supplement and FCS, and in the absence of exogenous 
growth factors such as FGF resulted in generation of P-III-tubulin positive neurons 
with very few astrocytes. Further analysis revealed that a proportion of the neurons 
were positive for GABA, which is the principal neurotransmitter of the striatal MSNs. 
The expression of p-III-tubulin and GABA is consistent with previous in vitro 
differentiation analysis at the same time points (Bouhon et al., 2006). Although there 
was expression of GABA, there was no expression of the MSN marker DARPP-32 at 
this stage.
DARPP-32 expression has not been reported from mouse ES cells following 
either in vitro or in vivo differentiation. However, transplantation of human ES cell-
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derived neural precursors has produced DARPP-32 positive cells following short (4-6 
weeks) and long-term (13-21 weeks) survival, but only when precursors were ‘late’ 
stage and not ‘early’ stage induced in vitro (Aubry et al., 2008). The day 8 precursor 
cells here are likely to be too immature in terms of their gene expression profile and 
are therefore not yet capable of generating the mature marker DARPP-32. Later stage 
precursors, and those that have undergone further patterning to specify their fate, 
would be more likely to generate DARPP-32.
Analysis at day 8, with FGF2 treatment from day 4, revealed that 74% of the 
population were expressing Foxgl/LacZ. Following 7 days under neuronal 
differentiation conditions, 34% of the forebrain population expressed the immature 
neuronal marker P-III-tubulin, and nearly 40% of the total population expressed p-III- 
tubulin. In neural induction of mouse ES cells, cells do not respond synchronously 
(Ying et al., 2003), and therefore it is likely that there are precursor cells as well as 
those that have begun to differentiate and those that are further differentiated. Due to 
the heterogeneity of the cell population at day 8, it is highly probable that there are 
cells of other lineages present, and of the neuronal linage, there are likely to be 
phenotypically different neurons characteristic of different regions of the CNS.
Conclusions
Results presented in this chapter demonstrate the use of mouse ES cells and 
reporter gene systems in neural induction assays. Forebrain specification of NEBs can 
be up-regulated by addition of FGF2 at a specific time point, but there was no effect 
on Foxgl/LacZ expression following addition of the Wnt inhibitor DKK-1 in the 
ADF+ culture system. Mature neurons can be yielded from these cultures following 
differentiation, but further specification of cells is required to generate the DARPP-32 
phenotype.
Importantly, this chapter highlights some discrepancies between different 
culture systems employed and demonstrates the need for caution when interpreting 
and comparing results between the different systems. Previous work within this group 
has only analysed gene expression of neurally induced ES cells at relatively early time 
points (Bouhon et al., 2005). It has been reported that addition of FGF2 is necessary 
for continued culture beyond day 8 (Bouhon et al., 2005). Subsequent chapters will 
look at cultures beyond day 8, with analysis of later stage precursors.
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Chapter 4
In vivo characterisation of NEBs 
(xenograft model)
4.1 Summary
Neural transplantation of mouse ES cell-derived neural precursors (NEBs) into 
excitotoxic lesion models of HD has shown that these cells have the ability to 
generate neurons in vivo. Furthermore, they have been shown to generate AChE and 
GABAergic neurons. However, to date DARPP-32 positive neurons generated from 
these cells in vivo has not been reported. Here, mouse ES cell-derived neural 
precursors generated from the FoxglZ cell line were subjected to neural induction for 
8 and 16 days, and were transplanted into the QA-lesioned rat striatum. The day 8 
NEB grafts developed large cell masses and survival time was only two weeks post­
transplantation. All animals in the day 16 NEB group had surviving grafts after six 
weeks post-transplantation. Day 16 NEB grafts appeared to be comprised of areas of 
both neural and non-neural tissue. Since use of the mouse specific markers, M2 and 
M6, was unsuccessful in our study, only those cells expressing Foxgl and the LacZ 
reporter gene could be positively identified as donor cells. Analysis of these cells 
showed that grafted cells had generated neurons and glia, and further neuronal 
analysis showed differentiation of donor cells into calbindin and parvalbumin positive 
neurons, but not AChE or DARPP-32 positive neurons.
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Cell replacement strategies for neurodegenerative diseases such as HD offer 
great potential for the repair of damaged circuitry and replacement of the lost cells. 
Primary neural stem cells taken from the developing striatum at the appropriate 
developmental age have been shown to generate beneficial results in both rodent 
models and human patients (Watts et al., 1997; Bachoud-Levi et al., 2006). However, 
for clinical studies this source of tissue is in limited supply and as well as the ethical 
issues surrounding use and collection of the tissue, there are also difficulties with 
coordination of tissue collection, the amount required for transplantation and the 
logistics of the transplantation itself.
ES cells offer an alternative cell source for replacement because of their 
pluripotency and self-renewal characteristics. However, one caveat associated with 
the use of ES cells is their uncontrolled proliferation, with the continued presence of 
ES cells following differentiation increasing the potential for teratoma formation, 
which is clearly not acceptable for clinical transplantation.
Neural transplantation of ES cell-derived neural precursors into the QA 
lesioned-striatum model of HD has to date been limited, which is in part due to 
difficulties in generating the desired phenotype for repair in HD ie MSNs. Studies 
have reported generation of neuronal phenotypes, such as AChE and GABAergic 
neurons, following transplantation of mouse ES cell-derived neural precursors into the 
rat lesioned striatum (Dinsmore et al., 1996). Transplantation of pre-differentiated 
GABAergic neurons derived from an immortalised striatal neural cell line (ST 14A) 
have been shown to maintain their phenotype and also elicit a beneficial effect on 
reducing the number of apomorphine rotations (Bosch et al., 2004).
Precursors derived from both human and non-human-primate ES cells have 
been shown to generate mature neurons expressing DARPP-32 following 
transplantation into the rat striatum (Aubry et al., 2008; Ferrari et al., 2006). Non­
human primate ES cells subjected to sequential addition of SHH and FGF8 then 
BDNF and ascorbic acid were transplanted at a progenitor (pES) stage (day 28) and as 
differentiated (dES) neurons (day 42) into the striatum of 6-OHDA lesioned rats 
(Ferrari et al., 2006). The pES cells generated very large grafts with heterogeneous 
morphology whereas the dES grafts were significantly smaller and exhibited no
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overgrowth. D-amphetamine-induced rotations at twelve weeks post-transplantation 
were improved in 50% of the pES group and 80% of the dES group, and interestingly 
there was no difference in numbers of TH positive cells within the grafts of the two 
groups, which also expressed DARPP-32 within TH-positive regions (Ferrari et al.,
2006). Aubry et al (2008) employed N2 and BDNF followed by SHH and DKK-1 for 
neural induction of human ES cells and reported teratoma formation and no DARPP- 
32 expression when cells were transplanted at early culture time points (29 days in 
vitro). Later stage cells (59 days in vitro) resulted in no teratomas and expression of 
DARPP-32 positive neurons. However, following longer survival post-transplantation 
grafts showed overgrowth, as well as DARPP-32 positive neurons (Aubry et al., 
2008).
A longitudinal transplant study of human ES cells neurally induced in the 
presence of bFGF and noggin, grafted into the non-lesioned striatum resulted in no 
overgrowth or teratoma formation (Nasonkin et al., 2009). At three months there was 
no DARPP-32 expression but by six months 30% of graft-derived cells were DARPP- 
32 positive. To date, differentiation of mouse ES cell-derived precursors into DARPP- 
32 positive neurons following transplantation has not been reported.
The previous chapter involved the characterization of FoxglZ NEBs up to 8 
days in a neural induction protocol. In this chapter FoxglZ NEBs were maintained in 
culture in ADF+ for either 8 or 16 days and transplanted into the QA lesioned 
striatum model. Oct-3/4 expression has been reported in neurally induced mouse ES 
cells at day 8 (Bouhon et al., 2005; Watanabe et al., 2005), albeit at low levels, but 
due to its presence at this time point (also shown here; Figure 4.1), longer term 
cultures were analysed and two cell groups were taken forward; short term (day 8) 
and long term (day 16).
The original aims were to analyse the potential of these cells and characterise 
their phenotypic differentiation in vivo at six weeks post-transplantation, in particular 
looking for differentiation to striatal phenotypes. Due to adverse events the group that 
received the day 8 NEB grafts were sacrificed at two weeks post-transplantation. The 
group that received the day 16 NEB grafts did not exhibit signs of ill-health and 
survived the six week experimental period. Morphological analysis was carried out on 
both grafted groups, but more detailed analysis of specific cell phenotypes generated 
in vivo was only carried out on the day 16 NEB grafted group.
87
Chapter 4
4.3 Experimental Procedures
in vivo characterisation o f NEBs (xenografts)
Cell Culture and Immunocytochemistry
The mouse ES cell line Foxgl-lacZ was used in this study. FoxglZ NEBs 
were derived from the FoxglZ mouse ES cell line as described in Chapter 2. Briefly, 
ES cells were transferred from ES cell culture medium to ADF+ medium at a density 
of 50,000 cells per ml, medium was replaced every 2 days and FGF2 (20ng/ml) was 
added from day 4. Cells were plated onto PLL/laminin treated cover-slips at a density 
of 50,000 cells per 30pl drop on each cover-slip. Cells were fixed 2-4 hours after 
plating, on adhering to the substrate. Fluorescent immunocytochemistry was 
performed according to the protocol detailed in Chapter 2. Primary antibodies used 
were anti-Oct-3/4 (1:100), anti-Nestin (1:400) and anti-Pax6 (1:50).
Neural Transplantation
Adult female Sprague-dawley rats received a unilateral QA lesion of the right 
striatum. Two-three weeks after lesioning rats received transplants of FoxglZ NEBs 
of either 8 days or 16 days following neural induction (n=9 for each group) into the 
lesioned striatum. Lesions and grafts were carried out as described in Chapter 2.
On the day of grafting, cells were harvested and dissociated following 
incubation with accutase, as detailed in Chapter 2. Cells were counted and 
resuspended at 250,000 cells per pi and 2pl cell suspension was grafted per animal. 
From the day prior to grafting, animals received immunosuppression in the form of 
daily intra-peritoneal injections of cyclosporin A (lOmg/kg) for the duration of the 
experiment.
Histology and Immunohistochemistry
Animals were intended to survive for six weeks however the ‘day 8 NEB’ 
graft group were sacrificed at two weeks post-transplantation due to adverse events 
and as a requirement of our licensing protocols. The ‘day 16 NEB’ graft group were 
sacrificed at six weeks post-transplantation as originally planned. Animals were 
transcardially perfused and brains were taken for histological analysis. Brains were 
sectioned coronally on the freezing-stage microtome at 40pm. 1:12 series’ were 
processed for Nissl staining using cresyl violet, histochemical staining for AChE, and
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further 1:12 or 1:24 series’ were processed for immunohistochemistry with anti-M2 
(1:50), anti-M6 (1:50), anti- P-galactosidase (1:1000), anti-GFAP (1:2000), anti-NeuN 
(1:4000), anti-DCX (1:500), anti-DARPP-32 (1:10,000) (a gift from Paul Greengard), 
anti-FoxPl (1:500), anti-calbindin (1:20,000) and anti-parvalbumin (1:4000).
The immunohistochemical staining protocol was the same for each antibody, 
as described in Chapter 2. For double-labelling, the anti-p-galactosidase was always 
processed first and visualised using DAB (brown), and then the second antibody was 
processed and visualised using the Vector SG kit (blue). The only exception to this 
was for the AChE stain, where the anti-p-galactosidase was processed first and 
visualised using the Vector SG kit, since the colour reaction for the AChE stain yields 
a brown product.
Lesion-only animals were generated at a later time-point for comparison of 
immunohistochemical stains.
Quantification
Cells expressing markers of interest were counted using a Leitz light 
microscope and stereology software. Graft volume was determined as described in 
Chapter 2. Statistical analyses were performed using two-sample t-tests and one-way 
ANOVA with Tukey-Kramer post-hoc comparisons when appropriate, using Minitab 
15 software.
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In vitro characterisation o f  NEBs pre-transplantation
Expression o f the ES cell marker Oct-3/4 in NEBs decreased over time in 
ADF+ neural induction culture (Figure 4.1). There was a highly significant difference 
between Oct-3/4 expression and day o f neural induction culture (day, Fg,27 = 115.81, 
p<0.001). The proportion o f cells that expressed Oct-3/4 on day 0 o f the neural 
induction protocol was 89.25 ± 0.26%; at day 4 the proportion was 8.43 ± 3.21% and 
at day 8 it was 2.25 ± 0.31%. The detection o f 2% Oct-3/4 positive cells still present 
in the cultures at day 8 prompted a longer time-point for analysis. Oct-3/4 expression 
has ‘sw itched-off by day 16 in the neural induction culture, suggesting there are no 
longer ES cells present.
Figure 4.1. FoxglZ NEBs were harvested, dissociated and plated onto substrate every two 
days following initiation of the neural induction protocol. Cultures were fixed after 4 hours 
and immuno-labelled for the undifferentiated ES cell marker Oct-3/4 (red) and Hoechst 
nuclear stain (blue) (A and B). Oct-3/4 immuno-positive cells were counted and are 
represented as a percentage of total Hoechst stained cells (C). At day 8 few Oct-3/4 positive 
cells were present (A) and at day 16 there were no Oct-3/4 positive cells detected (B). Each 
bar on the graph represents a mean of 3 different neural induction cultures and error bars 
represent SEM. Significant post-hoc differences are indicated with brackets. (***p<0.001). 
Scale bars = 100pm.
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FoxglZ NEBs were analysed following 8 and 16 days in neural induction 
culture for the expression of nestin; a neural precursor marker and Pax6; a marker of 
the developing dorsal telencephalon. Cultures were dissociated, plated onto 
PLL/laminin substrate and fixed after 4 hours. There was a highly significant 
difference in nestin expression between NEB cultures at day 8 (63.46 ± 8.45%) (mean 
± SEM) and at day 16 (18.07 ± 2.33%) (day, u  = 8.67, p<0.001) (Figure 4.2; A, B and 
C). Pax6 expression did not differ significantly from day 8 (42.89 ± 2.87%) to day 16 
(45.16 ± 5.18%) (day, t5 = 0.41, p = n.s) (Figure 4.2; D, E and F).
Following in vitro differentiation of day 8 and day 16 NEBs for 7 days in the 
presence of FCS and B-27, incubation with X-gal revealed Foxgl-positive cells. Day 
8 differentiated cells (Figure 4.3; A) exhibited large clusters of cells including those 
with neuronal appearance. Within these cultures there was also the presence of large 
clusters of X-gal-negative cells which were not neural in appearance. Day 16 
differentiated cultures (Figure 4.3; B) exhibited a more even distribution of Foxgl - 
positive cells interspersed with Foxgl-negative cells, and appeared to have less 
heterogeneous morphology.
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Figure 4.2. FoxglZ NEBs were harvested, dissociated and plated onto substrate at day 8 (A 
and D) and day 16 (B and E) of neural induction. Cultures were fixed after 4 hours and 
immuno-labelled with nestin (red) (A - C) or Pax6 (red) (D - F) and Hoechst nuclear stain 
(blue). Nestin and Pax6 immuno-positive cells were counted and are represented as a 
percentage of total Hoechst cells (C and F). The neural precursor marker nestin is more highly 
expressed in day 8 NEBs compared with day 16 NEBs, and there is no difference in 
expression of the developing forebrain marker, Pax6 between day 8 and day 16 NEB cultures. 
Each bar on the graphs represents a mean of 3 different neural induction cultures and error 
bars represent SEM. (***p<0.001). Scale bar = 50pm.
Figure 4.3. FoxglZ NEBs were harvested, dissociated and plated onto substrate at day 8 and 
day 16, and allowed to differentiate for 7 days in neuronal differentiation medium. Cultures 
were incubated with X-gal staining solution (blue) and counterstained with eosin (pink). X- 
gal staining of day 8 cultures revealed clusters of blue cells including those showing neuronal 
morphology (red arrow). Within these cultures there were also large clusters of X-gal- 
negative cells (A). Day 16 cultures revealed a more even distribution of X-gal-positive cells 
throughout the platedown (B). Scale bars = 100pm.
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Day 8 NEB graft morphology
Analysis of day 8 NEB grafts at six weeks post-transplantation was not 
possible due to the observation of ill-health and this group was sacrificed at two 
weeks post-transplantation. Nissl-stained sections (Figure 4.4; A, B and C) reveal that 
these grafts exhibited what appeared to be uncontrolled proliferation, resulting in 
overgrowth and a cell mass with well-defined borders, which filled the striatum and 
pushed into the cortex. All animals within this group had similar looking grafts with 
‘swirling’ patches of tissue throughout, some of which appeared to be highly 
organised and were predominantly of non-neural cell composition.
The mouse neuron and mouse glia specific markers, M2 and M6 respectively, 
that were intended for use in order to identify grafted cells, proved non-specific and 
no graft-derived cells were labelled. The LacZ reporter incorporated in the FoxglZ 
cell line enabled the use of the p-galactosidase antibody to detect Foxgl-positive- 
graft-derived cells (Figure 4.4; D and E). Within these ‘teratoma-like’ grafts there are 
patches of dense p-galactosidase immunoreactivity alongside regions with no 
immuno-positive cells. Graft volume was estimated using cell counts of p- 
galactosidase positive cells and the mean graft volume for the day 8 NEB grafts was 
336.32 ± 129.16mm3 (mean ± SEM). There was huge variability in graft size between 
animals with the range of volumes from 19.24 to 962.32mm3.
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Figure 4.4. A representative 1:12 series, anterior to posterior, showing morphology of day 8 
NEB grafts by Nissl staining with cresyl violet, at two weeks post-transplantation (A). Scale 
bar = 500pm. Photomicrographs B and C show higher power images of the Nissl stain. Scale 
bars = 100pm. The cell mass does not integrate into the host brain, but appears to grow as an 
isolated mass, with ‘swirling’ patches throughout and well-defined borders. 
Photomicrographs D and E show staining for P-galactosidase, which reveals p-galactosidase- 
dense regions alongside regions with no immunopositive cells. Scale bars = 500pm.
Day 16 NEB grafts morphology
Surviving grafts were seen in all animals that were transplanted with day 16 
NEBs, as revealed by Nissl-stained sections (Figure 4.5; A, B and C) and p- 
galactosidase immunoreactivity (Figure 4.5; D and E). There are cell-dense regions 
present throughout the graft which are interspersed with less dense regions with a 
more even distribution o f p-galactosidase immunopositive cells throughout the graft 
and fewer ‘less-dense’ regions, when compared with the day 8 NEB grafts. The 
borders o f the day 16 NEB grafts are less well-defined than those o f the day 8 NEB 
grafts (Figure 4.4; A and C, and Figure 4.5; A and B), which indicates a degree o f 
integration of the day 16 NEB grafts into the host brain, rather than the distinctly 
isolated cell mass o f the day 8 NEB grafts. Estimating the graft volume using the 
number o f P-galactosidase positive cells revealed a range from 13.14 to 56.5 mm3 
with a mean value o f  21.87 ± 4.63m m 3. Day 16 NEB grafts exhibited a less 
heterogeneous appearance than day 8 NEB grafts. They had less non-neural tissue and
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their appearance was more similar to grafts observed with primary striatal donor 
tissue, although they were larger in volume.
mm
Figure 4.5. A representative 1:12 series of Nissl staining using cresyl violet, showing graft 
morphology of day 16 NEB grafts at six weeks post-transplantation (A). Scale bar = 500pm. 
Photomicrographs B and C show higher power Nissl-stained images which reveal an even 
distribution of cells throughout the graft. Photomicrographs D and E show p-galactosidase 
immuno-reactivity within the graft, showing even distribution of p-galactosidase 
immunopositive cells. Scale bars = 100pm.
Neural analysis o f  Day 16 NEB grafts
Grafts were analysed for the expression o f the neuronal markers DCX, which 
labels immature neurons, NeuN, which labels the nuclei o f more mature neurons and 
also the glial marker GFAP. Expression o f  the striatal markers DARPP-32, calbindin 
and parvalbumin was also assessed. Due to the lack o f specificity when staining with 
both M2 and M6 the only graft-derived cells which can be identified with confidence 
and analysed for expression o f markers o f  interest are those that are immunopositive 
for p-galactosidase.
P-galactosidase-positive cells were seen to double label with NeuN throughout 
the graft (Figure 4.6; A and B) in all animals, and there was a proportion of NeuN 
immunopositive cells that did not double label. Between animals the numbers o f 
NeuN positive cells as a percentage o f p-galactosidase positive cells ranged from 10 -  
25% with a mean o f 16.95 ± 1.44% (mean ± SEM) (Figure 4.7). DCX positive cells 
were identified within the graft and were seen to double label with p-galactosidase 
(Figure 4.6; C and D). There was variability in number o f co-labelled cells between
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animals, ranging from 4-16%, with a mean o f 8.24 ± 1.29% (Figure 4.7). All grafts 
exhibited some degree o f  immunoreactivity to the astrocyte marker GFAP with 
double labelling with p-galactosidase (Figure 4.6; E and F), within a range o f 3 -  12% 
(7.38 ± 1.12%) (Figure 4.7) across the group, but not all GFAP positive cells within 
the graft area were positive for p-galactosidase.
Figure 4.6. NeuN (blue)/p-galactosidase (brown) staining reveals NeuN positive cells within 
the graft seen to double label with the p-galactosidase graft-derived cells, as shown with the 
arrow (A and B). DCX (blue)/p-galactosidase (brown) staining shows some expression of 
DCX co-expressed with p-galactosidase (shown with the arrow) (C and D). GFAP (blue)/p- 
galactosidase (brown) staining shows double-labelling of the astrocyte marker with grafted 
cells, within the graft area (shown with the arrow) (E and F). Scale bars = 50pm.
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Co-expression of B-galactosidase immuno­
positive cells in Day 16 NEB grafts
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Figure 4.7. The percentage of P-galactosidase-positive cells expressing the neuronal markers 
NeuN, DCX, calbindin and parvalbumin, and the glial marker GFAP, in day 16 NEB grafts at 
six weeks post-transplantation. Error bars represent SEM.
Analysis o f striatal markers within the grafts
There was no DARPP-32 immunoreactivity seen within the graft area, very 
few immuno-positive cells were seen at the periphery of the graft and there was no co­
localisation with p-galactosidase (Figure 4.8; A and B). Sections stained for FoxPl 
showed some immuno-reactive cells at the graft periphery and within the graft area 
itself, but none of these cells were seen to double label with p-galactosidase (Figure 
4.8; D and E). Expression of both DARPP-32 and FoxPl were seen at the periphery of 
the lesion (Figure 4.8; C and F).
Other striatal neuronal markers assessed were calbindin and parvalbumin. Few 
calbindin positive cells were seen within the grafts and there was a degree of double­
labelling with p-galactosidase (Figure 4.8; G and H) although this was not the case 
with all animals. The situation was similar when sections were stained with 
parvalbumin, where few immunopositive cells were seen to double label with p- 
galactosidase (Figure 4.8; J and K) but this was not evident in all animals. The range 
for co-localisation of p-galactosidase with calbindin was 0-5% with a mean of 1.62 ± 
0.77%, and with parvalbumin the range was 0-6%, with a mean value of 2.26 ± 0.76% 
(Figure 4.7). Calbindin expression was seen at the periphery of the lesion (Figure 4.8; 
I) and a few parvalbumin positive cells could be seen within the lesion, but they were 
very scarce (Figure 4.8; L).
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Day 16 NEB grafts Lesion only
Figure 4.8. Striatal markers analysed within day 16 NEB grafts at six weeks post­
transplantation. Sections were stained for DARPP-32 (A-C), FoxPl (D-F), calbindin (G-I) 
and parvalbumin (J-L). Photomicrographs in column 3 are sections from lesion-only brains 
(C, F, I and L). DARPP-32 immuno-reactive cells (blue) were observed at the periphery of the 
graft area as shown with the arrow in B. No P-galactosidase (brown) positive cells were seen 
to double label with DARPP-32 (A and B). FoxPl positive cells (blue) were also seen at the 
edge of the graft area (arrow in D), and again there was no co-expression of FoxPl with the 
graft-derived p-galactosidase (brown) (C and D). Calbindin staining revealed some calbindin- 
positive cells (blue) within the graft area, and some of these cells were seen to double label 
with p-galactosidase (brown) (E and F). Parvalbumin staining showed a small proportion of 
the p-galactosidase-graft-derived cells double-labelling (G and H). Scale bars = 50pm.
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AChE identifies the characteristic patch-matrix structure o f the striatum, 
outside the grafted area however, there is no evidence o f the patch-matrix within the 
graft, since the AChE histochemical staining revealed no double-labelling with p- 
galactosidase positive cells (Figure 4.9).
AChE
Figure 4.9. Photomicrographs of a representative day 16 NEB graft at various magnifications 
following AChE hisotchemical staining, p-galactosidase (blue) and AChE (brown) show no 
co-localisation. The AChE identifies the patch-matrix structure of the striatum outside the 
grafted area however there is no evidence of the patch-matrix within the graft. Scale bars = 
50pm.
4.5 Discussion
In vitro expression o f  precursors pre-transplantation
Oct-3/4 is a member o f  class V o f the POU (Pit, Oct, Unc)-domain 
transcription factor family and is expressed by pluripotent cells (Niwa et al., 2000). It 
is expressed in ES cell lines derived form the ICM when the cells are in an 
undifferentiated state and when ES cells begin to differentiate the expression o f Oct- 
3/4 rapidly down regulates. When ES cells are subjected to our neural induction 
protocol (ADF+), expression o f  Oct-3/4 is seen to decrease over time from 89.25% at 
day 0 to 2.25% at day 8. Bouhon et al report that Oct-3/4 expression at day 4 is lower
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in CDM culture than when cells are cultured in 10% serum (Bouhon et al., 2006). 
After 8 days in CDM with and without addition of FGF2 at day 4, RT-PCR revealed a 
faint band representing Oct-3/4 expression relative to Gapdh (Bouhon et al., 2005) 
and cell counts following immunocytochemistry revealed 2.43% cells still expressing 
Oct-3/4 at day 8 (Bouhon et al., 2006). Oct-3/4 expression in cultures in this study 
was analysed using fluorescent immunocytochemistry with the Oct-3/4 antibody and 
is consistent with the evidence of Oct-3/4 positive cells in cultures at day 8, albeit a 
low proportion of cells. The few cells that still express Oct-3/4 are an issue that needs 
to be addressed before cells after this short period in CDM culture can be used for 
transplantation. After 16 days in ADF+ culture Oct-3/4 expression is shown to have 
‘switched off.
Expression of nestin following neural induction in ADF+ significantly 
decreased from day 8 to day 16. This is consistent with a report that showed nestin 
expression in neurally induced ES cells decreases over time in culture from day 0 to 
day 8, with a further decrease by day 12 (Bouhon et al., 2005). Analysis of nestin- 
positive cells present in neural induction culture prior to transplantation revealed that 
the lower the proportion of nestin-positive cells, the lower the risk of teratoma 
development (Dihne et al., 2006). Addition of FGF2 to CDM cultures has been shown 
to maintain the proportion of nestin-positive cells over time, up to day 8, when 
compared with CDM alone and the same study also reported that NEBs older than day 
8 depend on exogenous FGF2 (Bouhon et al., 2005). Pax6 expression, a marker of 
dorsal telencephalic cells, was not significantly different between day 8 and day 16 
cultures. Bouhon et al., (2005) reported an increase in Pax6 expression between day 4 
and day 8 in CDM, but expression beyond day 8 was not analysed.
Day 8 NEB graft survival and morphology
During post-mortem analysis there is a need for detection of transplanted cells 
in order to distinguish between graft-derived and host-derived phenotypes generated 
following implantation, subsequent survival time and in vivo differentiation. When 
grafting cells of mouse origin into the host rat brain this identification can prove 
difficult since there are very few mouse specific markers available. M2 and M6 
markers which are reported to specifically label mouse neurons and mouse astrocytes 
respectively, were initially used in our study, but proved unreliable and unsuccessful 
when tested using our current protocols.
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The FoxglZ ES cell line used in this study enables the detection of cells 
expressing LacZ and therefore Foxgl, by using antibodies against the enzyme p- 
galactosidase. Only those cells immunopositive for P-galactosidase can be positively 
identified as donor cells, and thus, due to lack of any other reliable marker, only these 
cells were further characterised. It is therefore not always straight forward to draw 
conclusions regarding whether or not a single-labelled cell is graft or host-derived.
The number of P-galactosidase immuno-positive cells in the day 8 NEB grafts 
varied greatly between animals. Histological analysis showed that all animals in the 
group exhibited grafts with massive overgrowth, as shown in figure 4.4, and due to 
signs of ill-health observed in the animals, the group was sacrificed at the early time 
point of two weeks. The difference in graft survival time between the two graft 
groups, and the fact that the day 8 NEB grafts suffered the uncontrolled proliferation 
and generation of ‘teratoma-like’ masses, make it difficult to draw comparisons 
between them.
The potential of ES cells to develop teratomas following transplantation is one 
major down-fall in their consideration as an alternative cell source for clinical 
applications. The appearance of non-neural-like regions of cells within the day 8 NEB 
grafts in this study, and the overgrowth observed indicates generation of teratomas, 
which can be recognised by the presence of a range of differentiated tissue types, 
representative of the three germ layers (Przyborski, 2005). Mouse ES cell-derived 
EBs implanted into the embryonic rat brain and left to survive until 2 weeks after birth 
have been shown to migrate to various brain regions and generate neural cell types 
(Brustle et al., 1997). Benninger et al (2000) generated EBs from ES cells using 
neurobasal medium supplemented with B27 and following 8 days in these culture 
conditions the cells were grafted into the adult mouse striatum where graft-derived 
cells differentiated into neurons, glia and oligodendrocytes (Benninger et al., 2000). 
Furthermore, donor cells have shown some degree of expression of region-specific 
markers such as Foxgl, Dlx and Pax6 (Wemig et al., 2004). However along with 
these encouraging observations for the potential of these cells to develop into desired 
phenotypes, other findings, within the same host brains, include undifferentiated ES 
cells, non-neural tissue clusters (Brustle et al., 1997), including epithelium, muscle 
and cartilage (Benninger et al., 2000), and teratomas (Wemig et al., 2004).
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Day 16 NEB graft survival and morphology
At six weeks post-transplantation, during which time daily immuno­
suppression was administered, all animals receiving day 16 NEB grafts had what 
appeared to be healthy, surviving grafts. The Nissl staining showed that these grafts 
did not cause distortion of the brain and they did not show signs of over-growth. 
There was an indication though that the grafts comprised heterogeneous cell types of 
both neural and non-neural derivation. However, this finding is not remarkable since 
non-neural differentiation has previously been reported following neural 
transplantation, as outlined earlier (Brustle et al., 1997; Benninger et al., 2000; 
Wemig et al., 2004).
Graft volume was variable within the day 16 NEB graft group and looked 
comparable to graft sizes from a previous study where mouse ES cell-derived 
precursors were grafted into the adult rat QA lesioned striatum (Dinsmore et al., 
1996), although this study reported no cell numbers or graft volumes. Primary rat 
striatal tissue grafted into the rat lesioned striatum (450,000 - 500,000 cells grafted) 
yielded grafts with a range of volumes that are around 20 times smaller than that 
reported in this chapter, and interestingly, MGE-derived grafts were smaller than 
LGE-derived grafts (Pakzaban et al., 1993; Olsson et al., 1995).
Phenotype o f Foxgl Z cells in day 16 NEB grafts
Due to the problem of reliably identifying all donor cells, further graft analysis 
considers those cells that are P-galactosidase positive. Donor cells were shown to 
generate immature and more mature neurons, shown by co-expression of p- 
galactosidase with the markers DCX and NeuN, respectively, and also glial cells, 
shown by co-expression with GFAP. Analysis of striatum-specific neurons revealed 
expression of donor-derived calbindin and parvalbumin, but neither DARPP-32 nor 
AChE. Co-expression of p-galactosidase and FoxPl was not observed indicating the 
absence of graft-derived striatal precursor cells.
The 28 kD calcium-binding protein calbindin is expressed in projection 
neurons originating in the striatal matrix compartment. The presence of calbindin 
immunopositive cells within the day 16 NEB grafts indicates striatonigral projection 
neurons characteristic of the matrix compartment of the striatum (Gerfen, 1992). 
Parvalbumin immunoreactivity is evidence of striatal medium aspiny neurons and 
intemeurons within the graft.
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There are only a handful of reports on the survival and phenotype of mouse ES 
cell-derived precursors transplanted into the QA lesioned striatum. Dinsmore et al 
(1996) transplanted mouse ES cell-derived precursors that were grown as free-floating 
spheres with the addition of RA. Following six weeks in vivo, they found neurons 
within the graft area that were positive for neuron-specific enolase (NSE), neuron- 
specific tubulin, GABA and AChE (Dinsmore et al., 1996).
Bosch et al (2004) used the immortalised striatal neural stem cell line, ST14A 
and following sequential treatment with RA and KC1, and pre-differentiation to a 
GABAergic phenotype, cells were transplanted into the lesioned rat striatum. They 
observed that three days post-transplantation cells maintained their GABAergic 
phenotype, and at both one and five weeks post-transplantation apomorphine-induced 
rotations were reduced in grafted animals compared with non-grafted controls, 
suggesting a degree of benefit from GABAergic pre-differentiated neurons 
transplanted into QA-lesioned rats (Bosch et al., 2004).
Although there have been no reports on the generation of DARPP-32 positive 
neurons following transplantation of mouse ES cell-derived precursors, this has been 
shown for human NEBs (Aubry et al., 2008; Nasonkin et al., 2009). Transplantation 
of neurally induced human ES cell-derived precursors involving long-term addition of 
BDNF, Shh and Dkk-1, gave rise to grafts containing DARPP-32 and calbindin 
positive cells, following six weeks in vivo (Aubry et al., 2008). Nasonkin et al (2009) 
cultured human ES cells in FGF2 and noggin for four weeks and then transplanted 
into the unlesioned rat striatum. At three months post-transplantation there was no 
graft-derived DARPP-32 but at six months 30% of grafted cells were DARPP-32 
positive (Nasonkin et al., 2009).
The absence of DARPP-32 within the grafts in our study might be because the 
cells were not exposed to all the necessary differential cues while in culture prior to 
transplantation, and also the in vivo maturation period might not have been long 
enough to encourage induction of more mature neuronal phenotypes such as DARPP- 
32.
Conclusions
Work presented in this chapter supports the evidence that ES cells have the 
potential to be beneficial for neural transplantation. It is clear however that further 
controlled directed differentiation of these cells is required in order to remove
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unwanted cell populations and achieve the desired striatal progenitor population. 
Analysis of the day 16 NEB grafts reveals that when transplanted these cells have the 
ability to generate neurons, a low proportion of which exhibit striatal markers. The 
presence of striatal neurons such as calbindin and parvalbumin is an encouraging 
result and longer term in vivo differentiation of these cells might generate increasing 
numbers of striatal-like cells including DARPP-32 expressing neurons.
Cells originating from the developing striatum that are transplanted for cell 
replacement in HD, have been exposed to the necessary complement of factors and 
cues to steer them towards the desired phenotype. Even these cells, when grafted into 
lesion models, do not appear to generate all the cell types in the necessary proportions 
to achieve the desired functional recovery. It is ambitious to suppose that ex-vivo 
derived NEBs, with initial differentiation in vitro and subsequent maturation in vivo in 
the adult striatum, will be sufficiently induced to generate the required cell identities, 
and it is understandable therefore that a complex of factors will need to be added to 
NEBs in order to generate LGE-like progenitor cells.
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Chapter 5
Generation of ventral telencephalon-like 
precursors
5.1 Summary
NEBs cultured under standard neuralising conditions without attempting 
directed differentiation showed some evidence, in Chapter 4, of differentiation typical 
of striatal neuronal markers. Others have reported similar cells in these conditions to 
express gene markers of the developing telencephalon, and more specifically markers 
which are characteristic of specific dorso-ventral regions of the telencephalon. Here, 
analysis of such markers in NEBs at day 8 and day 16 following standard neural 
induction culture, using semi-quantitative RT-PCR, showed that expression levels of 
all markers were lower than their comparative levels in the cells of the dorsal or 
ventral telencephalon. Addition of a range of concentrations of the SHH agonist 
purmorphamine resulted in reduced expression of dorsal markers Pax6 and Ngn2, and 
low concentrations (0.5pM) resulted in an increase in ventral markers Nkx2.1 and 
Dlx2. Analysis of SHH-pathway components revealed that expression of SHH and 
Patched was higher in NEBs at both day 8 and day 16 than expression in the E14 
mouse ventral telencephalon. Treatment of NEBs with various concentrations of the 
SHH antagonist cyclopamine did not significantly alter expression of dorsal markers, 
but caused a decrease in expression of ventral markers Nkx2.1, Dlx2 and Gsx2. 
Interestingly, Mashl expression was not changed.
Fluorescent immunocytochemistry indicated that the dorsal marker Pax6 was 
reduced with purmorphamine treatment and increased with cyclopamine treatment, at 
both day 8 and day 16. The MGE marker Nkx2.1 was increased at day 8 with 
purmorphamine and decreased with cyclopamine, and at day 16 this response was 
more substantial. Mashl expression was reduced by addition of purmorphamine at 
day 8 and day 16, and was shown to increase with cyclopamine treatment at both 
days.
In summary, although gene expression changes in NEBs were demonstrated in 
response to purmorphamine and cyclopamine, this was not consistent for all the 
dorso-ventral genes analysed and no conclusive patterns were identified.
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5.2 Introduction
The developing telencephalon expresses markers that are characteristic of 
distinct regions of origin and are responsible for the subsequent generation of mature 
phenotypes present in the adult forebrain. The dorsal-most region of the telencephalon 
gives rise to the cortex, whilst the ventral-most region is the origin of cells that go on 
to populate the striatum, cortex, GP and olfactory bulb. It is the LGE of the ventral 
portion that is predominantly the origin of DARPP-32-positive MSNs.
Mouse NEBs cultured in serum-free suspension medium have been reported to 
express genetic markers of the developing telencephalon, and in addition, markers 
typical of specific regions along the dorsal-ventral axis (Bouhon et al., 2005; 
Watanabe et al., 2005; Gaspard et al., 2008). Supplementation of neural induction 
cultures with factors known to be important for development of the neural tube, in 
particular patterning of cells, has proved fruitful in generating such precursors (see 
section 1.6 Introduction).
SHH is a morphogen released from the prechordal plate, which underlies the 
telencephalon (Rubenstein et al., 1998) and it acts in a concentration-dependent 
gradient within the developing neural tube (Jessell, 2000). Addition of a range of 
doses of SHH (3-300nM) to serum-free suspension cultures of mouse ES cells 
decreased expression of the dorsal telencephalon markers Pctx6 and Emxl, whilst 
increasing expression of the ventral telencephalon markers Gsx2 and Nkx2.1 within 
the Foxgl population, which was not significantly changed (Watanabe et al., 2005). 
Treatment of neural induction cultures of mouse ES cells with the SHH antagonist 
cyclopamine has been reported to increase expression of the dorsal telencephalon 
markers Pax6, Emxl and Emx2, and decrease expression of the ventral telencephalon 
markers Gsx2 and Nkx2.1 (Gaspard et al., 2008).
A sonic hedgehog agonist, purmorphamine, was discovered by Wu et al, 
(2002), who screened a ‘heterocycle combinatorial library’ for small molecules with 
osteogensis-inducing activity. Purmorphamine showed significant activity in the 
alkaline phosphatase (ALP) enzymatic assay, which is an osteoblast specific gene 
highly expressed during differentiation (Wu et al., 2002). Wu et al (2004) investigated 
how purmorphamine induced bone differentiation and found that the same genes that
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are induced by Hedgehog are also upregulated by purmorphamine and, when 
Hedgehog signalling was blocked, the effect of purmorphamine disappeared (Wu et 
al., 2004). More recently, it has been shown that purmorphamine directly targets 
smoothened in the SHH signalling pathway and has opposing activity to smoothened 
inhibitors (Sinha and Chen, 2006; Briscoe, 2006).
Following the generation of optimal numbers of forebrain precursors from 
mouse ES cells in neural induction culture with the addition of 20ng/ml FGF2 at day 
4, as demonstrated in Chapter 3, the next step was to further specify the forebrain 
precursors to enrich for ventral telencephalon-like precursors. This chapter analysed 
gene expression of NEBs relative to expression in corresponding regions of the 
developing mouse brain at gestational age E l4. The SHH agonist purmorphamine was 
added to cultures at day 4 at various concentrations in order to determine if there was 
a dose-response effect on NEBs with analysis at day 8 and at day 16, and markers 
indicating dorso-ventral patterning in the developing telencephalon were analysed. 
Upon further analysis, endogenous SHH levels were found to be higher than 
anticipated and subsequently cultures were treated with the SHH antagonist 
cyclopamine and analysed for dorso-ventral specification.
Analysis of purmorphamine and cyclopamine treatments revealed changes in 
expression of both dorsal and ventral markers, and some patterns of expression were 
observed. However, this was not entirely consistent across all the markers analysed 
and there was no conclusive pattern regarding effects on dorso-ventral patterning. 
Semi-quantitative RT-PCR and fluorescent immunocytochemistry analysis were 
carried out on untreated and treated NEBs, looking at markers indicative of 
specification along the dorso-ventral telencephalic axis, comparing expression with 
that in the developing telencephalon.
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5.3 Experimental Procedures
Cell Culture
The mouse ES cell line Foxgl-lacZ was used in this study. NEBs were derived 
from the FoxglZ mouse ES cell line as described in Chapter 2. Briefly, ES cells were 
transferred from ES cell culture medium to CDM (ADF+ medium) at a density of 
50,000 cells per ml, medium was replaced every 2 days and FGF2 (20ng/ml) was 
added from day 4.
For analysis of effects of the SHH agonist purmorphamine, the range of 
concentrations 0.5,1,2 and 5pM was used, and was added from day 4.
For analysis of effects of the SHH antagonist cyclopamine, the range of 
concentrations 0.1,0.5,1 and 2pM was used, and was added from day 4.
Dissection o f mouse forebrain regions
Control samples for gene expression analysis were taken from the E14 mouse 
forebrain. Cortex, WGE, LGE and MGE were dissected from E14 mouse embryos as 
described in Chapter 2. Each region was dissected, washed and finely chopped before 
RNA extraction for gene expression analysis. Tissue from the same regions was also 
enzymatically dissociated and plated down onto substrate for immunocytochemistry 
(as described in Chapter 2).
Gene expression analysis
NEBs were analysed at days 8 and 16. RNA was extracted for subsequent 
cDNA synthesis and QPCR analysis was then carried out using the SYBR Green 
assay, as detailed in Chapter 2.
Primer pairs used were p-actin, Pax6, Ngn2, Emx2, Nkx2.1, Dlx2, Mashl, 
Gsx2, Shh, Gli3 and Patchedl (see Appendix 4 for sequences). Opticon Monitor 3 
software was used and the differential gene expression of different samples was 
measured relative to the expression of P-actin (as described in Chapter 2).
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Immunocytochemistry
NEBs were harvested, dissociated and plated onto PLL/laminin treated cover- 
slips at a density of 50,000 cells per 30pl drop on each cover-slip, as described in 
Chapter 2. Cells were fixed 2-4 hours after plating on adhering to the substrate. 
Fluorescent immunocytochemistry was performed according to the protocol detailed 
in Chapter 2. Primary antibodies used were anti-Pax6 (1:50), anti-Nkx2.1 (1:200) and 
anti-Mashl (1:200).
Microscopy and Statistical Analysis
Cells were visualised under UV fluorescence using a Leitz microscope. 
Hoechst positive nuclei were detected and cells immuno-labelled with the marker of 
interest were counted, as described in Chapter 2. Images were processed using 
Optronics MagnaFire Software and Adobe Photoshop.
Statistical analyses were carried out using Minitab 15 statistical software. One­
way ANOVA with Tukey-Kramer post-hoc comparisons when appropriate were 
performed.
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5.4 Results
Dorsal-ventral telencephalic gene expression in NEBs
NEBs were analysed for gene expression following 8 and 16 days of the 
ADF+ neural induction protocol, using semi-quantitative RT-PCR. Expression of the 
dorsal telencephalon markers Pax6, Ngn2 and Emx2 in ES cell-derived NEBs were 
analysed relative to developing mouse cortex at E14 (Figure 5.1). Pax6 expression in 
NEBs was significantly different from that in the E14 mouse cortex (F2 ,9  = 17.25, 
p<0.01) (Figure 5.1; A). Post-hoc analysis confirmed that expression at day 8 (0.27 ± 
0.05) was significantly lower than cortical expression, but at day 16 (0.63 ± 0.18) 
there was no statistical significance. There was a highly significant difference in Ngn2 
expression between E14 cortex and NEBs (F2 ,9  = 251.68, p<0.001) (Figure 5.1; B), 
with NEB cultures at day 8 (0.08 ± 0.03) having significantly lower expression than 
the cortex. Expression of Ngn2 at day 16 (0.39 ± 0.05) was not significantly different 
from E14 cortex, and there was no significant difference between day 8 and day 16. 
Emx2 expression revealed a significant difference between NEBs and cortex (F2 ,9  = 
9.92, p<0.05) (Figure 5.1; C); expression was statistically significant between cortex 
and NEB cultures at day 8 (0.42 ± 0.06), but not at day 16 (0.59 ± 0.16).
The ventral telencephalon can be subdivided, and for the purpose of this study 
we have used the MGE and LGE divisions. In the developing telencephalon, Nkx2.1 
expression is restricted to the MGE and is a specific marker of this region. There was 
a significant difference in expression of Nkx2.1 between that in mouse E14 MGE and 
day 8 NEBs (0.12 ± 0.05), but not day 16 NEBs (0.37 ± 0.17) (F2,9 = 7.99, p<0.05) 
(Figure 5.2; A).
Markers of the LGE include Dlx2, Mashl and Gsx2, and although their 
expression is not exclusive to the LGE (as Nkx2.1 expression is to the MGE) they are 
widely used as markers for this region, but caution is necessary when attempting to 
draw definitive conclusions. Dlx2 expression (Figure 5.2; B) was significantly lower 
than E14 LGE at both day 8 (0.01 ± 0.00) and day 16 (0.22 ± 0.13), and there was 
also a significant difference in expression between day 8 and day 16 NEBs, with 
greater expression at day 16 (F2 ,9  =42.36, p<0.001). Expression of Mashl (Figure 5.2; 
C) was significantly lower than LGE at day 8 (0.10 ± 0.03), but not at day 16 (0.49 ±
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0.11); also Mashl expression at day 16 was significantly higher than that at day 8 (F2 ,9  
= 17.45, p<0.01). Gsx2 expression (Figure 5.2; D) revealed significantly lower 
expression than LGE at both day 8 (0.04 ± 0.01) and day 16 (0.17 ± 0.15) (F2 ,9  =
22.08, p<0.01).
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Figure 5.1. Expression of dorsal markers Pax6 (A), Ngn2 (B) and Emx2 (C) was analysed 
using semi-quantitative RT-PCR on cDNAs prepared from E14 mouse cortex and NEBs 
harvested at day 8 and day 16 of neural induction in ADF+ with 20ng/ml FGF2 present from 
day 4. Gene expression is shown relative to fi-actin. The broken line crossing the y-axis at 1 
represents relative expression in the E14 mouse cortex. Each bar on the graphs represents a 
mean of 3 different neural induction cultures and error bars represent SEM. (*<p0.05,
**p<0.01, ***p<0.001).
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Figure 5.2. Expression of ventral markers Nkx2.1 (A), Dlx2 (B), Mashl (C) and Gsx2 (D) 
was analysed using semi-quantitative RT-PCR on cDNAs prepared from E14 mouse MGE, 
LGE and NEBs harvested at day 8 and day 16 of neural induction in ADF+ with 20ng/ml 
FGF2 present from day 4. Gene expression is shown relative to p-actin. Nkx2.1 expression in 
NEBs was determined relative to that in MGE, whilst Dlx2, Mashl and Gsx2 expression in 
NEBs was determined relative to that in LGE. The broken line crossing the y-axis at 1 
represents relative expression in the E14 mouse MGE (A) and LGE (B-D). Each bar on the 
graphs represents a mean of 3 different neural induction cultures and error bars represent 
SEM. * = significant difference from MGE/LGE control, t  = significant difference between 
day 8 and day 16 NEB groups. (*p<0.05, **p<0.01, ***p<0.001, tttp<0.01).
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Effect o f the SHH agonist purmorphamine on dorsal-ventral expression
To determine if NEBs are responsive to the SHH agonist purmorphamine, 
ADF+ neural induction medium was supplemented with a range of purmorphamine 
concentrations and expression of SHH-pathway components was analysed (Figure 
5.3). Purmorphamine was added at day 4 and NEBs were harvested for analysis at day 
8  or day 16. At both day 8  and day 16 expression of SHH (Figure 5.3; A) was shown 
to increase following addition of purmorphamine and this was similar for Patched 
expression (Figure 5.3; B). Expression of Patched was always higher at day 16 than at 
day 8 . Gli3 expression was reduced slightly following addition of purmorphamine 
(Figure 5.3; C).
Expression of dorsal and ventral telencephalic markers in NEB cultures were 
analysed in response to the addition of purmorphamine, and analysis was compared 
relative to E14 cortex or MGE/LGE (expression relative to E14 WGE is shown in 
Appendix 6 ). Pax6 expression was shown to decrease with addition of 
purmorphamine (Figure 5.4; A). There was no significant difference between the day 
of analysis (two-way ANOVA, F1 3 0  = 2.35, p = n.s) however there was a significant 
difference between concentrations (F4 3 0  = 4.48, p<0.05). At day 16, NEBs treated 
with 0.5, 1.0 or 2.0pM purmorphamine had significantly lower expression of Pax6 
than untreated cultures. Expression of Ngn2 (Figure 5.4; B) revealed a similar pattern 
to that of Pax6. There was no significant difference between days (Fij3 0 = 0.04, p = 
n.s), but there was a significant difference between concentrations (F4 3 0  = 3.93, p 
<0.05), with 1.0 and 2.0pM purmorphamine yielding significantly lower expression in 
NEBs at day 16 than untreated cultures on the same day.
Nkx2.1 expression in NEBs following purmorphamine addition is shown 
relative to that in E14 mouse MGE (Figure 5.5; A). There was a significant difference 
in expression between day 8  and day 16 (F1 3 0  = 10.41, p<0.01) and concentration 
(F4 .3 0  = 5.41, p<0.01). With 0.5pM purmorphamine there was significantly more 
Nkx2.1 expression at day 16 than at day 8 . In day 16 cultures there appeared to be an 
increase in expression with 0.5 pM purmorphamine, although this was not significant; 
expression then declined, and 2pM purmorphamine yielded significantly lower 
expression than untreated cultures. Dlx2 expression in NEBs following addition of 
purmorphamine is shown relative to LGE (Figure 5.5; B). There was a significant 
difference in expression between days (Fi>30 = 47.02, p<0 .0 0 1 ), with significantly 
higher expression at day 16 than at day 8  following addition of 0.5 and l.OpM
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purmorphamine. There was also a significant difference in expression between 
concentrations (F4 3 0  = 5.39, p<0.01), with a significant decrease in expression 
following addition of 2pM purmorphamine at day 16. Although there was no 
significant increase in Dlx2 expression with purmorphamine treatment, at day 16 
addition of 0.5pM resulted in a slight increase. Expression of Mashl in NEBs 
following addition of purmorphamine is shown relative to LGE (Figure 5.5; C). There 
was a significant difference in expression between day 8  and day 16 (F 1 ,30 = 47.63, 
p<0 .0 0 1 ), with expression at day 16 significantly higher than at day 8  following 
addition of 0.5 and 2pM purmorphamine. There was also a significant difference in 
expression between concentrations (F4 3 0  = 4.28, p<0.05), with 1 pM purmorphamine 
yielding significantly less expression than untreated cultures at day 16. Gsx2 
expression in NEBs following addition of purmorphamine is shown relative LGE 
(Figure 5.5; D). There was no significant difference between days (F1 3 0  = 0.00, p = 
n.s), but there was a significant difference between concentrations (F4 3 0  = 3.44, 
p<0.05).
NEBs exhibited more of a response to purmorphamine following 16 days in 
neural induction culture than 8  days, when analysing dorsal and ventral telencephalic 
markers. Increasing concentrations of purmorphamine yielded tendencies towards a 
decrease in expression of dorsal telencephalic genes Pax6 and Ngn2 (Figure 5.4). At 
day 8  expression of the MGE marker Nkx2.1 appeared unchanged as purmorphamine 
concentration was increased, whereas at day 16 there appeared to be an increase in 
expression following addition of 0.5pM purmorphamine, which then decreased with 
higher concentrations (Figure 5.5; A). Expression of Dlx2, Mashl and Gsx2 were not 
changed at day 8  with purmorphamine addition (Figure 5.5; B, C, and D respectively). 
At day 16, Dlx2 expression increased following addition of 0.5pM purmorphamine 
and decreased with higher concentrations, similar to the response seen in Nkx2.1 
expression. There was not a big response in Gsx2 expression at day 16, although there 
was a tendency towards a decrease and expression of Mashl showed a decrease with 
increasing concentrations of purmorphamine.
One point of note was that long-term treatment of cultures with high 
concentrations of purmorphamine (2 and 5pM) resulted in formation of crystal-like 
structures within the culture medium. In these cultures, cell numbers were reduced 
when compared with untreated cultures and those treated with lower purmorphamine 
concentrations (0.5 and lpM).
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A Shh expression following purmorphamine addition
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Figure 5.3. Dose-response of expression of components of the SHH pathway. Expression of 
SHH (A), Patchedl (B) and Gli3 (C) was analysed using semi-quantitative RT-PCR on 
cDNAs prepared from NEBs at day 8 and day 16 of neural induction in ADF+ with 20ng/ml 
FGF2 and different concentrations of the SHH agonist purmorphamine present from day 4. 
Gene expression is shown relative to f$-actin. Each bar on the graph represents a mean of 3 
different neural induction cultures and error bars represent SEM.
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Pax6 expression following purmorphamine addition
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Figure 5.4. Expression of dorsal markers Pax6 (A) and Ngn2 (B) was analysed using semi- 
quantitative RT-PCR on cDNAs prepared from NEBs at day 8 and day 16 of neural induction 
in ADF+ with 20ng/ml FGF2 and different concentrations of the SHH agonist 
purmorphamine present from day 4. Gene expression is shown relative to p-actin. The broken 
line crossing the y-axis at 1 represents relative expression in E14 mouse cortex. Each bar on 
the graph represents a mean of 3 different neural induction cultures and error bars represent 
SEM. (*p<0.05).
117
Chapter 5 Ventral telencephalon-like precursors
Nkx2.1 expression following purmorphamine addition Dlx2 expression following purmorphamine addition
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Figure 5.5. Expression of the ventral markers Nkx2.1 (A), Dlx2 (B), Mashl (C) and Gsx2 (D) 
were analysed using semi-quantitative RT-PCR on cDNAs prepared from NEBs at day 8 and 
day 16 of neural induction in ADF+ with 20ng/ml FGF2 and different concentrations of the 
SHH agonist purmorphamine present from day 4. Gene expression is shown relative to p- 
actin. The broken line crossing the y-axis at 1 represents relative expression in the E14 mouse 
MGE (A) and LGE (B-D). Each bar on the graphs represents a mean of 3 different neural 
induction cultures and error bars represent SEM. Brackets indicate significance between the 
day 8 and day 16 NEBs at a particular concentration. * = significant difference from WGE 
control, f  = significant difference between NEB groups. (*p<0.05, **p<0.01, -ftKO.OS, 
ttpO .O l).
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Endogenous expression o f SHH-pathway components in NEBs
Since the response of NEBs to the addition of purmorphamine was not ‘clean’ 
across the range of dorso-ventral markers analysed, interpretation of results was not 
always straightforward. Therefore expression of SHH and Patchedl were analysed in 
NEBs, relative to their expression in the E14 mouse dorsal and ventral telencephalon, 
to determine if there was endogenous SHH present in the NEB cultures (Figure 5.6). 
As expected, analysis using semi-quantitative RT-PCR showed that there was less 
SHH and Patchedl in the cortex than in the WGE. Interestingly the expression of both 
SHH and Patchedl in NEBs at day 8 and day 16 was greater than seen in the WGE.
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Figure 5.6. Expression of SHH (A) and Patchedl (B) was analysed using semi-quantitative 
RT-PCR on cDNAs prepared from E14 mouse WGE, CTX and ES cell-derived NEBs 
harvested at day 8 and day 16 of neural induction in ADF+ with 20ng/ml FGF2 present from 
day 4. Gene expression is shown relative to fi-actin. Each bar on the graph represents a mean 
of 3 different neural induction cultures and error bars represent SEM.
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Effect o f the SHH antagonist cyclopamine on dorsal-ventral expression
To determine if NEBs are responsive to the Shh antagonist cyclopamine, 
ADF+ neural induction medium was supplemented with a range of cyclopamine 
concentrations and expression of SHH-pathway components was analysed (Figure 
5.7). Cyclopamine was added at day 4 and NEBs were harvested for analysis at day 8  
or day 16.
Expression of dorsal and ventral telencephalic markers in NEB cultures were 
analysed in response to the addition of cyclopamine, and analysis was compared 
relative to E14 cortex or MGE/LGE (expression relative to E l4 WGE is shown in 
Appendix 6 ). Expression of the dorsal marker Pax6 (Figure 5.8; A) did not change 
significantly with addition of cyclopamine relative to day (F1 3 0  = 2.15, p = n.s) or 
concentration (F4 3 0  = 1.40, p = n.s). Ngn2 expression (Figure 5.8; B) was also not 
altered significantly in the presence of cyclopamine with respect to day (F1 3 0  = 4.91, p 
= n.s) or concentration (F4 3 0  = 1.19, p = n.s).
Expression of the MGE specific marker Nkx2.1 was significantly reduced 
following addition of cyclopamine (Figure 5.9; A). There was a significant effect 
between days (F1 3 0  = 17.29, p<0 .0 1 ), and concentration (F4 3 0  = 20.39, p<0 .0 1 ), with 
addition of 0.1, 0.5, 1.0 and 2.0pM cyclopamine resulting in significantly lower 
expression of Nkx2.1 than untreated cultures at both day 8  and day 16. Dlx2 
expression was significantly reduced in the presence of cyclopamine (Figure 5.9; B). 
There was a significant effect between days (F1 3 0  = 10.10, p<0.05) and concentration 
(F4 3 0  = 5.74, p<0.05). Post-hoc analysis confirmed significance at day 16, with all 
cyclopamine concentrations yielding significantly lower Dlx2 expression. Expression 
of Mashl following addition of cyclopamine (Figure 5.9; C) was not significantly 
different with respect to days (F1 3 0  = 4.35, p = n.s) or concentration (F4 3 0  = 0.30, p = 
n.s). There was also no significant difference in Gsx2 expression in the presence of 
cyclopamine (Figure 5.9; D) with respect to days (F1 3 0  = 4.26, p = n.s) or 
concentration (F4 3 0  = 3.32, p = n.s).
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Figure 5.7. Dose-response of expression of components of the SHH pathway. Expression of 
SHH (A), Patchedl (B) and Gli3 (C) was analysed using semi-quantitative RT-PCR on 
cDNAs prepared from NEBs at day 8 and day 16 of neural induction in ADF+ with 20ng/ml 
FGF2 and different concentrations of the SHH antagonist cyclopamine present from day 4. 
Gene expression is shown relative to fi-actin. Each bar on the graph represents a mean of 3 
different neural induction cultures and error bars represent SEM.
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Pax6 expression following cyclopamine addition
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Figure 5.8. Expression of Pax6 (A) and Ngn2 (B) was analysed using semi-quantitative RT- 
PCR on cDNAs prepared from NEBs at day 8 and day 16 of neural induction in ADF+ with 
20ng/ml FGF2 and different concentrations o f the SHH antagonist cyclopamine present from 
day 4. Gene expression is shown relative to fi-actin. The broken line crossing the y-axis at 1 
represents relative expression in the E14 mouse CTX. Each bar on the graph represents a 
mean of 3 different neural induction cultures and error bars represent SEM.
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Figure 5.9. Expression of the ventral markers Nkx2.1 (A), Dlx2 (B), Mashl (C) and Gsx2 (D) 
were analysed using semi-quantitative RT-PCR on cDNAs prepared from NEBs at day 8 and 
day 16 of neural induction in ADF+ with 20ng/ml FGF2 and different concentrations of the 
SHH antagonist cyclopamine present from day 4. Gene expression is shown relative to /?- 
actin. The broken line crossing the y-axis at 1 represents relative expression in the E14 mouse 
MGE (A) and LGE (B-D). Each bar on the graphs represents a mean of 3 different neural 
induction cultures and error bars represent SEM. Brackets indicate significance between the 
day 8 and day 16 NEBs at a particular concentration. * = significant difference to untreated 
NEBs at day 8. t  = significant difference to untreated NEBs at day 16. (**p<0.01, tp<0.05).
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Fluorescent immunocytochemistry o f dorsal-ventral markers
Fluorescent immunocytochemistry, using antibodies against the dorsal 
telencephalon marker Pax6 (Figure 5.10 and 5.11), the MGE marker Nkx2.1 (Figure 
5.12 and 5.13) and the LGE marker Mashl (Figure 5.14 and 5.15), was performed to 
further analyse the effects of purmorphamine and cyclopamine with respect to 
untreated cultures and the appropriate regions of the developing mouse brain.
Fluorescent immunocytochemistry revealed that the proportion of Pax6- 
expressing cells was significantly lower in NEBs than in E14 cortex (F2 ,9  = 16.42, 
p<0.01) (Figure 5.11), but there was no significant difference between day 8 and day 
16 NEBs. Following purmorphamine treatment expression of Pax6 decreased 
significantly compared with untreated NEBs at day 8 (F4)is = 62.95, p<0.001), and at 
day 16 (F4,i5 = 62.95, p<0.001). There was no significant difference in Pax6 
expression between NEBs treated with 0.5pM purmorphamine and l.OpM 
purmorphamine. Cyclopamine treatment resulted in significantly more Pax6-positive 
cells than purmorphamine treated NEBs, but there was no significant difference 
between 0.1 pM and l.OpM cyclopamine treated NEBs, and no significant difference 
from untreated cultures.
The proportion of Nkx2.1 immuno-positive cells was significantly lower in 
NEBs than in E14 MGE (F2 ,9  = 22.79, p<0.01) (Figure 5.13). There was no significant 
difference between untreated NEBs and those treated with purmorphamine or 
cyclopamine at day 8 (F4>i5 = 2.89, p=n.s) or day 16 (F4>i5 = 2.88, p=n.s).
There were significantly more Mashl immuno-positive cells in E14 LGE than 
in NEBs at day 8 and day 16, and there were significantly more at day 16 than at day 
8 (F2 ,9  = 97.51, p<0.001) (Figure 5.15). There was no significant difference between 
untreated NEBs and those treated with purmorphamine or cyclopamine at day 8 (F4,i5 
= 2.25, p=n.s) or day 16 (F4>i5 = 1.32, p=n.s).
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Figure 5.10 (overleaf). Pax6 expression using fluorescent immunocytochemistry. E14 mouse 
cortex (A-C) was dissected and dissociated for plating. NEBs cultured in ADF+ and 20ng/ml 
FGF2 were taken at day 8 following no additional treatment (D-F), treatment with 0.5pM 
purmorphamine (G-I) or treatment with l.OpM cyclopamine (J-L), or at day 16 following no 
additional treatment (M-O), treatment with 0.5pM purmorphamine (P-R) or treatment with 
l.OpM cyclopamine (S-U). Cells were harvested, dissociated and plated onto PLL/laminin 
substrate. After 2-4 hours, when cells had adhered to the substrate; they were fixed and 
double-labelled for Pax6 (red) and Hoechst nuclear stain (blue). The third column is a merged 
image of the first two photomicrographs in each row. Scale bars = 50pm.
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Figure 5.11. Pax6 expression using fluorescent immunocytochemistry. E14 mouse cortex was 
dissected and dissociated for plating. NEBs cultured in ADF+ and 20ng/ml FGF2 were taken 
at day 8 or day 16 following no additional treatment, or treatment with 0.5pM 
purmorphamine, l.OpM purmorphamine, 0.1 pM cyclopamine or l.OpM cyclopamine. Cells 
were harvested, dissociated and plated onto PLL/laminin substrate. After 2-4 hours, when 
cells had adhered to the substrate; they were fixed and double-labelled for Pax6 and Hoechst 
nuclear stain. Each bar on the graph represents a mean of 3 different neural induction cultures 
and error bars represent SEM. (* indicates significant difference from E14 cortex; f  indicates 
a significant difference from untreated cultures at the same day; # indicates a significant 
difference from other treated cultures at the same day). (**p<0.01, ft^O.Ol, ##p<0.01).
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Figure 5.12 (overleaf). Nkx2.1 expression using fluorescent immunocytochemistry. E14 
mouse WGE (A-C) and MGE (D-F) were dissected and dissociated for plating. NEBs 
cultured in ADF+ and 20ng/ml FGF2 were taken at day 8 following no additional treatment 
(G-I), treatment with purmorphamine (J-L) or treatment with cyclopamine (M-O), or at day 
16 following no additional treatment (P-R), treatment with purmorphamine (S-U) or treatment 
with cyclopamine (V-X). Cells were harvested, dissociated and plated onto PLL/laminin 
substrate. After 2-4 hours cells had adhered to the substrate; they were fixed and double­
labelled for Nkx2.1 (red) and Hoechst nuclear stain (blue). The third column is a merged 
image of the first two photomicrographs in each row. Scale bars = 50pm.
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Figure 5.13. Nkx2.1 expression using fluorescent immunocytochemistry. E14 mouse MGE 
was dissected and dissociated for plating. NEBs cultured in ADF+ and 20ng/ml FGF2 were 
taken at day 8 or day 16 following no additional treatment, or treatment with 0.5pM 
purmorphamine, l.OpM purmorphamine, 0.1 pM cyclopamine or l.OpM cyclopamine. Cells 
were harvested, dissociated and plated onto PLL/laminin substrate. After 2-4 hours, when 
cells had adhered to the substrate; they were fixed and double-labelled for Nkx2.1 and 
Hoechst nuclear stain. Each bar on the graph represents a mean of 3 different neural induction 
cultures and error bars represent SEM. (* indicates significant difference from E14 MGE).
(**p<0.01).
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Figure 5.14 (overleaf). Mashl expression using fluorescent immunocytochemistry. E14 
mouse WGE (A-C) and LGE (D-F) were dissected and dissociated for plating. NEBs cultured 
in ADF+ and 20ng/ml FGF2 were taken at day 8 following no additional treatment (G-I), 
treatment with purmorphamine (J-L) or treatment with cyclopamine (M-O), or at day 16 
following no additional treatment (P-R), treatment with purmorphamine (S-U) or treatment 
with cyclopamine (V-X). Cells were harvested, dissociated and plated onto PLL/laminin 
substrate. After 2-4 hours cells had adhered to the substrate; they were fixed and double­
labelled for Mashl (red) and Hoechst nuclear stain (blue). The third column is a merged 
image of the first two photomicrographs in each row. Scale bars = 50pm.
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Figure 5.15. Mashl expression using fluorescent immunocytochemistry. E14 mouse LGE 
was dissected and dissociated for plating. ES cell-derived NEBs cultured in ADF+ and 
20ng/ml FGF2 were taken at day 8 or day 16 following no additional treatment, or treatment 
with 0.5pM purmorphamine, l.OpM purmorphamine, 0.1 pM cyclopamine or l.OpM 
cyclopamine. Cells were harvested, dissociated and plated onto PLL/laminin substrate. After 
2-4 hours, when cells had adhered to the substrate; they were fixed and double-labelled for 
Nkx2.1 and Hoechst nuclear stain. Each bar on the graph represents a mean of 3 different 
neural induction cultures and error bars represent SEM. (* indicates significant difference 
from E14 LGE; t  indicates a significant difference between untreated cultures at day 8 and 
day 16). (**p<0.01, #p<0.01).
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5.5 Discussion
Ventral telencephalon-like precursors
Dorso-ventral expression in NEBs
Following culture in neural induction medium, NEBs express genes which 
give an indication of their position along the dorso-ventral axis within the neural tube. 
In comparison to expression in the developing mouse E14 cortex, expression of the 
dorsal telencephalic marker genes Pax6, Ngn2 and Emx2 were all lower in untreated 
neurally induced NEBs at day 8. At day 16, expression of these 3 markers did not 
differ significantly from that in the cortex. Expression of the ventral markers Nkx2.1, 
Dlx2, Mashl and Gsx2 were also lower in NEBs at day 8 than in cells of their regional 
position within the neural tube, MGE or LGE. However, at day 16 expression of 
Nkx2.1, Mashl and Gsx2 in NEBs were not significantly different from expression in 
the MGE (Nkx2.1) and LGE (Mashl and Gsx2). This indicates a more mature 
precursor at day 16 which more closely resembles in vivo telencephalic precursors 
than the earlier day 8 precursors.
Bouhon et al (2005 and 2006) reported that neurally induced mouse ES cells 
following 8 days in CDM express the dorsal marker Pax6 and ventral markers Gsx2 
and Dlxl (Bouhon et al., 2005; Bouhon et al., 2006), using semi-quantitative RT- 
PCR. Fluorescent immunocytochemistry revealed Pax6-positive cells with few Gsx2 
and Nkx2.1-expressing cells following 10 days in serum-free suspension culture 
(Watanabe et al., 2005). A more recent study using CDM showed an increase in 
expression of Dlxl and Nkx2.1 from day 7 through to day 14 using RT-PCR, and with 
fluorescent immunocytochemistry revealed a low proportion of Pax6-expressing cells, 
with few Gsx2-expressing cells (Gaspard et al., 2008).
Addition o f the SHH agonist, purmorphamine to NEBs
The response of SHH pathway components to different concentrations of 
purmorphamine at day 8 analysis was more typical of the expected dose response than 
analysis at day 16. Duration of SHH signalling, as well as concentration, has been 
shown to influence the expression of transcription factors which subsequently specify 
different neuronal subtypes. Chronic exposure results in desensitization of cells to 
SHH which is caused by upregulation of Patched; increasing Patched levels decreases 
responsiveness of cells to Hedgehog (Taipale et al., 2002; Dessaud et al., 2007).
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Dessaud et al (2007) reported that SHH concentration and duration of exposure are 
proportional to each other, and demonstrated that chick neural cells convert different 
SHH concentrations into time-limited periods of signal transduction.
Analysis of dorso-ventral markers revealed that purmorphamine treatment at 
day 4 of the ADF+ neural induction protocol did not appear to elicit a profound 
response in NEBs by day 8, however there was more of a response when NEBs were 
analysed after 16 days. Purmorphamine resulted in down-regulation of the dorsal 
markers Pax6 and Ngn2, which was consistent with a decrease in Pax6-expressing 
cells following addition of Shh protein at day 4 and analysis at day 10 (Watanabe et 
al., 2005). At low purmorphamine concentrations there was an increase in expression 
of the ventral marker Nkx2.1 at day 16, but at increasing purmorphamine 
concentrations Nkx2.1 expression was reduced. Watanabe et al observed that with 
addition of the Shh protein at low concentrations Nkx2.1 expression was increased, 
although not significantly, and at higher concentrations expression reached a plateau 
(Watanabe et al., 2005). Expression of Dbc2 was shown to increase at low 
purmorphamine concentrations, although at increasing purmorphamine concentrations 
the expression declined, and Mashl expression decreased with increasing 
purmorphamine concentrations, as did expression of Gsx2, although base-line 
expression of Gsx2 was much lower than Mashl when compared relative to their 
expression in the E14 LGE. It has previously been reported that addition of increasing 
concentrations of SHH protein did not have a significant effect on Gsx2-expressing 
cells (Watanabe et al., 2005).
Although addition of purmorphamine resulted in a degree of up- or down- 
regulation of some dorso-ventral genes in the direction expected, this was not 
consistent across all the markers analysed. As a result, there was no distinctive pattern 
of expression in purmorphamine-treated NEBs, with respect to dorso-ventral 
patterning. Purmorphamine directly targets smoothened in the Hedgehog signalling 
pathway and it has been shown that Patched, upstream of smoothened, is not required 
for purmorphamine activity (Sinha and Chen, 2006). Moreover, in cells lacking 
smoothened, purmorphamine was not able to induce the Hedgehog signalling pathway 
(Sinha and Chen, 2006). Analysis of neurally induced ES cells following 8 and 16 
days in ADF+ demonstrated relatively high expression of Patched when compared 
with mouse E14 WGE. As a result of high levels of Patched there would be 
subsequently low levels of smoothened which is the target of purmorphamine.
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During development, one role of SHH is to inhibit the Gli3 repressor that 
plays a role in dorsal patterning, and induce the Gli3 activator (Gulacsi et al., 2006). 
With low levels of SHH signalling Gli3 is converted from the activator form to the 
repressor form, which induces a switch from ventral patterning to dorsal patterning. 
Since the level of SHH is definitive in this decision in the developing neural tube, this 
could equally be the case when treating neural induction cultures with various 
concentrations of SHH, and might be one explanation for the mixed responses in 
expression of genes of the dorso-ventral axis.
Ventral patterning in the telencephalon does not solely rely on Hedgehog 
signalling, but a combination of activities of a number of different signalling centres. 
SHH is involved in maintaining normal expression patterns of FGF8 and BMP4 in the 
developing telencephalon (Ohkubo et al., 2002; Hayhurst et al., 2008). Changes in 
SHH signalling early in development results in changes in other signalling centres, so 
altering SHH expression in NEBs might have a knock-on affect on other signals and 
modify subsequent gene expression according to these signals, as well as SHH.
Another hypothesis for the limited response of NEBs to purmorphamine 
treatment is the presence of endogenous SHH activity. Semi-quantitative RT-PCR 
comparing gene expression in NEBs relative to that in E14 WGE revealed higher 
expression of SHH in both day 8 and day 16 NEBs than in WGE. ES cells cultured in 
CDM culture have been shown to express low levels of SHH at day 6, with an 
increase at day 8 (Bouhon et al., 2005). A different study, also culturing mouse ES 
cells in CDM, showed induction of SHH expression at day 4 with an increase through 
to day 14 (Gaspard et al., 2008). Although initiation of SHH expression in neurally 
induced ES cells, as well as its continued presence in culture (showing an increase 
over time), has been reported, it has not previously been demonstrated relative to that 
in the developing mouse striatum.
Since chronic administration of high concentrations of purmorphamine 
resulted in the formation of crystal-like structures within the culture medium and cell 
numbers were reduced in these cultures when compared with untreated cultures and 
those treated with lower purmorphamine concentrations (0.5 and 1 pM), data from the 
high concentrations (2 and 5pM) needs to be analysed with caution. The cells that 
survived in culture appeared healthy, but further analysis is required to determine 
what population of cells remained, i.e. forebrain population.
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Addition o f the SHH antagonist, cyclopamine to NEBs
Cyclopamine is an antagonist of the Hedgehog signalling pathway, inhibiting 
smoothened activity by influencing the balance between the active and inactive forms 
of smoothened. Treatment of neurally induced ES cells with cyclopamine resulted in a 
significant decrease in expression of the ventral markers Nkx2.1, Dlx2 and Gsx2. This 
was consistent with previous findings which revealed abolishment of Dlxl and Nkx2.1 
(using RT-PCR analysis) and Gsx2 (using fluorescent immunocytochemistry) 
(Gaspard et al., 2008). Interestingly here, expression of the ventral marker Mashl was 
not significantly reduced following addition of cyclopamine, however expression of 
this gene has not been reported in other neural induction studies, either in untreated 
cultures or those following addition of SHH agonists and antagonists.
Dorsal markers Pax6 and Ngn2 were not significantly altered following 
addition of cyclopamine in ADF+ culture from day 4 with analysis at day 8 and day 
16, which was not consistent with findings that reported a significant increase in 
Pax6-expressing cells at day 14, with cyclopamine treatment from day 2 to day 10 
(Gaspard et al., 2008).
Semi-quantitative RT-PCR analysis resulted in the observation of relatively 
high levels of deviation between cultures, with samples from 3 different neural 
induction cultures taken for analysis of gene expression. Generation of neural 
precursors from ES cell cultures involves harvesting ES cells and then transfer to 
neural induction medium. The ‘state* of ES cells in terms of their proliferation 
capacity and colony structure, immediately prior to harvesting, might result in the 
generation of more diverse NEB cultures, with different rates of proliferation and 
aggregation that might impact on subsequent cell patterning. There is a need to 
minimise these differences in order to maintain consistency and reproducibility 
between neural induction cultures.
Dorso-ventral expression in the developing mouse telencephalon
The ventral genes Dlx2, Mashl and Gsx2 show similar expression in the 
telencephalic vesicles of the developing mouse, however their roles in influencing 
other precursors and their destined mature phenotypic fates differ. Gsx2 expression is 
required for subsequent expression of various genes necessary for specification and 
differentiation of the LGE (Corbin et al., 2000). Mice lacking Gsx2 expression fail to 
express Mashl and Dlx2 (Szucsik et al., 1997; Corbin et al., 2000; Toresson et al.,
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2000), demonstrating a requirement for Gsx2 expression for the expression of these 
other ventral genes. Neuronal phenotypes lost in the Gsx2 mutant are the striatal 
projection neurons which originate in the LGE (Deacon et al., 1994; Olsson et al., 
1998) and the olfactory bulb intemeurons (Corbin et al., 2000), whereas the cortical 
intemeurons remain unaffected.
Dlx 1/2-expressing cells are found in the LGE and MGE (Liu et al., 1997), and 
these cells are highly migratory prior to differentiation (Anderson et al., 1997a). Fate- 
mapping studies have reported Dlx-expressing cells in the hippocampus, olfactory 
bulb (Nery et al., 2003), and cortex, where they co-express GABA (Stuhmer et al., 
2002b). Mice lacking Dlxl/2 expression show reduced expression of cortical 
GABAergic intemeurons and also striatal matrix neurons (Anderson et al., 1997a; 
Anderson et al., 1997b).
Mashl expression is also observed throughout the ventral telencephalon (Fode 
et al., 2000). Mice lacking expression of Mashl exhibit reduced expression of cortical 
intemeurons (Casarosa et al., 1999), FoxPl-expressing striatal neuronal precursors, 
DARPP-32-expressing MSNs and calbindin-expressing striatal matrix neurons (Wang 
et al., 2009).
Taken together, these developmental loss-of-function studies demonstrate that 
although expression of these genes is geographically similar, they each play different 
roles in development and respond to various signals differently.
Gsx2 expression (at a certain level) might be required in neurally induced ES 
cells for induction of expression of other ventral genes such as Mashl and Dlx2. 
However, since Gsx2 is a downstream target of SHH signalling (shown by mis- 
expression of SHH resulting in ectopic Gsx2 expression) (Corbin et al., 2000) and 
SHH expression is relatively higher in NEBs than in E14 WGE, perhaps over­
expression of SHH has negative effects on Gsx2 expression.
Heterogeneity of the neural induction cultures might account for the mixed 
response of gene expression to purmorphamine and cyclopamine, making results 
difficult to interpret. It is not uncommon in neurally induced ES cells to observe an 
array of dorso-ventral position-specifying markers that taken together do not produce 
a predominant pattern of expression, indicating the lack of a predominant precursor- 
type within the culture population. In neurally induced human ES cells a range of 
dorso-ventral markers have been shown to up- or down-regulate over time, which 
individually appear to be interesting, nevertheless failing to demonstrate a
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predominant pattern overall (Nasonkin et al., 2009). It is also important to remember 
that the heterogeneity within cultures is not just restricted to the neural precursor 
population, but there are almost certainly other cell lineages present as well, which 
might impact on the patterning and fate of the neural precursors.
Conclusions
Neurally induced mouse ES cells are responsive to treatment with both 
purmorphamine and cyclopamine. Interestingly, data in this chapter demonstrates that 
SHH is endogenously expressed in these neural precursors at relatively high levels, 
when compared to mouse WGE. Although no distinctive patterns were revealed 
following treatment of mouse ES cell neural induction cultures with either 
purmorphamine or cyclopamine, a low purmorphamine concentration supplemented 
through to day 16 resulted in increased expression of Dlx2 and the MGE specific 
marker Nhc2.1, indicating an increase in ventral telencephalon precursors. Further 
analysis of these precursors following differentiation in vitro and in vivo, which will 
be assessed in the next two chapters, will demonstrate the fate of these cells as mature 
phenotypes and determine subsequent effects that purmorphamine might have on cell 
maturation.
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Chapter 6
in vitro differentiation: 
Looking for DARPP-32
6.1 Summary
DARPP-32 is a marker of terminally differentiated MSNs and is currently the 
most commonly used marker for MSNs of the striatum, which are lost in HD. These 
neurons originate in the LGE region of the ventral telencephalon. Various studies 
have shown that in vitro culture of LGE cells yield a lower-than-expected proportion 
of DARPP-32 positive neurons. This proportion can be increased by a number of 
different methods, including addition of BDNF, RA or co-culture with LGE-derived 
glia. The rationale in this chapter was to determine conditions for terminal 
differentiation of MSNs using cells which are already specified (LGE), and then apply 
these conditions to neuronal differentiation cultures of NEBs. DARPP-32 expression 
in LGE neuronal differentiation cultures was shown to increase with the addition of 
BDNF and with co-culture on LGE-derived glia, but not with the addition of RA, and 
neuronal proportion was not altered. The highest proportion of DARPP-32 positive 
neurons was yielded following addition of BDNF to the neuronal differentiation 
cultures. Expression of the striatal marker FoxPl was not altered in the various 
conditions but DARPP-32 positive neurons expressed as a percentage of FoxPl was 
increased with BDNF. Day 16 NEBs, with or without addition of the SHH agonist 
purmorphamine, were allowed to differentiate for a further 7 or 14 days in neuronal 
differentiation medium with or without addition of BDNF, in order to determine if 
DARPP-32 positive neurons could be generated. Neuronal yield was unaffected in the 
various treatments, with no effect of purmorphamine. Within the neuronal population, 
GABAergic yield was not affected and DARPP-32 positive neurons showed a slight 
increase following BDNF addition at both 7 and 14 days, but this was not significant. 
FoxPl expression was also not affected with the various treatments. This suggests that 
day 16 NEBs are not optimally specified to be responsive to the same cues as LGE- 
derived precursors.
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6.2 Introduction
in vitro differentiation
DARPP-32 is at present the most commonly used marker of the striatal 
projection MSNs, which are the predominant neurons of the adult striatum. More than 
90% of MSNs in rodents are DARPP-32 positive (Ouimet et al., 1998). In the 
developing brain, striatal projection neurons originate in the LGE region of the ventral 
telencephalon, making this an obvious choice for use as an in vitro cell culture model 
for optimising DARPP-32 output in terminal neuronal differentiation cultures.
In vitro expansion of E14 mouse LGE in the presence of FCS and EGF, 
followed by differentiation in the absence of these factors resulted in generation of P- 
III-tubulin positive neurons which, although they were largely GABAergic, were not 
seen to express DARPP-32 (Skogh et al., 2001). Differentiation of LGE-derived 
neurons in homotopic co-culture, on monolayers of LGE-derived glia, resulted in up 
to 15% DARPP-32 positive neurons, in comparison to co-culture on MGE-derived 
glia, which yielded 7% DARPP-32 (Skogh and Campbell, 2003).
The LGE has been reported to be a source of retinoid signalling and retinoids 
from LGE glia have been implicated in striatal neuronal differentiation (Toresson et 
al., 1999). RA has been implicated in forebrain development (Schneider et al., 2001; 
Haskell and LaMantia, 2005; Marklund et al., 2004; Ribes et al., 2006) and in 
regulation of DARPP-32 expression in the developing brain (Waclaw et al., 2004). In 
vitro E14 mouse LGE cultures have shown an increase in DARPP-32 expression in 
response to addition of exogenous RA (Toresson et al., 1999), which is similar to the 
increase in DARPP-32 expression seen following homotopic co-culture of LGE- 
derived neurons with LGE-derived glia (Skogh and Campbell, 2003).
Addition of brain-derived neurotrophic factor (BDNF) has been reported to 
promote the survival of DARPP-32 positive neurons, as well as increase neurite 
outgrowth and the number of branching points on the neurites (Nakao et al., 1995). 
Differentiating neuronal cells treated with BDNF have been shown to be multipolar 
rather than bipolar, and they display enhanced neuronal fates, as demonstrated by 
altered cell morphology (Lachyankar et al., 1997). BDNF has also been shown to 
increase expression of DARPP-32 in E l5 mouse striatal neuronal differentiation 
cultures and moreover, has been shown to regulate DARPP-32 transcription in MSNs 
(Ivkovic et al., 1997).
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To date there is very little literature demonstrating the in vitro terminal 
differentiation of ES cell-derived neural precursors with the subsequent generation of 
DARPP-32 positive neurons. Human ES cell-derived neural precursors cultured for 
50 days with addition of BDNF, SHH and DKK-1, and terminally differentiated for a 
further 10 days in the absence of SHH and DKK-1, generated 22% MAP2-positive 
neurons, of which 36% expressed GABA and 53% expressed DARPP-32 (Aubry et 
al., 2008). Interpretation of these data requires a degree of caution since DARPP-32 
positive neurons are also GABAergic neurons and co-expression would be expected 
in the DARPP-32 positive neurons. This therefore reinforces the requirement for more 
reliable markers of MSNs. Mouse ES cell-derived neural precursors have been shown 
to generate p-IH-tubulin positive neurons (Bouhon et al., 2005; Bouhon et al., 2006; 
Dihne et al., 2006) including a proportion of GABAergic neurons (Bouhon et al., 
2006).
DARPP-32 is currently the most commonly used marker of striatal MSNs and 
it is restricted to terminally differentiated neurons, therefore identification of other 
markers including those expressed in MSN precursors are being sought. FoxPl is one 
such marker which was shown to upregulate in the developing mouse striatum from 
E12 through to E l6 (Kelly et al., in preparation). Expression of FoxPl is maintained 
to adulthood, and in the striatum, is restricted to the striatal projection neurons and not 
the intemeurons (Ferland et al., 2003; Tamura et al., 2004).
In this chapter, the rationale was to use foetal striatal cells as a model system 
to explore cues to induce terminal differentiation of MSNs from already-specified 
precursors, and then apply these conditions to neuronal differentiation cultures of 
mouse ES cell-derived neural precursors, with the aim to generate MSNs. E14 LGE- 
derived neurons were analysed using immuno-fluorescence to assess the effects of 
various treatments in neuronal differentiation culture on the neuronal phenotype, in 
particular expression of DARPP-32 and also the earlier-onset striatal marker FoxPl. 
Mouse ES cell-derived neural precursors, following 16 days in ADF+ neural 
induction culture, were subjected to the same treatments as the LGE cultures in order 
to determine the neuronal phenotypes yielded, again, looking for DARPP-32 positive 
neurons. Neural induction cultures were untreated or purmorphamine treated, to 
determine if further specification prior to neuronal differentiation affected subsequent 
expression of DARPP-32, GABA and FoxPl.
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6.3 Experimental Procedures
Dissection and dissociation o f mouse E l 4 LGE
LGE was dissected from E14 mouse forebrain and dissociated to generate a 
single-cell suspension, as described in Chapter 2. Briefly, tissue was incubated in 
trypsin and DNAse for 20 minutes at 37°C followed by a further 5 minute incubation 
in trypsin inhibitor. The tissue was then washed in DMEM/F-12, centrifuged at 
lOOOrpm for 3 minutes, the remaining pellet was resuspended in 200pl DMEM/F-12 
and triturated 10-15 times to generate a single cell suspension which was counted 
using a haemocytometer.
Generation o f LGE-derived glia
E14 mouse LGE cells were seeded in glial expansion medium (DMEM/F-12, 
1% PS, 10% FCS, 2mM glutamine and 20ng/ml EGF) in tissue-culture treated flasks. 
Medium was changed every 2-3 days and cultures were passaged using trypsin-EDTA 
when 80-90% confluency was reached, and re-seeded for further expansion. Glial 
cultures at passage 4 were used for co-culture studies.
24 hours before plating LGE cells or day 16 NEBs for neuronal 
differentiation, LGE glia were resuspended in glial differentiation medium 
(DMEM/F-12, 1% PS, 10% FCS and 2mM glutamine) and plated onto PLL-coated 
glass cover-slips.
Generation and maintenance o f ES cell-derived NEBs
The mouse ES cell line Foxgl-lacZ was used in this study. NEBs were derived 
from the FoxglZ mouse ES cell line as described in Chapter 2. Briefly, ES cells were 
transferred from ES cell culture medium to ADF+ medium at a density of 50,000 cells 
per ml, medium was replaced every 2 days and 20ng/ml FGF2 was added from day 4. 
Neural induction cultures were untreated (ADF+ plus 20ng/ml FGF2 at day 4) or 
treated with the SHH agonist purmorphamine (ADF+ plus 20ng/ml FGF2 and 0.5 pM 
purmorphamine at day 4) prior to differentiation.
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Plating cells and neuronal differentiation
On the day of plating NEBs were harvested and dissociated as described in 
Chapter 2. Cells were plated onto either PLL/laminin treated cover-slips or LGE- 
derived glia, at a density of 50,000 cells. 2-4 hours after plating, on adhering to the 
substrate, cells were flooded with 500pl differentiation medium (DMEM/F-12, 1% 
PS, 2% B-27 and 1% FCS). Cells plated onto LGE-derived glia were flooded 
immediately after plating to prevent cultures from drying out. Cells were allowed to 
differentiate for 7 or 14 days, and medium was replaced every 2-3 days. To determine 
the effects of addition of factors neuronal differentiation medium was supplemented 
with factors including BDNF at 50ng/ml and RA at lOOnm.
Immunocytochemistry
Following 7 or 14 days in neuronal differentiation medium cells were fixed. 
Fluorescent immunocytochemistry was performed according to the protocol detailed 
in Chapter 2. Primary antibodies used were anti-p-III-tubulin (1:1000), anti-GFAP 
(1:1000), anti-DARPP-32 (1:20,000), anti-FoxPl (1:500) and anti-GABA (1:500).
Microscopy and Statistical analysis
Cells were visualised under UV fluorescence using a Leitz microscope. 
Hoechst positive nuclei were detected and cells immuno-labelled with the maker of 
interest were counted, as described in Chapter 2. Images were processed using 
Optronics MagnaFire software and Adobe Photoshop.
Two-sample t-tests or one- and two-factor ANOVA with Tukey Kramer post 
hoc comparisons when appropriate, were performed using Minitab 15 statistical 
software.
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DARPP-32 expression in LGE-derived neurons
Since the LGE is the origin of DARPP-32 positive MSNs of the adult 
striatum, this region of the developing forebrain was used as a ‘standard’ to assess the 
effects in vitro, of various treatments in neuronal differentiation cultures on the 
expression of DARPP-32. LGE was dissected from E14 mouse forebrain, plated onto 
PLL/laminin substrate and allowed to differentiate for 7 days. Cultures were fixed and 
triple-labelled for p-III-tubulin, DARPP-32 and the nuclei marker, Hoechst. For 
analysis of effects of BDNF and RA on neuronal (p-III-tubulin) and DARPP-32 yield, 
neuronal differentiation medium was supplemented with 50ng/ml BDNF and/or 
lOOnm RA, or left untreated. Overall total of Hoechst positive nuclei was not different 
between cultures which suggests there were no differences in proliferation or cell 
death between cultures. There was no significant difference in the proportion of P-III- 
tubulin positive neurons with the different treatments (treatment, F3 ,i2  = 0.06, p = n.s) 
(Figure 6.1). The proportion of P-III-tubulin positive neurons that co-expressed 
DARPP-32 was significantly higher in cultures treated with BDNF (10.93 ± 0.88%) 
than untreated cultures (3.74 ± 0.11%), and those cultures treated with RA (2.29 ± 
0.47%) or treated with both BDNF and RA (5.27 ± 0.68%) (treatment, F3J 2 = 38.90,
p<0.001).
Since expression levels of DARPP-32 in MSNs in vivo is initially low 
compared to adult levels, we increased the neuronal differentiation culture time in 
vitro to determine if this would increase DARPP-32 expression. When LGE cultures 
were allowed to differentiate for 14 days in untreated neuronal differentiation 
medium, generation of p-III-tubulin positive neurons was not significantly changed 
from that at day 7 (day, U = 0.74, p = n.s) (Figure 6.2). However the yield of DARPP- 
32 positive neurons as a percentage of p-III-tubulin positive neurons was significantly 
increased following 14 days differentiation (13.38 ± 2.37%) compared with 7 days 
differentiation in untreated neuronal differentiation medium (3.74 ± 0.11%) (day, U = 
4.70, p<0.05).
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3-lll-tubulin and DARPP-32 expression: 
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Figure 6.1. p-III-tubulin and DARPP-32 expression in LGE differentiation cultures.
Mouse E14 LGE was dissected, dissociated and plated onto PLL/laminin substrate in 
neuronal differentiation medium and allowed to differentiate for 7 days. Differentiating 
cultures were: i) untreated (neuronal differentiation medium alone), ii) treated with 5Qng/ml 
BDNF, iii) treated with lOOnm RA, or iv) treated with 50ng/ml BDNF and lOOnm RA. 
Following neuronal differentiation for 7 days, cultures were fixed and triple-labelled for p-III- 
tubulin, DARPP-32 and Hoechst nuclear marker. P-III-tubulin positive neurons are 
represented as a percentage of total Hoechst cells and DARPP-32 positive neurons are 
represented as a percentage of P-III-tubulin positive neurons. Each bar on the graph represents 
a mean of 3 different LGE dissections and error bars represent SEM. (***p<0.001).
P-III-tubulin and DARPP-32 expression: 
LGE differentiated in neuronal differentiation 
medium on substrate
80 i
70
20
: : :  T /W 7 / I
7 days 14 days
□ p-1-tubuln
□ DARPP-32
Days
Figure 6.2. p-III-tubulin and DARPP-32 expression in LGE differentiation cultures.
Mouse E14 LGE was dissected, dissociated and plated onto PLL/laminin substrate in 
neuronal differentiation medium and allowed to differentiate for 7 or 14 days. Cultures were 
fixed and triple-labelled for P-III-tubulin, DARPP-32 and Hoechst nuclear marker. p-III- 
tubulin positive neurons are represented as a percentage of total Hoechst cells and DARPP-32 
positive neurons are represented as a percentage of P-III-tubulin positive neurons. Each bar on 
the graph represents a mean of 3 different LGE dissections and error bars represent SEM. 
(*p<0.05).
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DARPP-32 yield from LGE neuronal cultures using different differentiation 
conditions, including plating substrate and BDNF addition to medium, was analysed 
(Figure 6.3). Following 7 days in neuronal differentiation medium there was a 
significant difference in DARPP-32 expression between differentiation treatments 
(treatment, F2 ,9  = 26.13, p<0.01); DARPP-32 expression was not significantly higher 
in LGE cultures plated on PLL/laminin substrate and treated with 50ng/ml BDNF 
than those plated on LGE-derived glia and left untreated; but both these conditions 
resulted in significantly higher DARPP-32 expression than cultures plated on 
PLL/laminin substrate and left untreated. Following 14 days differentiation there was 
no significant difference in DARPP-32 expression between the different 
differentiation treatments (treatment, F2 ,9  = 4.05, p = n.s). When LGE was plated on 
PLL/laminin substrate in neuronal differentiation medium with addition of 50ng/ml 
BDNF, there was no significant difference in DARPP-32 yield between day 7 (10.93 
± 0.88%) and day 14 (11.68 =t 2.30%) (day, U = 0.31, p = n.s), and similarly, when 
LGE was plated on LGE-derived glia in untreated neuronal differentiation medium 
there was no significant difference in DARPP-32 yield between day 7 (7.77 ± 0.96%) 
and day 14 (4.42 ± 2.82%) (day, U — 1.82, p = n.s).
Photomicrographs of LGE cultures that were subjected to the various 
differentiation treatments and subsequent fluorescent immunocytochemistry are 
shown in Figure 6.4, demonstrating p-III-tubulin and DARPP-32 expression.
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DARPP-32 expression following LGE differentiation
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Figure 63. DARPP-32 expression in LGE differentiation cultures. Mouse E14 LGE was 
dissected, dissociated and plated onto PLL/laminin substrate or LGE glia, and allowed to 
differentiate for 7 or 14 days. Neuronal differentiation medium was either left untreated or 
50ng/ml BDNF was added. Cultures were fixed and triple-labelled for P-III-tubulin, DARPP- 
32 and Hoechst nuclear stain. DARPP-32 positive neurons are represented as a percentage of 
P-III-tubulin positive neurons. Each bar on the graph represents a mean of 3 different LGE 
dissections and error bars represent SEM. (* = significance between days 7 and 14 with each 
treatment; f  = significance between treatments at either day 7 or day 14). (*p<0.05, 
ttpO.Ol).
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Figure 6.4. DARPP-32 expression in LGE differentiation cultures. Mouse E14 LGE was
dissected, dissociated and plated onto substrate or LGE glia and allowed to differentiate for 7 
or 14 days in neuronal differentiation medium. LGE was plated on PLL/laminin substrate and 
differentiated for 7 days (A) or 14 days (B); or plated on LGE-derived glia and differentiated 
for 7 days (C) or 14 days (D) in untreated neuronal differentiation medium. BDNF (50ng/ml) 
was added to neuronal differentiation medium and cultures were differentiated for 7 days on 
PLL/laminin substrate (E and F). Cultures were fixed and triple-labelled for p-III-tubulin 
(green), DARPP-32 (red) and Hoechst nuclear stain (blue). Scale bars = 50pm (A-E) and 
100pm (F).
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Co-expression o f FoxPl and DARPP-32 in LGE-derived neurons
Currently the most commonly used marker for the striatal MSNs is DARPP- 
32, and it only labels mature neurons. Ongoing work in our group focuses on finding 
novel markers for these cells including markers of MSN precursors. One such marker, 
which was identified by a study of striatal genes during embryonic development, is 
FoxPl, which was shown to label striatal precursor cells (Kelly et al., in preparation). 
Following 7 days in neuronal differentiation medium on PLL/laminin substrate, there 
was no significant difference in FoxPl expression between untreated LGE cultures 
(39.59 ± 3.80%) and those treated with 50ng/ml BDNF (35.10 ± 3.15%) (treatment, t5 
= 0.30, p = n.s) (Figure 6.5; A). DARPP-32 positive neurons, expressed as a 
percentage of FoxPl positive cells, were significantly higher when cultures were 
treated with 50ng/ml BDNF (26.36 ± 3.23%) than when cultures were untreated (9.51 
± 3.16%) (treatment, t7 = 3.73, p<0.05) (Figure 6.5; B).
Photomicrographs of LGE differentiation cultures (untreated and treated with 
50ng/ml BDNF for 7 days) that were labelled for FoxPl and DARPP-32 using 
immuno-fluorescence are shown in Figure 6.6. All DARPP-32 positive neurons 
observed co-expressed FoxPl, but not all FoxPl positive cells were DARPP-32 
positive.
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Figure 6.5. FoxPl and DARPP-32 expression in LGE differentiation cultures. Mouse 
E14 LGE was dissected, dissociated and plated onto PLL/laminin substrate and allowed to 
differentiate for 7 days in neuronal differentiation medium either untreated or with addition of 
50ng/ml BDNF. Cultures were fixed and triple-labelled for FoxPl, DARPP-32 and Hoechst 
nuclear stain. FoxPl positive cells are represented as a percentage of Hoechst positive nuclei
(A) and DARPP-32 positive neurons are represented as a percentage of FoxPl positive cells
(B). Each bar on the graph represents a mean of 3 different LGE dissections and error bars 
represent SEM. (*p<0.05).
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Figure 6.6. FoxPl and DARPP-32 expression in LGE differentiation cultures. Mouse 
E14 LGE was dissected, dissociated, plated onto substrate and allowed to differentiate for 7 
days in neuronal differentiation medium in the absence of growth factors (A-D) or in the 
presence of 50ng/ml BDNF (E-H). Cultures were fixed and triple-labelled for FoxPl (green), 
DARPP-32 (red) and Hoechst nuclear stain (blue). Arrows (D and H) indicate cells co­
expressing FoxPl and DARPP-32, and insets (D and H) show higher magnifications of 
double-labelled cells. Scale bars = 50pm.
Neuronal differentiation o f  day 16 N EBs
NEBs following 16 days in A D F+ neural induction m edium with the addition 
o f 20ng/ml FGF2 at day 4, can generate neurons when cultured in neuronal 
differentiation medium  for 7 days, in the presence o f  FCS and B27 (Figure 6.7).
Figure 6.7. Phase contrast photom icrographs of day 16 NEBs following 7 days neuronal 
differentiation. NEBs were harvested, dissociated and plated on PLL/laminin substrate 
following 16 days in ADF+ with addition of 20ng/ml FGF2 from day 4. Following 7 days 
differentiation in neuronal differentiation medium cultures were fixed for analysis. Cultures 
did not appear overgrown as was the case with day 8 NEB differentiating cultures. 
Photomicrograph B is a higher powered image o f A, as indicated by the box in A. Scale bars 
= 100pm (A) and 50pm (B).
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Fluorescent immunocytochemistry o f  day 16 ES cell-derived neural precursors 
following 7 and 14 days in neuronal differentiation medium on PLL/laminin substrate, 
confirmed the presence o f  P-III-tubulin positive neurons and GFAP positive glia 
(Figure 6.8). Although there appeared to be proportionally fewer neurons at day 14 
(21.20 ± 2.01%) than at day 7 (30.71 ±  4.89%) this did not prove to be statistically 
significant (day, is = 2.95, p = n.s) (Figure 6.8). The proportion o f GFAP-positive 
cells was significantly higher at day 14 (25.84 ±  2.24%) than at day 7 (14.92 ± 1.48%) 
(day, ts = 4.01, p<0.05).
Neuron and astrocyte yield from day 16 NEBs
40
35
8  30
25
20
COno
CD01
jS 15 2
O 10
*  5
7 14
□  B-tubulin 
0  GFAP
Days in neuronal differentiation medium
Figure 6.8. Neuron and astrocyte yield from day 16 NEBs. NEBs following 16 days in 
neural induction medium were harvested, dissociated and plated onto PLL/laminin substrate 
allowed to differentiate for 7 or 14 days in neuronal differentiation medium. Cultures were 
fixed and triple-labelled for P-III-tubulin, GFAP and Hoechst nuclear stain. p-III-tubulin and 
GFAP positive cells are represented as a percentage o f total Hoechst cells. Each bar on the 
graph represents a mean of 3 different neural induction cultures and error bars represent SEM. 
(*p<0.05).
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Neuronal yield of day 16 NEBs was analysed under conditions previously 
used for induction of DARPP-32 in LGE cultures (Figure 6.9; A and B). Since the 
proportion of P-III-tubulin positive neurons is calculated as a percentage of total 
Hoechst cells, neuronal yield from NEBs plated on PLL/laminin substrate and those 
plated on top of LGE-derived glia is not directly compared because the total Hoechst 
cell count is not equal due to the presence/absence of the glia. When expression of 
DARPP-32 is calculated as a percentage of p-III-tubulin positive neurons, the two 
plating conditions can be compared.
There was no significant difference in the proportion of p-III-tubulin positive 
neurons when cultures were plated on PLL/laminin substrate, after 7 days 
differentiation without BDNF (30.71 ± 4.89%), 7 days with BDNF (30.58 ± 0.69%) 
14 days without BDNF (21.20 ± 2.01%) and 14 days with BDNF (23.13 ± 3.39%) 
(treatment x day, ¥\,i2 = 139, p = n.s) (Figure 6.9; A). There was also no significant 
difference in the proportion of p-HI-tubulin positive neurons when cultures were 
plated on LGE-derived glia, after 7 days differentiation without BDNF (25.08 ± 
7.67%), 7 days with BDNF (28.12 ± 3.56%) 14 days without BDNF (15.18 ±0.31%) 
and 14 days with BDNF (20.03 ± 2.24%) (treatment x day, Fi,i2 = 1-22, p = n.s) 
(Figure 6.9; B).
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Neuronal yield from Day 16 NEBs following neuronal 
differentiation on PLL/laminin substrate
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Figure 6.9. Neuronal yield from day 16 NEBs. NEBs following 16 days in neural induction 
medium were harvested, dissociated and plated onto PLL/laminin substrate (A) or LGE- 
derived glia (B). Cultures were allowed to differentiate for 7 or 14 days in neuronal 
differentiation medium in the presence or absence of 50ng/ml BDNF. Cultures were fixed and 
double-labelled for p-III-tubulin and Hoechst nuclear stain. p-III-tubulin positive cells are 
represented as a percentage o f total Hoechst cells. Each bar on the graph represents a mean of 
3 different neural induction cultures and error bars represent SEM.
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Generation o f striatal neurons from day 16 NEBs
Addition of low concentrations of the SHH agonist purmorphamine to ES cell- 
derived neural precursor induction cultures resulted in a slight increase in expression 
of some ventral telencephalic markers; Nkx2.1 and Dlx2, detailed in Chapter 5. In this 
chapter, ‘purmorphamine treated’ precursors have been subjected to the neuronal 
differentiation protocol in parallel with ‘untreated’ precursors, to determine if the 
untreated and treated precursors respond differently to the various neuronal 
differentiation treatments and generate different proportions of striatal neuronal 
phenotypes.
Since DARPP-32 expression has not previously been reported following in 
vitro neuronal differentiation of NEBs, GABA (the principal neurotransmitter of 
striatal MSNs), which has been demonstrated following in vitro neuronal 
differentiation of NEBs (see section 6.2), was included for additional analysis.
Expression of p-III-tubulin positive neurons was not significantly different in 
day 16 precursors following 7 days in neuronal differentiation medium, with respect 
to addition of purmorphamine to neural induction medium (purmorphamine, Fi,i2  = 
0.11, p = n.s) or addition of BDNF to neuronal differentiation medium (BDNF, Fi,i2 = 
0.14, p = n.s) (Figure 6.10; A). There was also no significant difference in expression 
of p-III-tubulin positive neurons in day 16 precursors following 14 days 
differentiation, with respect to addition of purmorphamine to neural induction 
medium (purmorphamine, Fi,i2 = 2.10, p = n.s) or addition of BDNF to neuronal 
differentiation medium (BDNF, Fi,i2  -  168, p = n.s) (Figure 6.10; D).
Fluorescent immunocytochemistry of day 16 ES cell-derived neural precursors 
following 7 and 14 days differentiation in neuronal differentiation medium on 
PLL/laminin substrate, revealed the presence of GABAergic neurons (Figure 6.10; B 
and E; and Figure 6.11). There was no significant difference in the proportion of 
GABA positive neurons as a percentage of P-III-tubulin neurons when cultures were 
plated on PLL/laminin substrate, after 7 days differentiation with respect to 
purmorphamine concentration (purmorphamine, Fi,i2 = 0.09, p = n.s) or 
differentiation treatment (BDNF, FU2 = 0.99, p = n.s); untreated precursors without 
BDNF (62.75 ± 7.28%), purmorphamine treated precursors without BDNF (60.18 ± 
6.95%), untreated precursors with BDNF (68.52 ± 3.82%) and purmorphamine treated 
precursors with BDNF (67.26 ± 7.10%) (Figure 6 .10;B). There was also no significant 
[ difference in the proportion of GABA positive neurons when cultures were plated on
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PLL/laminin substrate and allowed to differentiate for 14 days, with respect to 
addition of purmorphamine (purmorphamine, Fi5i2 = 0.35, p = n.s) or differentiation 
treatment (BDNF, Fj,i2 = 2.03, p = n.s); untreated precursors without BDNF (57.42 ± 
6.73%), purmorphamine treated precursors without BDNF (54.88 ± 7.05%), untreated 
precursors with BDNF (67.24 ± 4.51%) and purmorphamine treated precursors with 
BDNF (62.53 ± 5.92%) (Figure 6.10;E). The proportion of GABAergic positive 
neurons was not significantly different between the 7 day and 14 day neuronal 
differentiation cultures (day, t2 i = 0.99, p = n.s).
Fluorescent immunocytochemistry of day 16 ES cell-derived neural precursors 
following 7 and 14 days differentiation in neuronal differentiation medium on 
PLL/laminin substrate, revealed the presence of p-III-tubulin positive neurons co­
expressing DARPP-32 (Figure 6.10; C and F; and Figure 6.12). There was no 
significant difference in the proportion of DARPP-32 positive neurons as a percentage 
of p-III-tubulin neurons when cultures were plated on PLL/laminin substrate, after 7 
days differentiation with respect to purmorphamine concentration (purmorphamine, 
Fi,i2 = 0.28, p = n.s) or differentiation treatment (BDNF, Fi,i2 = 2.13, p = n.s); 
untreated precursors without BDNF (4.16 ± 1.77%), purmorphamine treated 
precursors without BDNF (3.82 ± 0.89%), untreated precursors with BDNF (6.91 ± 
2.04%) and purmorphamine treated precursors with BDNF (5.60 ± 1.24%) (Figure 
6.10; C). There was also no significant difference in the proportion of DARPP-32 
positive neurons when cultures were plated on PLL/laminin substrate and allowed to 
differentiate for 14 days, with respect to addition of purmorphamine (purmorphamine, 
F 1,12 = 0.65, p = n.s) or differentiation treatment (BDNF, Fi,i2 = 1.50, p = n.s); 
untreated precursors without BDNF (2.26 ± 0.54%), purmorphamine treated 
precursors without BDNF (2.38 ± 0.49%), untreated precursors with BDNF (6.42 ± 
2.76%) and purmorphamine treated precursors with BDNF (3.58 ± 1.85%) (Figure 
6.10; F).
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Figure 6.10. p-III-tubulin, GABA and DARPP-32 yield from day 16 NEBs. NEBs 
following 16 days in neural induction medium were harvested, dissociated and plated onto 
PLL/laminin substrate and allowed to differentiate for 7 days (A, B and C) or 14 days (D, E 
and F). Neural induction cultures were untreated or treated with 0.5 pM purmorphamine, and 
subsequent differentiation was in neuronal differentiation medium either untreated or with 
addition of 50ng/ml BDNF. Cultures were fixed and triple-labelled for P-III-tubulin, GABA 
and Hoechst nuclear stain, or p-III-tubulin, DARPP-32 and Hoechst nuclear stain. p-III- 
tubulin positive neurons are represented as a percentage o f total Hoechst cells (A and D), 
GABA positive neurons are represented as a percentage o f P-III-tubulin positive neurons (B 
and E) and DARPP-32 positive neurons are represented as a percentage of P-III-tubulin 
positive neurons (C and F). Each bar on the graphs represents a mean of 3 different neural 
induction cultures and error bars represent SEM.
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Figure 6.11. Photomicrographs showing expression of p-III-tubulin and GABA from day 
16 NEBs following differentiation, using immuno-fluorescence. Since there was no 
significant difference in p-III-tubulin and GABA yield between cultures of the various 
treatments, this figure shows a representative selection of photomicrographs from some of the 
different culture conditions. NEBs following 16 days in neural induction medium were 
harvested, dissociated and plated onto PLL/laminin substrate and allowed to differentiate for 
7 days (A-H) or 14 days (I-P). Neural induction cultures were untreated or treated with 0.5pM 
purmorphamine, and subsequent differentiation was in neuronal differentiation medium either 
untreated or with addition of 50ng/ml BDNF. Cultures were fixed and triple-labelled for p-III- 
tubulin (red), GABA (green) and Hoechst nuclear stain (blue). Untreated precursors without 
BDNF for 7 days (A-D); untreated precursors with addition of BDNF for 7 days (E-H); 
untreated precursors without BDNF for 14 days (I-L); 0.5 pM purmorphamine treated 
precursors with addition of BDNF for 14 days (M-P). Arrows (D, H, L and P) indicate cells 
co-expressing P-III-tubulin and GABA. Scale bars = 50pm.
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Figure 6.12. Photomicrographs showing expression of p-III-tubulin and DARPP-32 
from day 16 NEBs following differentiation, using immuno-fluorescence. Since there was 
no significant difference in p-III-tubulin and DARPP-32 yield between cultures of the various 
treatments, this figure shows a representative selection of photomicrographs from some of the 
different culture conditions. NEBs following 16 days in neural induction medium were 
harvested, dissociated and plated onto PLL/laminin substrate and allowed to differentiate for 
7 days (A-H) or 14 days (I-P). Neural induction cultures were untreated or treated with 0.5pM 
purmorphamine, and subsequent differentiation was in neuronal differentiation medium either 
untreated or with addition of 50ng/ml BDNF. Cultures were fixed and triple-labelled for P-III- 
tubulin (green), DARPP-32 (red) and Hoechst nuclear stain (blue). Untreated precursors 
without BDNF for 7 days (A-D); 0.5pM purmorphamine treated precursors with addition of 
BDNF for 7 days (E-H); untreated precursors without BDNF for 14 days (I-L); 0.5pM 
purmorphamine treated precursors with addition of BDNF for 14 days (M-P). Arrows (D, H, 
L and P) indicate cells co-expressing P-III-tubulin and DARPP-32. Scale bars = 50pm.
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Expression of FoxPl was analysed in day 16 precursors with and without 
purmorphamine addition to neural induction medium, and with and without BDNF 
addition to subsequent neuronal differentiation cultures (Figure 6.13 and 6.14). 
Fluorescent immunocytochemistry demonstrated co-expression of FoxPl and 
DARPP-32 in day 16 NEBs following 7 days in neuronal differentiation medium 
(Figure 6.14). There was no significant difference in the proportion of FoxPl positive 
cells yielded when day 16 precursors, with or without purmorphamine, were plated on 
PLL/laminin substrate and differentiated for 7 days in neuronal differentiation 
medium with or without BDNF, with respect to addition of purmorphamine 
(purmorphamine, FU2 = 0.29, p = n.s) or addition of BDNF (BDNF, FU2 = 1.34, p = 
n.s); untreated precursors without BDNF (16.89 ± 0.81%), purmorphamine treated 
precursors without BDNF (22.25 ± 2.14%), untreated precursors with BDNF (24.10 ± 
2.91%) and purmorphamine treated precursors with BDNF (21.92 ± 4.65%) (Figure 
6.13; A).
There was no significant difference in the proportion of DARPP-32 positive 
neurons yielded, as a percentage of FoxPl positive cells, when day 16 precursors, 
with or without addition of purmorphamine, were plated on PLL/laminin substrate 
and differentiated for a further 7 days in neuronal differentiation medium with or 
without BDNF, with respect to addition of purmorphamine (purmorphamine, Fj,i2 = 
2.94, p = n.s) or addition of BDNF (BDNF, F i,i2 = 2.64, p = n.s); untreated precursors 
without BDNF (2.04 ± 0.81%), untreated precursors with BDNF (3.14 ± 0.65%), 
purmorphamine treated precursors without BDNF (3.19 ± 0.58%) and
purmorphamine treated precursors with BDNF (5.67 ± 2.29%) (Figure 6.13; B).
A summary of the neuronal expression in LGE-derived neurons and day 16 
NEBs following neuronal differentiation under the various culture conditions is 
shown in Appendix 7.
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Figure 6.13. FoxPl and DARPP-32 expression in day 16 NEBs. NEBs following 16 days 
in neural induction medium were harvested, dissociated and plated onto PLL/laminin 
substrate and allowed to differentiate for 7 days (A and B). Neural induction cultures were 
untreated or treated with 0.5pM purmorphamine, and subsequent differentiation was in 
neuronal differentiation medium either untreated or with addition of 50ng/ml BDNF. Cultures 
were fixed and triple-labelled for FoxPl, DARPP-32 and Hoechst nuclear stain. FoxPl 
positive cells are represented as a percentage o f total Hoechst cells (A) and DARPP-32 
positive neurons are represented as a percentage o f FoxPl positive cells (B). Each bar on the 
graphs represents a mean o f 3 different neural induction cultures and error bars represent 
SEM.
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Figure 6.14. Photomicrographs showing expression of FoxPl and DARPP-32 from day 
16 NEBs following differentiation, using immuno-fluorescence. Since there was no 
significant difference in FoxPl and DARPP-32 yield between cultures of the various 
treatments, this figure shows a representative selection of photomicrographs from some of the 
different culture conditions. NEBs following 16 days in neural induction medium were 
harvested, dissociated and plated onto PLL/laminin substrate and allowed to differentiate for 
7 days (A-H) or 14 days (I-P). Neural induction cultures were untreated or treated with 0.5pM 
purmorphamine, and subsequent differentiation was in neuronal differentiation medium either 
untreated or with addition of 50ng/ml BDNF. Cultures were fixed and triple-labelled for 
FoxPl (green), DARPP-32 (red) and Hoechst nuclear stain (blue). Untreated precursors 
without BDNF for 7 days (A-D); 0.5pM purmorphamine treated precursors with addition of 
BDNF for 7 days (E-H); untreated precursors without BDNF for 14 days (I-L); 0.5pM 
purmorphamine treated precursors without BDNF for 14 days (M-P). Arrows (D, H, L and P) 
indicate cells co-expressing FoxPl and DARPP-32, and insets (D, H, L and P) show higher 
magnifications of double-labelled cells. Scale bars = 50pm.
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DARPP-32 expression in LGE-derived neurons
The commitment of striatal projection neurons to the patch or matrix 
compartment of the striatum is related to the embryonic stage at which neurons are 
generated (van der Kooy and Fishell, 1987). The early-born neurons (by E l2 in the 
mouse) are destined to the patch compartment whereas the mid to late-born neurons 
(by E l5-16 in the mouse) populate the matrix compartment (van der Kooy and 
Fishell, 1987). The two compartments emerge clearly in vivo at PO-2 (Passante et al., 
2008). MSNs are found in both the patch and matrix striatal compartments and 
therefore include a combination of early and mid to late-born neurons. Peak 
production of MSNs is at E l5 (Marchand et al., 1986), but DARPP-32 is not 
expressed until later. DARPP-32 expression in the mouse is detected at low levels at 
P0, with an increase to adult levels over the first four post-natal weeks (Ehrlich et al., 
1990).
The LGE is the origin of the DARPP-32 positive MSNs found in the adult 
striatum. When mouse E14 LGE was differentiated in vitro for 7 days, in the presence 
of FCS and B27, the proportion of neurons that expressed DARPP-32 was shown to 
increase by nearly 3 times with the addition of 50ng/ml BDNF when compared with 
untreated differentiation cultures. Since there was no increase in the total neuron 
number, as determined by P-III-tubulin expression, the BDNF-induced increase in 
DARPP-32 positive neurons appears to be specific and not just due to an overall 
enrichment of neuronal differentiation. BDNF has previously been reported to exert a 
dose-dependent survival effect on DARPP-32-positive neurons derived from 
embryonic rat striatum (Nakao et al., 1995), and in mouse primary striatal cultures, 
addition of lOOng/ml BDNF to serum-free culture medium resulted in a 4-fold 
increase in DARPP-32 expression after 24 hours (Ivkovic et al., 1997).
In the neuronal differentiation culture system applied here, addition of RA to 
LGE differentiation cultures did not result in an increase in DARPP-32 expression. 
When both BDNF and RA were added concomitantly, there was a slight increase in 
DARPP-32 expression when compared with untreated cultures, however, this was 
only half that seen in cultures treated with BDNF alone. This was not consistent with
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a previous study, also using mouse LGE at E l3.5, which reported that addition of 
exogenous RA (lOnm and lpM) to LGE-derived neuronal cultures resulted in an 
increase in DARPP-32 expression which was twice that of untreated control cultures 
(Toresson et al., 1999). In contrast to the neuronal differentiation medium employed 
in this study, Toresson et al used serum-free differentiation medium, in order to 
exclude the effects of undefined growth factors present at varying levels in FCS, 
including retinol. This might be one explanation for the different responses of LGE 
cultures following addition of exogenous RA. Retinyl acetate is also a component of 
the growth supplement B-27, which is added to neuronal differentiation medium in 
this study and aids survival of neurons in culture, but is absent from the other 
differentiation protocols mentioned (Nakao et al., 1995; Ivkovic et al., 1997; Toresson 
et al., 1999). In our study we were interested in optimising the DARPP-32 output 
from the neuronal differentiation culture system. Since the presence of FCS and B-27 
encourages neuronal differentiation, we used this as our baseline system for 
expression of striatal markers.
The effect of BDNF on DARPP-32 expression in E14 mouse LGE neuronal 
cultures might be to induce neurons to become DARPP-32 positive, since we, and 
others (Nakao et al., 1995; Ivkovic et al., 1997) demonstrate an increase in DARPP-32 
positive neurons following BDNF addition to LGE neuronal cultures. Nakao et al also 
reported that BDNF acted as a survival factor for DARPP-32 positive neurons (Nakao 
et al., 1995). Another possibility is that BDNF might decrease the time taken for 
DARPP-32 to be ‘switched on’ in those neurons whose fates are already specified to 
become DARPP-32 positive neurons. Our results would favour the latter hypothesis, 
since longer-term neuronal differentiation of LGE cultures, up to 14 days, in untreated 
neuronal differentiation medium resulted in 3 times more DARPP-32-expressing 
neurons than LGE cultures that were differentiated for 7 days. DARPP-32 expression 
yielded from untreated LGE cultures differentiated for 14 days, was only slightly 
higher than BDNF treated LGE cultures differentiated for 7 days. When BDNF was 
added to LGE cultures that were differentiated for 14 days, there was no difference in 
DARPP-32 between untreated cultures differentiated for the same time. This suggests 
that in this neuronal differentiation system, BDNF reduces the differentiation time of 
DARPP-32 positive neurons in LGE cultures.
Differentiation of LGE-derived neurons in homotopic co-culture on LGE- 
derived glial cells resulted in increased DARPP-32 expression following 7 days
161
Chapter 6 in vitro differentiation
differentiation when compared with LGE-derived neurons differentiated on 
PLL/laminin substrate for the same period of time. When LGE-derived neurons were 
differentiated in LGE-derived glia co-culture for 14 days, there was no difference in 
DARPP-32 expression compared with 7 days differentiation in co-culture. In our 
study, there was a two-fold increase in DARPP-32 positive neurons following 7 days 
differentiation in co-culture (up to 8%) compared with differentiation on substrate. 
Skogh and Campbell reported 10-15% DARPP-32 positive neurons following 7 days 
in co-culture and noted a decrease in DARPP-32 yield with higher passage numbers 
of LGE-derived glia prior to co-culture (Skogh and Campbell, 2003). This suggests 
that glial cells are releasing different factors or different levels of factors following 
different periods of time in culture. Although differentiation of LGE cultures on 
PLL/laminin substrate for 14 days yielded significantly more DARPP-32 positive 
neurons than those differentiated for 7 days, the differentiation cultures at day 14 were 
not consistently healthy in appearance and therefore not reliable for subsequent 
immuno-fluorescent analysis. This might suggest that the in vitro neuronal 
differentiation culture system used here is not (always) favourable for long-term 
differentiation of mouse striatal cultures.
In the CNS, glial cells release soluble factors and signal to neurons regulating 
neuronal activity. In vitro, glia-derived factors have been shown to be important for 
the development of synapses (Pffieger and Barres, 1997; Vicario-Abejon et al., 1998; 
Blondel et al., 2000). Factors such as BDNF and neurotrophin-3 (NT-3) have been 
shown to regulate synaptogenesis in hippocampal cultures, and these factors do not 
require the presence of glia to act on neurons (Song et al., 1997).
In vitro studies using organotypic cultures looking at development of striatal 
neurons and the formation of the patch compartment of the striatum have suggested 
that the cortex provides signals to the developing striatum, and the corticostriatal 
afferents might be necessary for correct development of the early-born striatal neurons 
(Snyder-Keller et al., 2001; Snyder-Keller, 2004; Snyder-Keller et al., 2008). 
Furthermore, it has been demonstrated that the stage of development of the cortical 
neurons is important for the maturation of striatal neurons (Snyder-Keller, 2004; 
Snyder-Keller et al., 2008). Thus a co-culture system of LGE-derived neurons or 
NEBs, with neurons from the developing cortex or ventral mesencephalon might 
prove beneficial in increasing the proportion of striatal projections neurons within 
cultures.
162
Chapter 6 in vitro differentiation
Since DARPP-32 is a marker of mature striatal MSNs, it would be useful to 
identify a reliable marker of MSN precursor cells. FoxPl was identified as a potential 
candidate following a screen to analyse up-regulation of striatal genes during 
embryonic development (Kelly et al., in preparation). Further analysis using RT-PCR, 
in situ hybridization and fluorescent immunocytochemistry on developing mouse 
striatum, revealed that FoxPl is expressed in the striatum and is upregulated from E12 
through to E l6 by 6 fold, with expression maintained through to adulthood (Kelly et 
al., in preparation; Ferland et al., 2003). Immunofluorescence shown here 
demonstrates that FoxPl and DARPP-32 are co-expressed in mature striatal neurons. 
Neuronal differentiation of LGE cultures showed no significant difference in FoxPl 
expression when cultures were untreated or treated with BDNF, but expression of 
DARPP-32 positive neurons, as a percentage of FoxPl cells, was increased with 
addition of BDNF. Expression of FoxPl in MSNs, both prior to their expression of 
DARPP-32 and then concomitantly with their expression of DARPP-32, suggests that 
in the 7 day differentiation period of LGE-derived neurons, BDNF does not induce 
cells to become striatal precursors, but simply pushes the striatal precursors which are 
already present to express DARPP-32.
Neuronal differentiation o f day 16 NEBs
ES cell-derived neural precursors subjected to 16 days in neural induction 
medium followed by a further period in neuronal differentiation medium as a 
monolayer culture, are shown to generate neurons, among other cell types. To date 
there is no literature in mouse which assesses the neuronal analysis of these neural 
precursors with the aim to generate DARPP-32 positive MSNs in vitro. When day 16 
neural precursor cultures are allowed to differentiate on PLL/laminin substrate for 7 
and 14 days they generate P-III-tubulin positive neurons along with GFAP positive 
glia. There was significantly more GFAP expression at day 14 than at day 7, but the 
proportion of p-III-tubulin positive neurons did not differ significantly between the 
two time points. Terminal differentiation of earlier stage neural precursors has been 
reported to generate p-III-tubulin positive neurons (Bouhon et al., 2005; Dihne et al., 
2006) and, with longer-term differentiation up to 14 days, GFAP positive glia 
(Bouhon et al., 2005). Later stage neural precursors at day 20 have also been reported 
to generate p-III-tubulin positive neurons as well as GFAP-positive cells and 
oligodendrocytes (Bouhon et al., 2006). It has been proposed that ES cell-derived
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neural precursors undergo a transition period from early stage ‘neurogenic’ to late 
stage ‘gliogeneic’ precursors (Bouhon et al., 2006).
The neuronal yield of day 16 neural precursors did not change when cultures 
were differentiated on PLL/laminin for 7 and 14 days with and without the addition of 
BDNF. There was also no difference in neuronal yield when cultures were 
differentiated on LGE-derived glia for 7 and 14 days with and without the addition of 
BDNF. As with LGE cultures, there was variable consistency in generation of healthy 
cultures that could be taken forward for further analysis, following long-term 
differentiation of neural precursors for 14 days.
The previous chapter looked at generating a greater proportion of ventral 
telencephalic precursors within the neural precursor population, as a way to attempt to 
increase mature striatal neurons following subsequent terminal differentiation. 
Addition of low concentrations of the SHH agonist purmorphamine resulted in a 
marginal increase in Nkx2A and Dlxl/2  expression of day 16 neural precursors. These 
purmorphamine treated neural precursors, along with untreated neural precursors, 
have been subjected to the neuronal differentiation protocol that was applied to the 
LGE-derived neurons to assess whether or not DARPP-32 expression can be 
generated from the neuronal population.
Neuronal yield was not changed between the different conditions of neural 
induction or neuronal differentiation, and within the neuronal population, there was no 
effect on the expression of DARPP-32 or GABA. The percentage of P-III-tubulin 
positive neurons that co-expressed GABA was about 60%, which is similar to that 
previously reported following 7 days differentiation of day 8 neural precursors, where 
55% of p-III-tubulin positive neurons expressed GABA (Bouhon et al., 2006). 
Terminal differentiation of human ES cell-derived neural precursors resulted in the 
generation of neuronal cells, 36% of which co-expressed GABA and 53% of which 
co-expressed DARPP-32 (Aubry et al., 2008). Assessment of the novel striatal marker 
FoxPl revealed that there was no difference in expression between the different 
culture conditions and there was also no difference in the proportion of cells that co­
expressed FoxPl and DARPP-32 in the day 16 neural precursors.
It appears that the day 16 neural precursors are not responsive to BDNF in the 
same way as the LGE-derived neurons. The heterogeneous nature of the ES cell- 
derived neural precursor cultures might make it difficult to see an effect on a specific 
cell type, and there might be an effect on other cell lineages that are present. The
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LGE-derived neurons have been pre-specified in the developing brain to become 
striatal cells whereas the ES cell-derived neural precursors have undergone only 
limited specification. It is possible that the neural precursors are not at the optimal 
stage required for responsiveness to certain inductive cues. Results presented in this 
chapter also indicate the differences between cultures, where cell counts show wide 
variation, due to heterogeneity and differences in the proportions of cell lineages 
within cultures, which results in large error bars and in turn influences the statistical 
significance of findings.
In this study the immature neuronal marker P-III-tubulin was used. The use of 
more mature neuronal markers such as MAP2A, NeuN and neurofilament, in 
conjunction with P-III-tubulin would allow assessment of the maturity of the cultures. 
One explanation for the differences between LGE-derived neurons and day 16 NEB- 
derived neurons in their response to factors such as BDNF, other than the 
heterogeneity of cells present in the NEB cultures, might be the degree of maturity of 
the neural cells. Data in Chapter 5 demonstrating the lower expression of dorso- 
ventral markers in NEBs compared with LGE or MGE, suggested that NEBs were not 
at the same developmental stage as the developing striatum. The data in this chapter 
revealing lower FoxPl expression in NEBs and also lower ratio of DARPP-32:FoxPl 
double-labelled cells suggest that NEBs are immature in comparison to the cells of the 
developing striatum.
The next step will be to explore the effects of the conditions applied here 
within a population of forebrain or, more specifically, ventral telencephalic-like cells 
derived from ES cells. Generation of a pure population of cells using cell-sorting 
techniques would enable determination of direct responses of these specific cells to 
the different conditions.
Conclusions
Work presented in this chapter demonstrates the potential of ES cell-derived 
neural precursors to differentiate into various striatal phenotypes. The expression of 
DARPP-32 positive neurons, from day 16 NEBs following neuronal differentiation, 
albeit at a low percentage of total neurons and therefore an even lower percentage of 
the total cell population, demonstrates the potential of these cells to generate the 
desired mature phenotype, MSN, which is encouraging. However, the presence of 
true, mature MSNs needs to be confirmed with other markers, including markers
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which demonstrate the presence of more mature neurons. Differentiation of the LGE- 
derived neurons suggests that if an LGE-like population of precursors can be 
generated from ES cells, there is the potential to increase the DARPP-32 yield from 
NEBs, however this likely requires further directed differentiation of NEBs in the 
neural induction culture prior to neuronal differentiation both in vitro and in vivo.
Since DARPP-32 positive neurons were generated from NEBs in vitro, the 
next chapter will analyse NEBs produced using the same protocol, following 
transplantation into the adult mouse lesioned striatum. In the in vivo host environment 
NEBs will have access to additional diffusible and contact factors that may prove 
important in further specifying and directing cells towards the mature neuronal 
phenotype.
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Chapter 7
in vivo characterisation o f NEBs 
(allograft model)
7.1 Summary
Neural transplantation of NEBs into the QA lesioned striatum was reported in 
Chapter 4, using a xenograft paradigm (mouse-to-rat). In Chapter 4, NEBs derived 
using standard neuralising conditions were insufficient to produce striatal-like grafts 
following in vivo differentiation. Subsequent chapters attempted to further direct cells 
and resulted in some expression of DARPP-32 in vitro. This chapter applies 
information gained from previous chapters, comparing transplantation of NEBs (day 
16 untreated or purmorphamine treated) and E14 mouse striatum (LGE, MGE and 
WGE) into the mouse host brain. Allografts offer the potential for donor cells to 
develop in a same-species environment, which might also enhance their 
responsiveness to host signals by providing species-specific signals. Six and twelve 
weeks post-transplantation no teratomas were detected in the NEB grafts and there 
was no significant difference in graft volume between any group. Grafts were small 
with a notable presence of dead cells. NEB donor cells contained the LacZ reporter 
gene to allow for post-transplantation identification of Foxgl positive cells (as used in 
Chapter 4). Neither the antibody against P-galactosidase nor the X-gal reaction 
detected any positive cells in the NEB-derived grafts. All analysis was carried out 
using Nissl staining to mark the graft area, and without being able to positively 
identify cells as graft or host-derived, counts represent cell numbers present within 
this area. Grafts were analysed for neuronal phenotype, in particular striatal neurons. 
There was no significant difference in NeuN positive cells within the graft area of 
NEB-derived or E14-derived grafts at both 6 and 12 weeks post-transplantation. 
DARPP-32 expression was not significantly different between groups at 6 weeks, but 
at 12 weeks there were significantly more DARPP-32 positive neurons in WGE- 
derived grafts compared with untreated day 16 NEB grafts. There was no significant 
difference in FoxPl, parvalbumin and calbindin expression between transplant groups 
at both survival time points, suggesting no difference between NEB-derived and El 4- 
derived grafts. Assessment of the mouse striatum as a viable host for transplantation 
needs to be addressed, and identification of all donor cells in a systematic study would 
help to give a clearer indication of what is happening to donor cells post­
transplantation.
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In Chapter 4 of this thesis, mouse ES cell-derived neural precursors following 
8 and 16 days in neural induction medium, were grafted into the QA-lesioned rat 
striatum. Following transplantation the day 8 NEB grafts developed teratomas and 
analysis for this group was performed earlier than anticipated, at 2 weeks post­
transplantation. The day 16 NEB grafts, at 6 weeks post-transplantation, generated 
grafts which comprised a heterogeneous mix of cells including cells of neuronal 
lineage, some of which expressed calbindin and parvalbumin, however there was no 
DARPP-32 expression in Foxgl-positive donor-derived cells, as identified using an 
antibody against p-galactosidase to detect the LacZ reporter gene. Chapter 5 
attempted further directed differentiation of NEBs looking at the effect of SHH on 
expression of markers of the ventral telencephalon. Addition of the SHH agonist 
purmorphamine at low concentrations (0.5pM) resulted in increased expression of the 
ventral markers Nkx2.1 and Dlx2. In this chapter, day 16 NEBs were transplanted with 
or without the addition of 0 .5 jiM  purmorphamine.
Since mouse-to-rat grafts are a xenograft paradigm there was the requirement 
for immunosuppression in the form of daily administration of CsA to prevent graft 
rejection. Allograft studies bypass the need for immunosuppression, allowing for 
longer-term survival post-transplantation and eliminating confounding factors such as 
slow, ongoing immune rejection. There is also the potential for donor cells to be 
receptive to species-specific signals and thus develop more thoroughly.
Currently, the assessment of allograft studies prior to the translation of human 
ES cells to clinical trials can only be performed in the mouse or monkey paradigm, 
since rat ES cell lines, which have only recently been established, are still undergoing 
development (Buehr et al., 2008; Li et al., 2008). The mouse-to mouse system is more 
readily accessible to researchers than the monkey-to-monkey system, with the 
potential to use larger transplant cohorts, the development of various mouse models of 
HD, and for functional analysis, there are numerous behavioural tests which have 
been optimised in mice, including those that reveal deficits in HD mice genetic 
models, and would therefore be useful when attempting to demonstrate improvements 
following transplantation.
Transplantation of mouse ES cell-derived neural precursors into mouse 
models of HD has not been widely reported. Dihne et al (2006) transplanted mouse
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ES cell-derived neural precursors at different stages during neural precursor 
induction, into the QA-lesioned mouse striatum. Differences in the expression of 
nestin (neural precursor marker), BrdU (marker of dividing cells) and P-III-tubulin 
(immature neuronal marker) prior to transplantation, resulted in generation of 
macroscopically different grafts. In precursor populations with relatively high 
expression of nestin (>95%) and BrdU (42%), and low P-III-tubulin expression 
(<3%), there was a much greater risk of tumour formation, with graft volume up to 
26mm3. When nestin and BrdU expression were lower (14% and 6%, respectively), 
and P-III-tubulin expression was higher (76%) there was no tumour formation at 16 
weeks post-transplantation (Dihne et al., 2006).
Transplantation of El 3-14 mouse LGE into the striatum of the R6/2 transgenic 
mouse model of HD resulted in graft survival following 6 weeks post-transplantation, 
with limited integration and only marginal improvements in the behavioural 
phenotype (Dunnett et al., 1998). The authors reported that grafts in the transgenic 
striatum behaved similarly to those in the control striatum, suggesting that the 
transgenic host environment is able to accommodate the introduction of donor cells.
Work in our group looking at striatal graft projections has shown that grafts 
derived from expanded mouse neural precursors generate more axonal projections 
than those grafts derived from E14 mouse primary foetal striatum (Kelly et al., 2007). 
This study reported 94% graft survival in mouse-to-mouse grafts in the unilateral QA- 
lesion model. Graft volumes were not significantly different between mouse foetal
'y
primary cells and mouse expanded neural precursors, (0.80 ± 0.09mm and 0.88 ± 
0.87mm3, respectively). However, long-term expanded neural precursors, of both 
mouse and human origin, exhibit reduced neurogenic potential compared to short­
term expanded neural precursors (Anderson et al., 2007) and reduced survival 
following long-term post-transplantation time points (Zietlow et al., 2005).
In this chapter mice with unilateral striatal QA lesions received transplants of 
(i) day 16 NEBs untreated, (ii) day 16 NEBs purmorphamine treated, (iii) E14 mouse 
LGE, (iv) E14 mouse MGE or (v) E14 mouse WGE, and were allowed to survive 
post-transplantation for 6 or 12 weeks. Morphological analysis was carried out, 
including assessment of graft volume, and more detailed analysis of phenotype 
looking in particular at striatal cell type was performed and compared between 
transplant groups.
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ES cell culture
The mouse ES cell line Foxgl-lacZ was used in this study. NEBs were derived 
from FoxglZ mouse ES cells as described in Chapter 2. Briefly, ES cells were 
transferred from ES cell culture medium to ADF+ medium at a density of 50,000 cells 
per ml, medium was replaced every 2 days and 20ng/ml FGF2 was added from day 4. 
Neural induction cultures were untreated (ADF+ plus 20ng/ml FGF2 from day 4) or 
treated with the SHH agonist purmorphamine (ADF+ plus 20ng/ml FGF2 and 0.5pM 
purmorphamine from day 4) prior to transplantation. On day 16 NEBs were harvested, 
incubated in accutase and a single-cell suspension was generated (see section 2.1.4). 
Cells were counted using a haemocytometer and viability was determined using 
trypan blue exclusion.
Dissection and dissociation o f  mouse E l 4 LGE, MGE and WGE
The three striatal dissections were used because of the differences in gene 
expression of the LGE and MGE regions, and the subsequent differences in neuronal 
phenotypes which originate in the two regions.
LGE, MGE and WGE were dissected from E14 C57B16/J mouse forebrain and 
dissociated to generate a single-cell suspension, as described in Chapter 2. Briefly, 
tissue was incubated in trypsin and DNAse for 20 minutes at 37°C followed by a 
further 5 minute incubation in trypsin inhibitor. Tissue was then washed in DMEM/F- 
12, centrifuged at lOOOrpm for 3 minutes, the remaining pellet was resuspended in 
200pl DMEM/F-12 and triturated 10-15 times to generate a single-cell suspension 
which was counted, and viability was determined using trypan blue exclusion.
Neural transplantation
Adult female C57B16/J mice received a unilateral QA lesion of the right 
striatum. Two weeks after lesioning mice received transplants of: (i) day 16 FoxglZ 
NEBs untreated (FGF2 alone) (n = 8), (ii) day 16 FoxglZ NEBs purmorphamine 
treated (FGF2 and purmorphamine) (n = 8), (Hi) LGE (n = 8), (iv) MGE (n = 8) and 
(v) WGE (n = 8), into the lesioned striatum. Lesions and grafts were carried out as 
described previously in Chapter 2.
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Histology and Immunohistochemistry
At 6 and 12 weeks post-transplantation animals were transcardially perfused 
and brains were taken for histological analysis. Brains were sectioned coronally on 
the freezing-stage microtome at 40pm. 1:12 series’ were processed for Nissl staining 
using cresyl violet, histochemical staining for AChE, and further 1:12 series’ were 
processed for immunohistochemistry with anti-p-galactosidase (1:1000), anti-NeuN 
(1:4000), anti-DARPP-32 (1:10,000) (a gift from Paul Greengard), anti-FoxPl 
(1:500), anti-calbindin (1:20,000) and anti-parvalbumin (1:4000).
The immunohistochemical staining protocol was the same for each antibody, 
as described in Chapter 2. Antibody staining was visualised using the Vector SG kit, 
and to determine graft area in stained sections, a Nissl stain was performed using 
cresyl violet, since neither p-galactosidase nor X-gal were detected.
Controls were carried out in parallel, where the primary antibody was omitted 
from the procedure.
Quantification and Statistical analysis
Cells expressing markers of interest were counted using a Leitz light 
microscope and stereology software. Graft volume was determined as described in 
Chapter 2.
Statistical analyses were performed using two-sample t-tests and one-way 
ANOVA with Tukey-Kramer post-hoc comparisons when appropriate, using Minitab 
15 software.
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1A Results
Graft survival and morphology
NEBs were cultured in neural induction medium and at day 4 addition of 
either 20ng/ml FGF2 alone (day 16 NEBs untreated), or 20ng/ml FGF2 and 0.5pM 
purmorphamine (day 16 NEBs purmorphamine treated) (see Chapter 5), which was 
then maintained to day 16 when NEBs were harvested for transplantation. E l4 mouse 
LGE, MGE and WGE were dissected, dissociated and transplanted as primary tissue, 
without expansion. Adult mice received unilateral QA lesions to the right striatum and 
two weeks later day 16 NEBs or E14 mouse striatal cells were transplanted into the 
lesion site. Prior to transplantation cell viability was determined using the trypan blue 
exclusion method: (i) day 16 NEBs untreated 80.99%; (ii) day 16 NEBs 
purmorphamine treated 78.85%; (iii) E14 mouse LGE 91.05%; (iv) E14 mouse MGE 
92.19% and (v) E14 mouse WGE 91.18%. Grafts were allowed to survive for 6 and 
12 weeks post-transplantation.
Nissl staining using cresyl violet revealed the presence of very small, pencil­
like grafts in all transplant groups at 6 weeks (Figure 7.1) and 12 weeks (Figure 7.2) 
post-transplantation. Grafted tissue can be identified by increased density in Nissl 
staining in the right striatum. The QA lesion resulted in enlargement of the right 
ventricle caused by cell death in the lesioned striatum. Higher power images of Nissl 
staining further demonstrated the small grafts and revealed the notable presence of 
dead cells within the graft areas (Figure 7.3). Graft volume was estimated using graft 
area as determined by Nissl staining (Figure 7.4), but there was no significant 
difference between groups at 6 weeks (F4,2 o = 0.68, p = n.s.) or 12 weeks (F4)i9 = 1.79, 
p = n.s.). There were also no significant differences between the two survival time 
points for each group; day 16 NEBs untreated (t7 = 0.12, p = n.s.); day 16 NEBs 
purmorphamine treated (t7 = 0.71, p = n.s.); E14 mouse LGE (t7 = 1.08, p = n.s.); E14 
mouse MGE (t7 = 0.18, p = n.s.) and E14 mouse WGE (t6 = 0.57, p = n.s.).
Interestingly, however, combining the transplant groups to make two groups 
(day 16 NEBs versus E14 mouse) for analysis of graft volume revealed a significant 
difference, with E14 mouse derived grafts (1.00 ± 0.15mm3) generating significantly 
bigger grafts than day 16 NEB derived grafts (0.52 ± 0.08mm3) (t3 9  = 2.41, p<0.05) 
(Figure 7.5).
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Anterior Posterior
Figure 7.1. Coronal sections of Nissl staining, using cresyl violet, at 6 weeks post­
transplantation of transplant groups: Day 16 untreated NEBs (A), Day 16 purmorphamine 
treated NEBs (B), E14 mouse LGE (C), E14 mouse MGE (D), E14 mouse WGE (E) and QA 
lesion only (F), in mouse striatum. Grafted tissue is identified by increased density in staining 
in the right striatum. One representative brain per group is shown in each row, and left to right 
shows anterior to posterior positioning in the brain. Red dotted lines outline graft area. Scale 
bars = 500pm. Abbreviations: purm -  purmorphamine; LGE -  lateral ganglionic eminence; 
MGE -  medial ganglionic eminence; WGE -  whole ganglionic eminence.
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Figure 7.2. Coronal sections o f Nissl staining, using cresyl violet, at 12 weeks post­
transplantation of transplant groups: Day 16 untreated NEBs (A), Day 16 purmorphamine 
treated NEBs (B), E14 mouse LGE (C), E14 mouse MGE (D) and E14 mouse WGE (E), in 
mouse striatum. Grafted tissue is identified by increased density in staining in the right 
striatum. One representative brain per group is shown in each row, and left to right shows 
anterior to posterior positioning in the brain. Red dotted lines outline graft area. Scale bars = 
500pm. Abbreviations: purm -  purmorphamine; LGE -  lateral ganglionic eminence; MGE -  
medial ganglionic eminence; WGE -  whole ganglionic eminence.
Figure 73  (overleaf). Photomicrographs showing higher power images of Nissl staining at 6 
weeks (A-E) and 12 week (F-J) post-transplantation following transplants of day 16 NEBs or 
E14 mouse tissue, into the QA-lesioned mouse striatum. There was a notable presence of 
dead cells within the grafts (seen as brown cells). Scale bars = 200pm. Abbreviations: purm -  
purmorphamine; LGE -  lateral ganglionic eminence; MGE -  medial ganglionic eminence; 
WGE -  whole ganglionic eminence.
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Figure 7.4. Graft volumes were estimated using areas determined with Nissl staining. Each 
bar on the graph represents a mean o f 4 different animals and error bars represent SEM. 
Abbreviations: purm -  purmorphamine; LGE -  lateral ganglionic eminence; MGE -  medial 
ganglionic eminence; WGE -  whole ganglionic eminence.
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Figure 7.5. Estimation o f graft volumes o f combined transplant groups. Day 16 NEBs 
includes day 16 NEBs untreated and day 16 NEBs purmorphamine treated grafts at 6 and 12 
weeks survival (n = 16); E14 mouse includes LGE, MGE and WGE grafts at 6 and 12 weeks 
survival (n = 23). Bars on the graph represent mean graft volumes for the combined groups 
and error bars represent SEM. (*p<0.05).
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Neuronal analysis o f grafts
The day 16 NEB donor cells were derived from the FoxglZ mouse ES cell 
line and therefore contained the LacZ reporter gene, which would enable post­
transplantation identification of Foxgl positive cells (as in Chapter 4). However, in 
this instance, neither the antibody against p-galactosidase nor the X-gal histochemical 
reaction resulted in detection of any positive cells in the NEB-derived grafts. All 
analysis was therefore carried out using Nissl staining to mark the graft area, and 
without being able to positively identify cells as graft or host derived, counts represent 
cell numbers present within this area.
Grafts were analysed for expression of the neuronal marker NeuN (Figure 7.6; 
A-F and Figure 7.7). NeuN positive cells were seen within the graft areas of those 
grafts derived from day 16 NEBs and E14 mouse striatum (Figure 7.6; A-F). There 
was no significant difference in NeuN expression within grafts between transplant 
groups at 6 weeks (F4>2 o = 1-24, p = n.s.) or 12 weeks (F4,2 o = 0.47, p = n.s.) post­
transplantation.
Grafts were further analysed for striatal markers DARPP-32, FoxPl, 
parvalbumin and calbindin (Figure 7.6 and 7.7). DARPP-32 positive neurons were 
rarely seen within the graft areas of day 16 NEB-derived grafts, with immuno-positive 
cells detected at the graft periphery (Figure 7.6; G-L). E14 mouse striatum-derived 
grafts exhibited more frequent DARPP-32 positive neurons within the grafted area 
than the day 16 NEB-derived grafts, and there were almost no DARPP-32 positive 
cells detected in the lesion area of the QA-lesion only brains. Expression of DARPP- 
32 was not significantly different between transplant groups at 6 weeks post­
transplantation (F 4i2o = 0.21, p = n.s.), but there was a significant difference between 
transplant groups at 12 weeks post-transplantation (F4>i9 = 4.05, p<0.05) (Figure 7.8; 
A). Post-hoc comparisons revealed a significant difference between grafts from day 
16 untreated NEBs and grafts from E14 mouse WGE.
FoxPl expression was detected in grafts derived from both day 16 NEBs and 
E14 mouse striatum (Figure 7.6; M-R). FoxPl immuno-positive cells were 
occasionally seen within the lesion only site, and the presence of large numbers of 
FoxPl positive cells clearly marked the boundary of the QA lesion. Expression of 
FoxPl was not significantly different between transplant groups at 6 weeks (F4;2o = 
0.17, p = n.s.) or 12 weeks (F4>i9 = 0.54, p = n.s.) post-transplantation (Figure 7.8; B).
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Parvalbumin positive cells were detected within the grafted area of all 
transplant groups, and were occasionally seen within the lesion area of the QA lesion 
only brains (Figure 7.6; S-X). Expression of parvalbumin was not significantly 
different between transplant groups at 6 weeks (F4,20 = 0.08, p = n.s.) or 12 weeks 
(F4,i9 = 0.80, p = n.s.) post-transplantation (Figure 7.8; C); and the same was true for 
calbindin expression; 6 weeks (F4)2o = 0.21, p = n.s.) and 12 weeks (F4ji9 = 0.33, p = 
n.s.) (Figure 7.8; D).
Since the graft sizes were so small AChE staining failed to show any patch- 
matrix structure and did not demonstrate any differences between transplant groups 
(Figure 7.10).
When transplant groups were combined (day 16 NEBs versus E14 mouse), 
there was no significant difference in expression of NeuN positive cells, due to high 
standard deviation within the day 16 NEB graft group (t34 = 0.90, p = n.s.) (Figure 
7.10). There was also no significant difference in expression of FoxPl (t3 7  = 0.51, p = 
n.s.), parvalbumin (t3g = 0.53, p = n.s.) and calbindin (t3 7  = 0.67, p = n.s.) between the 
two groups when data were combined (Figure 7.10). DARPP-32 expression was 
significantly different between the two groups, with more DARPP-32 present in E14 
mouse grafts than Day 16 NEB graft (t3 7  = 2.96, p<0.05).
A summary of graft volumes and cell numbers of the various phenotypes 
found within graft areas is shown in Appendix 8.
Figure 7.6. (overleaf)* Photomicrographs showing NeuN (A-F), DARPP-32 (G-L), FoxPl 
(M-R) and parvalbumin (S-X) staining (grey), double-labelled with cresyl violet (purple). Red 
arrows indicate cells positive for the marker o f interest. Scale bars = 100pm for lower power 
images and 50pm for higher power images.
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Figure 7.7. NeuN expression within graft areas. Each bar on the graph represents a mean of 4 
different animals and error bars represent SEM. Abbreviations: purm -  purmorphamine; LGE 
-  lateral ganglionic eminence; MGE -  medial ganglionic eminence; WGE -  whole ganglionic 
eminence.
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Figure 7.8. Expression of DARPP-32 (A), FoxPl (B), parvalbumin (C) and calbindin (D) 
within graft areas. Each bar on the graph represents a mean of 4 different animals and error 
bars represent SEM. (*p<0.05). Abbreviations: purm — purmorphamine; LGE — lateral 
ganglionic eminence; MGE — medial ganglionic eminence; WGE — whole ganglionic 
eminence.
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Estimate of cells within graft areas of combined 
transplant groups
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Figure 7.9. Estimation of cell numbers o f markers o f interest within graft areas, of combined 
transplant groups. Day 16 NEBs includes day 16 NEBs untreated and day 16 NEBs 
purmorphamine treated grafts at 6 and 12 weeks survival (n = 16); E14 mouse includes LGE, 
MGE and WGE grafts at 6 and 12 weeks survival (n = 23). Bars on the graph represent mean 
graft volumes for the combined groups and error bars represent SEM. (*p<0.05).
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Figure 7.10. Photomicrographs of AChE staining in the transplant groups (A and B) and the 
QA lesion only brain (C). Scale bars = 200pm.
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Graft volume
The results presented here reveal the presence of very small grafts within the 
QA lesioned striatum of all transplant groups at both 6 and 12 weeks post­
transplantation. Analysis of graft volumes between all transplant groups at both 
survival time points revealed no significant differences. Interestingly, however, 
combining the transplant groups to make two groups (day 16 NEBs versus E14 
mouse) for analysis of graft volume revealed a significant difference, with E14 
mouse-derived grafts generating significantly bigger grafts than day 16 NEB-derived 
grafts. It is, however, encouraging to note the absence of any teratoma formation in 
the day 16 NEB-derived grafts. This supports previous findings reported in Chapter 4 
where we demonstrated no teratoma formation following transplantation of day 16 
NEBs into the rat QA lesioned striatum.
Dihne et al (2006) reported graft volumes of up to 26mm3 in grafts derived 
from early stage neural precursors, with high expression of nestin and BrdU, that 
generated tumours. Early stage precursor grafts that did not generate tumours 
exhibited volumes of 2.2 ± 0.3mm3 and grafts derived from late stage precursors 
exhibited volumes of 1.6 ± 0.3mm3 (Dihne et al., 2006). Striatal grafts derived from 
E14 mouse WGE generated volumes of 0.80 ± 0.09mm3 when cells were transplanted 
as primary tissue, and 0.88 ± 0.87mm3 when cells were expanded in culture for 10 
days prior to transplantation (Kelly et al., 2007). The graft volumes that we report 
here in all transplant groups are comparable with those reported in these studies and 
overall suggest a potential caveat regarding graft survival and development of mouse- 
to-mouse transplantation. Thus these small graft volumes are not necessarily an 
indicator of failed grafts, since the ‘gold standard’ of primary tissue has produced 
equally small grafts.
Immuno-suppression was not employed in our study because of the 
assumption that it is not required in allograft studies. The FoxglZ mouse ES cell line 
used in our study was derived using mice of the C57B16/J (Black6) background strain. 
To bypass potential graft rejection issues due to strain differences, we used C57B16/J
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mice as our transplant hosts and the E14 striatal tissue was taken from embryos of 
C57B16/J time-mated mice.
One study which appears to contradict this problem of small-volume mouse- 
to-mouse grafts looked at transplantation of E l3-14 mouse LGE into the striatum of 
the transgenic HD mouse model R6/2 (Dunnett et al., 1998). Photomicrographs 
representing Nissl staining of selected grafts, demonstrated the presence of large 
grafts in both the wild-type control striatum and the transgenic striatum following 6 
weeks survival post-transplantation. However, no graft volumes were reported in this 
study, which would indicate whether the grafts presented were representative of the 
whole cohort. The small, pencil-like grafts reported in this chapter are not unique to 
this study and have been demonstrated by other colleagues using the mouse-to-mouse 
system within our group, indicating a major limitation for further studies using this 
paradigm.
Identification o f donor cells post-transplantation
The FoxglZ mouse ES cell line used in this study has the LacZ reporter gene 
incorporated so that it is under the control of the Foxgl promoter and therefore when 
cells express Foxgl, expression of LacZ is switched on. LacZ can be detected using 
antibodies against p-galactosidase, or the histochemical X-gal assay. Following the 
demonstration of this as a marker of cells post-transplantation in Chapter 4, the aim 
was to apply this strategy here and again identify the Foxgl-expressing cells and 
analyse them for co-expression of markers of interest. However, in this instance 
neither method proved successful, and no positive cells could be identified in the day 
16 NEB-derived grafts. One possibility is that there are no Foxgl-expressing cells in 
the grafts which could be due to poor graft survival and development, as indicated by 
the Nissl staining. Another possible explanation is that Foxgl might have been 
switched off, as cells have developed beyond the stage at which they would express 
Foxgl. However, in Chapter 4 Foxgl was widely expressed throughout the graft areas 
at 6 weeks post-transplantation and expression was demonstrated following 
differentiation of cells both in vitro and in vivo (see Chapter 4).
Dihne et al (2006) used a transgenic mouse ES cell line that expressed 
enhanced green fluorescent protein (eGFP) under the control of the p-actin promoter, 
which yields ubiquitous expression of GFP, and were able to detect GFP-expressing 
cells at 16 weeks post-transplantation. The use of the GFP transgene reporter for post­
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transplantation analysis of primary mouse striatal grafts has demonstrated down- 
regulation of the GFP between 2 and 4 weeks post-transplantation (Eriksson et al., 
2003), with further down-regulation observed up to 12 weeks (Kelly et al., 2007).
Visualisation of human neural progenitor cells and human ES cell-derived 
neural precursors post-transplantation has been demonstrated using pre-labelling 
incubation with the DNA-specific fluorochrome bisbenzimide (Hoechst) 
(Aleksandrova et al., 2001; Song et al., 2007). However, in both of these reports only 
short-term survival post-transplantation was assessed (up to 3 weeks) and therefore 
more long-term analyses are required to determine if this is a viable option for long­
term visualisation of cells post-transplantation. Prior to transplantation cells can be 
incubated with viral vectors, such as the LacZ virus, which will label a proportion of 
the cells and these can later be visualised using antibodies against p-galactosidase. 
This has previously been demonstrated for both mouse and human foetal precursor 
cells (Kelly et al., 2007).
Neuronal analysis o f grafts
As a result of not being able to positively identify any graft-derived cells, all 
analysis was carried out using the Nissl stain to mark the area of the graft and cell 
counts are estimated as cell numbers present within graft area. There was no 
significant difference in NeuN positive cells between the transplant groups and even 
when transplant groups were combined (day 16 NEBs versus E14 mouse) there was 
no significant difference (Figure 7.10). There was also no significant difference in 
expression of FoxPl, parvalbumin and calbindin between all transplant groups and 
when data were combined (Figure 7.10). The high degree of deviation of the cell 
numbers of the various phenotypes within the transplant groups, and the small 
numbers of animals within each group, reduce the likelihood of a statistically 
significant outcome.
DARRP-32 expression was not significantly different at 6 weeks post­
transplantation between any of the transplant groups. However at 12 weeks post­
transplantation, there were significantly more DARPP-32 positive neurons within the 
graft area of E14 mouse WGE-derived grafts than day 16 untreated NEB-derived 
grafts. To date DARPP-32 expression has not been reported in mouse ES cell-derived 
neural precursors following transplantation, although graft-derived neurons 
expressing P-III-tubulin, neurofilament and GAD65/67 have been detected at 16
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weeks post-transplantation (Dihne et al., 2006) and mouse ES cell-derived neural 
precursors transplanted into the rat QA lesioned striatum generated neurons 
expressing GABA and AChE following 6 weeks survival in vivo (Dinsmore et al., 
1996). The demonstration of no significant difference in neuronal yield between all 
transplant groups is a somewhat remarkable and encouraging result for the potential 
of ES cells in cell-replacement therapies. Although we cannot positively distinguish 
between graft and host-derived cells, it is possible that at least a proportion of the 
DARPP-32 positive neurons observed within the graft area are graft-derived, or host- 
derived but as a result of the grafted cells, since there are very few DARPP-32 
positive neurons present in the lesion only striatum.
Transplantation studies looking at developing mouse primary striatum grafted 
into the adult rat QA-lesioned striatum show DARPP-32 expression at 2 weeks post­
transplantation (Olsson et al., 1995). Olsson et al (1995) looked at grafts derived from 
E14 mouse MGE versus E14 mouse LGE, and at 2 weeks post-transplantation there 
was no significant difference in graft volume, but whereas in the MGE-derived grafts 
only 5% DARPP-32 positive cells were observed, in the LGE-derived grafts this 
increased to about 50% of the cross-sectional area.
Striatal tissue grafts are made up of two distinct regions or zones. The P-zones 
comprise DARPP-32 and AChE positive neurons and these areas ‘intermingle’ with 
regions called NP-zones that don’t stain for striatal markers (Graybiel et al., 1989). In 
WGE grafts, P-zones are usually about one third of the total graft, whereas in LGE- 
alone grafts, P-zones can go up to 80-90% of graft (Pakzaban et al., 1993). LGE 
allografts of rat tissue at two to three months post-transplantation comprise AChE- 
positive regions, where DARPP-32 positive cells are also detected, interspersed with 
few AChE-poor regions (Deacon et al., 1994). Regarding behavioural effects of 
striatal grafts, there is correlation between the proportion of ‘striatal-like’ cells within 
grafts and the extent of recovery observed in paw-reaching tasks (Nakao et al., 1996).
In our study, transplantation of E14 mouse LGE, MGE and WGE into the QA- 
lesioned mouse striatum, did not result in a significant difference in DARPP-32 
expression between any of the striatal graft-derived regions. Also AChE staining 
shown in our study did not reveal any clear differences between transplant groups as 
was expected from the reports discussed previously.
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Conclusions
This chapter was an exploratory study which aimed to compare day 16 NEB- 
derived grafts, with E14 mouse striatum-derived grafts over two survival time points. 
The proportion of neurons in day 16 NEB-derived grafts was comparable to E14 
striatum-derived grafts. At 12 weeks post-transplantation there were significantly 
more DARPP-32 positive neurons in WGE-derived grafts than untreated day 16 NEB- 
derived grafts. However, DARPP-32 expression was not significantly different 
between purmorphamine-treated day 16 NEB-derived grafts and striatal-derived 
grafts, indicating the potential for ES cell-derived NEBs in cell-replacement 
strategies.
However, not only were the graft sizes small, but there was also no detection 
of the Foxgl-LacZ positive cells post-transplantation. Full confidence that cells were 
derived from the day 16 NEB grafts was therefore not possible, and cell counts could 
only be represented as number of cells present in the graft area, as determined by 
Nissl staining.
Work presented in this chapter highlights a potential caveat of the mouse-to- 
mouse allograft paradigm and suggests the need for a systematic assessment of the 
mouse striatum as a viable host for transplantation. In addition, reliable methods for 
identification of all donor-derived cells in order to distinguish them from host-derived 
cells must be applied in order to determine what is happening to donor cells post­
transplantation.
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Chapter 8
General Discussion
Neural transplantation in HD aims to replace the neurons that are lost, 
predominantly the MSNs o f  the striatum; reconstruct the affected circuitry; alleviate 
the associated symptoms; and possibly slow the disease progression. Primary foetal 
striatal tissue is currently the \standard’ cell source for transplantation and is the 
origin o f pre-programmed MSN precursors. However, tissue from this source is 
limited and raises ethical and logistical constraints suggesting the need for an 
alternative supply o f donor cells. The requirement o f any alternative donor cell source 
is to have the capability to generate the specific mature MSN phenotype, which could 
be utilised in cell-replacement strategies and fo r screening potential drug candidates.
This thesis looked at mouse ES cells as a model system for neural induction 
and directed differentiation o f  neurally induced ES cells to enrich for a population o f  
ventral telencephalon-like cells which could subsequently, under optimal terminal 
differentiation conditions, generate striatal projection neurons, both in vitro and in 
vivo.
8.1 In vitro neural induction o f  mouse ES cells
Mouse ES cells offer a potential alternative source of donor cells for 
transplantation strategies in neurodegenerative diseases and have been shown to 
generate neural precursors in vitro when cultured under defined serum-free 
conditions, with the formation of NEBs that express markers of the neuroectoderm 
including Soxl and Pax6 (Ying et al., 2003; Bouhon et al., 2005; Watanabe et al., 
2005). Not only are mouse ES cells a robust model for assessing development, but 
they can also be easily manipulated allowing incorporation of reporter genes which 
can readily permit visualisation of markers o f interest. Work in this thesis utilised a 
mouse ES cell line, FoxglZ, where the reporter gene LacZ was integrated into the 
genome replacing most of the Foxgl coding sequence so that expression of P- 
galactosidase is under the control of the Foxgl promoter (Xuan et al., 1995). Foxgl is
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the earliest known marker of the telencephalon (Tao and Lai, 1992) and the focus of 
Chapter 3 was to generate optimal numbers of Foxgl-expressing cells in the neural 
induction culture system, which would then be taken forward in subsequent chapters 
for further directed differentiation and terminal neuronal differentiation in vitro and in 
vivo. In Chapter 3, it was demonstrated that addition of FGF2 to neural induction 
cultures of mouse ES cells at day 4 results in an increase in Foxgl positive cells when 
analysed at day 8, which was consistent with data from a previous study (Bouhon et 
al., 2006). Addition of the Wnt inhibitor DKK-1 did not result in an increase in the 
Foxgl population which was surprising when compared with other reports (Aubert et 
al., 2002; Watanabe et al., 2005; ten Berge et al., 2008). However, interpretation of 
the results reported in Chapter 3 indicated some fundamental discrepancies between 
studies including culture systems and cell lines utilised, as well as composition of 
defined medium. As a result of the heterogeneity of the neural induction protocols 
applied, drawing comparisons between the findings in each study is not always 
straight forward. Differences in protocols can result in different outputs of expression. 
The presence of different components endogenously in culture medium alters the 
conditions, which might have a knock-on effect on expression of genes, since specific 
conditions might be required for induction of certain markers. Ideally, in order to 
achieve a more reliable and reproducible method for the neural induction of ES cells, 
standardisation of protocols is required, which is not a realistic option at this stage 
since protocols are still being developed. It is therefore important to approach 
similarities and differences with caution and with the mind-set that reported findings 
are restricted to each individual culture system. A comparison of different protocols in 
carefully controlled conditions would give a reliable indication and understanding of 
the differences between the various groups.
A recent comparison of gene expression profiles in three different mouse ES 
cell lines, revealed that undifferentiated ES cells in their pluripotent state, derived 
from different mouse strains (i.e. different genetic backgrounds) and carrying 
different genetic modifications exhibit almost invariant patterns of gene expression 
(Mansergh et al., 2009). However, it is possible that even slight deviations in gene 
expression early on in development might be responsible for more significant 
differences that occur later in development. Later analysis of gene expression using an 
EB-based method of ES cell differentiation, demonstrated a high degree of variability 
between EBs, even when the starting number of cells was controlled using the
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‘hanging drop’ protocol, and even in those EBs generated within the same culture 
(Mansergh et al., 2009). Application of a similar strategy to analyse NEB 
development in defined suspension conditions would enable the gain of more 
fundamental understanding of this culture system.
Another potential cause of the differences in gene expression observed 
between neural induction cultures derived from mouse ES cells, both within different 
studies and within experiments, is the stage of ES cell growth at which cells are 
transferred from ES cell culture conditions to neural induction conditions. In general, 
for maintenance of mouse ES cells, cells are cultured on gelatin and initially plated as 
a crude single cell suspension. Then, as cells divide and proliferate, they form 
colonies of daughter cells that gradually increase in size over time in culture, and are 
typically passaged and replated every two to three days, depending on the cell line. 
Observations made while culturing mouse ES cells indicate that relatively early 
passage, rather than later in this maintenance period, helps to maintain ‘neat’ ES cell 
colonies with few undifferentiated ES cells. It would be useful to determine if 
initiation of neural induction (or indeed induction of any other lineage) at different 
phases of ES cell growth alters subsequent differentiation of cells towards that 
lineage. This information might prove valuable in the generation of more reproducible 
protocols for lineage induction.
8.2 Transplantation o f  mouse ES cells
In mouse ES cell cultures with defined neural induction conditions, neural 
precursor markers, such as nestin, are initially shown to up-regulate over time through 
to day 8, and then decrease with continued culture (Bouhon et al., 2005), while the ES 
cell marker, Oct-3/4, down-regulates over time in culture (Bouhon et al., 2005; 
Bouhon et al., 2006). Although this was also demonstrated in Chapter 4, Oct-3/4 was 
seen to persist beyond day 8 with very low expression present even at day 12, and it 
was switched off by day 16. The persistence of undifferentiated ES cells in the cell 
population presents problems when considering cells for transplantation and one 
stigma attached to transplantation of ES cells is their potential for uncontrolled 
proliferation. Alongside encouraging observations of graft-derived differentiation to 
neurons and glia (Benninger et al., 2000) and region-specific neural markers (Wemig 
et al., 2004), development of non-neural tissue clusters and teratomas has been
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reported following transplantation of EBs and NEBs derived from mouse ES cells 
(Brastle et al., 1997).
The work presented in Chapter 4 demonstrates the problem of transplanting 
ES cells prematurely, when a proportion of cells still express ES-like and pluripotent 
markers. Transplants of early-stage NEBs (day 8) generated teratoma-like masses, 
whereas later-stage NEBs (day 16) generated large grafts that expressed heterogenous 
cell types including neurons, but no teratomas.
One way to overcome this might be longer-term culture prior to terminal 
differentiation and transplantation. However, although this might result in further 
down-regulation (abolishment) of ES cells, other important markers of interest might 
also down-regulate over time, since we show that the neural precursor marker nestin 
down-regulates between day 8 and day 16, and also beyond day 16, at day 24, 
expression of markers of the ventral telencephalon were decreased to levels below 
those seen at day 8 (data not shown).
Other strategies involve purification of cell populations using techniques such 
as FACS and MACS, where cells can be sorted according to expression markers of 
interest, either by labelling with cell surface antibodies or integrating reporter genes 
tagged to the specific cells of interest. An advantage of integrating a reporter gene into 
a cell line, as well as aiding visualisation of a specific gene of interest, enables 
purification of a population of cells that expresses the gene of interest and is a 
homogeneous population. The cleavage product of X-gal is non-fluorescent and toxic 
to viable cells, which deems it unsuitable for FACS analysis. For detection of p- 
galactosidase activity in living cells, the p-galactosidase substrate, 5- 
chloromethylfluorescein di-p-D-galactopyranoside (CMFDG) {Molecular Probes, 
Invitrogen) that yields a green fluorescent product, has been developed. Using an 
‘Influx pinocytic cell-loading’ reagent, CMFDG can be introduced into living cells 
without significantly altering normal cell function and will therefore allow FACS 
analysis of FoxglZ NEBs, using unstained cells to set the background and auto­
fluorescence controls, which should enable a pure population of Foxgl cells to be 
obtained. Unfortunately though, when we attempted to apply these techniques to 
NEBs, recovery of cells following enzymatic and mechanical dissociation, CMFDG 
incubation and hypotonic shock, followed by FACS collection was not sufficient for 
continued analysis; single cells did not re-form spheres or aggregates following FACS 
and viability dramatically decreased so that cells were no longer useable.
i
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Some studies have demonstrated success with FACS purification of cell 
populations both with mouse and human ES cells, using genetically labelled ES cell 
lines and cell surface antigens (Pruszak et al., 2007; Hedlund et al., 2008). However, 
both these studies utilised ‘refined’ and ‘gentle’ FACS conditions compared with 
‘standard’ FACS conditions, and for further in vitro analysis of cells post-FACS 
purification, co-culture with primary astrocytes was essential for their survival 
(Donaldson et al., 2005; Hedlund et al., 2008).
Another approach is to treat cultures in order to eliminate the proliferating 
cells. Mitomycin C is a chemotherapeutic agent that arrests cell proliferation and has 
previously been used to treat neurally induced human ES cells prior to transplantation 
(Sanchez-Pemaute et al., 2005). Although this could prove beneficial for prevention 
of tumours, it would not however prevent the heterogeneity of lineages that exists in 
cultures.
8.3 Directed differentiation
During neural development, induction and specification of specific cell types 
within the neural tube requires the presence of certain factors at precise levels in order 
to generate the full complement of cell types. The practicality of mimicking this in 
vitro is not straight forward, since concentrations and length of exposure time need to 
be determined. Refinement of factors involved and the windows of exposure for their 
optimal addition will require systematic studies with sequential application to 
determine the specific effects and requirements of each factor.
In Chapter 5, we attempted to direct the differentiation of NEBs using the 
SHH agonist purmorphamine and then the SHH antagonist cyclopamine, since SHH is 
important in ventralising the telencephalon. The gradient effect of SHH in the 
developing neural tube suggests that different concentrations of SHH will give rise to 
expression of various dorso-ventral markers at different levels. Following addition of 
these two factors to neurally induced mouse ES cells we demonstrated that NEBs are 
responsive to these factors, but did not observe a distinct pattern of dorso-ventral 
expression. Dessaud et al, (2007) demonstrated that cells in the neural tube can 
become desensitised to SHH following long periods of exposure, and this affects the 
way in which they respond. The desensitisation results in a precise duration and 
concentration of the SHH signal, which is responsible for the subsequent levels of
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gene expression (Dessaud et al., 2007). The challenge in vitro will be to analyse 
different exposure times of various SHH concentrations in the culture system, and 
determine the optimum of each in order to generate increased expression of ventral 
telencephalic precursors.
Generation of reporter cell lines with reporter genes tagged to ventral 
telencephalic markers should make for an efficient method of visualising cells of 
interest. In the lab we have initiated the generation of such cell lines, in particular, the 
Dlxl/2 gene tagged to the GFP reporter. This cell line will allow for fluorescent 
analysis of D/x-expressing cells, which enable simple demonstration of the effects of 
factors on the Dlx population.
It is important to note that even if we generate a population of ventral 
telencephalic-like precursors, this is not the overall solution, since differentiation of 
primary striatal precursors both in vitro and in vivo, does not generate vast quantities 
of DARPP-32 expressing MSNs, and will likely require some further signalling input 
to increase this.
8.4 Is generation o f  MSNs from  ES cells achievable?
In Chapter 6 the in vitro neuronal differentiation of mouse ES cells was 
addressed along with differentiation of striatal-derived neurons. The origin of MSNs, 
the LGE, used as a standard for DARPP-32 differentiation, did not generate vast 
numbers of DARPP-32 positive neurons. One explanation for this might be that MSN 
precursors are particularly susceptible to cell death following dissection and 
dissociation procedures. Another possibility is that, although the precursors are 
already specified to become MSNs, they still require specific signals to enable 
differentiation into the mature neuronal phenotype. Further work to identify and apply 
such signalling factors to striatal differentiation cultures is needed with subsequent 
application to neuronal differentiation cultures of ES cells to determine if, under the 
right conditions, these cells have the capacity to generate DARPP-32 positive 
neurons.
Since we demonstrated an increase in the proportion of DARPP-32 positive 
neurons following addition of BDNF to LGE-derived neurons, cells could benefit 
from transplantation with the addition of BDNF to the cell suspension. Delivery of 
neurotrophic factors, such as GDNF, prior to transplantation in models of PD, has
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proved beneficial both by increasing the yield of dopaminergic neurons and protecting 
the brain from lesion-induced impairments (Torres et al., 2005; Dowd et al., 2005).
If DARPP-32 can be achieved in vitro, one strategy might be to pre­
differentiate NEBs in neuronal differentiation medium (with inclusion of appropriate 
signalling factors) prior to transplantation. The degree of pre-differentiation would 
require optimisation and manipulation of cells might prove challenging, since 
differentiated neurons exhibiting projections, might be more susceptible to damage.
Presently, DARPP-32 is the standard mature MSN marker employed. To date 
limited expression of DARPP-32 from ES cells has been reported, and even then only 
from human ES cell differentiation (Aubry et al., 2008; Nasonkin et al., 2009). The 
‘Aubry’ DARPP-32 positive neurons were derived from cells subjected to a complex 
sequential addition of factors that were then transplanted into the rat QA lesioned 
striatum and allowed to differentiate for 4-6 weeks or 13-21 weeks (Aubry et al., 
2008). In contrast, the ‘Nasonkin’ DARPP-32 positive neurons were derived from 
cells that were subjected to limited factors in culture prior to transplantation and were 
allowed to differentiate in vivo in the unlesioned rat striatum for up to 6 months 
(Nasonkin et al., 2009). On the one hand, Aubry et al suggest the need for a complex 
‘cocktail* of factors with specific exposure times in culture followed by a relatively 
short in vivo period, whilst, conversely, Nasonkin et al suggest that a simple culture 
system but long term differentiation in vivo is required for DARPP-32 generation. A 
combination of the two protocols, with more defined directed differentiation in vitro 
followed by long term differentiation in vivo would be an obvious option, although 
with the longer-term graft survival in the ‘Aubry’ protocol, massive graft overgrowth 
was reported, along with the DARPP-32 positive neurons, suggesting that the in vitro 
differentiation phase needs to be refined.
Analysis of differentiation of DARPP-32, and other striatal markers, post­
transplantation is necessary to ascertain if the signals from the CNS environment are 
adequate to generate markers of the desired phenotype. The presence of DARPP-32 in 
graft-derived cells is encouraging but it does not necessarily mean these neurons will 
be functional and produce a beneficial behavioural effect. It will be important to 
determine if neurons within the graft are functional, using electrophysiology, and to 
assess behavioural recovery of graft recipients using a selection of tests known to be 
sensitive to the QA lesion model.
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8.5 Mouse-to-mouse allografts
In this thesis mouse ES cells were utilised, and in Chapter 7 were applied in 
the mouse-to-mouse allograft paradigm in the QA lesioned striatum model of HD. 
However, in this study we indicated a potential problem with this system, since only 
small, pencil-like grafts were identified exhibiting poor development. This finding 
was not remarkable, and it was later recognised as a recurring problem within our 
group and others. However, it has not been seen in the rat-to-rat allograft system. 
Addressing this issue will require a thorough assessment of different combinations of 
donor and host tissue, taking into account the developing brain region for dissection 
and donor cells, the species and strain of both donor and host, the state of the host 
brain (lesioned or non-lesioned), and the administration of immunosuppression.
With the recent emergence of rat ES cell lines, there is the potential for the 
allograft paradigm to be assessed in the rat system. However, although expression of 
the immature neuronal marker P-III-tubulin has been demonstrated following 
differentiation of rat ES cells (Li et al., 2008; Buehr et al., 2008), to date there have 
been no reports demonstrating specific neural induction of rat ES cells and subsequent 
directed differentiation. It is possible that induction and differentiation conditions 
required for rat ES cells will differ from those required for mouse and human ES 
cells.
8.6 Where next?
The aims of this thesis were to attempt to generate DARPP-32 positive 
neurons from mouse ES cells. However, this was not achieved here, either in vitro or 
in vivo. Firstly, re-addressing the initial neural induction stage of mouse ES cell 
cultures is necessary to attempt to generate a homogeneous population of cells of the 
neural linage. The subsequent directed differentiation protocol will then need to be 
refined, with systematic studies looking at the effects on gene expression of exposure 
times of the factors added. Effects of SHH in this study were only analysed following 
chronic administration, and it will be important to dissect the response of NEBs at 
different SHH concentrations and different exposure times, to try to mimic the actions 
of SHH in the developing neural tube and generate a range of precursor cell types.
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Since foetal striatal tissue is currently the standard used for transplantation in 
the HD paradigm and this has not been shown to generate vast quantities of DARPP- 
32 in vitro or in vivo, it is clear that optimisation of the culture of this source of cells 
is required. In this study, foetal striatal tissue was used for differentiation only. 
Expansion of these cells prior to terminal differentiation is an option that has been 
investigated in attempts to increase cell numbers and therefore reduce the amount of 
starting material required. However, over time in culture, although overall cell 
number is increased, the neuronal yield is decreased (Kelly et al., 2003). Addition of 
factors, such as SHH, might enhance the induction and survival of striatal neurons and 
therefore increase the yield of DARPP-32 positive neurons following differentiation. 
If DARPP-32 yield can be optimised from foetal striatal cells by manipulating culture 
conditions for expansion and differentiation, these conditions can be transferred to ES 
cells for differentiation.
There are limited reports on the transplantation of ES cells into models of HD 
and before these cells can be seriously considered for clinical application they need to 
be assessed in terms of the functional benefit they can offer within the HD brain. It 
will be important to determine the degree of benefit this cell source can provide with 
respect to both motor and cognitive tasks in animal models of HD.
Concluding remarks
This thesis highlights some important issues relating to neural induction of ES 
cells and their capacity to be directed towards more specific precursor types. 
Achieving a 100% neural population is an absolute requirement before these cells can 
be seriously considered for clinical application for cell-replacement in HD.
Generation of ventral telencephalic-like precursors with more stringent 
directed differentiation regimes will take us a step closer, but assessment of neuronal 
function using electrophysiological techniques, and graft function following 
transplantation using an array of behavioural tests will be required in order to further 
this work.
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Appendices
Appendix 1: Reagents and Suppliers
Reagent Supplier Address
Accutase PAA Labs Farnborough, Hampshire, UK
Advanced DMEM/F12 Gibco Paisley, Scotland, UK
B-27 Gibco
BDNF Peprotech New Jersey, USA
B-mercaptoethanol Sigma Gillingham, Dorset, UK
BSA Sigma
Cyclopamine Calbiochem Hull, UK
DKK1 R&D Systems Abingdon, Oxfordshire, UK
DMEM/F12 Gibco
DMSO Sigma
DNAse Sigma
EGF Sigma
FCS Gibco
FGF2 R&D Systems
FuGENE 6 Roche West Sussex, UK
Gelatin Chemicon Chandlers Ford, Southampton, UK
HBSS Gibco
Hoechst Fisher Loughborough, Leicestershire, UK
IMDM Gibco
Insulin Sigma
KSR Gibco
Laminin Sigma
L-Glutamine Gibco
Lipid concentrate Gibco
Lipofectamine Gibco
Non-Essential Amino acids (MEM) Gibco
Opti-MEM Gibco
PBS Gibco
Penicillin Streptomycin Gibco
PLL Sigma
Purmorphamine Calbiochem
RA Sigma
SYBR Green Bioline London, UK
Transferrin Sigma
Trypan blue Sigma
Trypsin Worthington Freehold, New Jersey, USA
Trypsin inhibitor Sigma
Trypsin/EDTA Gibco
a
Appendices
Appendix 2: Recipes
2a) Cell culture
Mouse ES cell culture medium: 
IMDM 
15% KSR 
1% PS
Non-essential amino acids (ImM) 
L-glutamine (2mM) 
(3-mercaptoethanol 
LIF
Neuralising medium (ADF+): 
Advanced DMEM/F-12 
1%PS
L-Glutamine (2mM)
Lipid concentrate 
Insulin 
Transferrin 
P-mercaptoethanol
Mouse ES ceU freezing medium: Neuronal differentiation medium:
10% DMSO DMEM/F-12
Mouse ES cell culture medium 1% PS
2% B-27
1% FCS
Glial expansion medium: Glial differentiation medium:
DMEM/F-12 DMEM/F-12
1%PS 1%PS
10% FCS 10% FCS
L-Glutamine (2mM) L-glutamine (2mM)
EGF (20ng/ml)
COS cell culture medium
DMEM
10% FCS
L-Glutamine (2mM)
1%PS
b
2b) Immunohistochemistry
Appendices
Prewash buffer
18g di-sodium hydrogen phosphate 
9g sodium chloride 
1L distilled water 
pH 7.3
Fixative (4% paraformaldehyde)
40g PFA
1L prewach buffer
Heat with addition of NaOH to dissolve 
pH 7.3
Sucrose
250g sucrose 
1L prewash buffer 
pH 7.3
4X TBS
48g Trizma base 
36g sodium chloride 
1L distilled water 
pH 7.4
TXTBS
0.2% Triton-XlOO in IX TBS 
pH 7.4
TBZ
0.02% sodium azide in IX TBS
X-Gal Assay 
X-Gal solution:
0.5g X-gal
5 ml N,N-Dimethylformamide 
Ferro/Ferri-cyanide solution:
1.050g Ferrocyanide "T «
0.825g Ferricyanide I ^  ,
0.2gM gCl2 f  4 C, dark.
495ml PBS _
Add 1ml X-Gal solution to 49ml Ferro/Ferri- 
cyanide solution.
Fix cells in 1% formalin, 5 minutes.
Wash 3x PBS.
Add X-gal staining solution, leave at 37°C for 
2-4 hours, then transfer to 4°C overnight.
TNS
6g Trizma base 
1L distilled water 
pH 7.4 with HC1
c
Appendix 3: Antibodies for immunohistochemistry and fluorescent immunocytochemistry
PRIMARY, SECONDARY and BLOC]KING SERA
Primary
Antibody
Species Supplier Dilution Normal
Serum
Blocking
dilution
Normal
dilution
Secondary Antibody Dilution Comments
Calbindin Mouse Sigma 1:20,000 Horse 3% 1% Horse anti mouse 1:200 2ary rat adsorbed
DARPP-32 Mouse Cornell 1:10,000 Goat 3% 3% Goat anti-mouse a 594 1:200 Already diluted 1:50,
Univ Horse 3% 1% Horse anti mouse 1:200 needs 1:200 dilution
Doublecortin Guinea pig Abeam 1:500 Goat 3% 1% Goat anti-guinea pig 1:200 Discontinued
FoxPl Rabbit Abeam 1:500 Goat
Goat
3%
3%
3%
1%
Goat anti-rabbit a 488 
Goat anti-rabbit
1:200
1:200
Antigen retrieval required
GABA Rabbit Sigma 1:500 Goat 3% 3% Goat anti-rabbit a 488 1:200 Fix with glutaraldehyde
GFAP Rabbit DAKO 1:2000 Goat
Goat
3%
3%
3%
1%
Goat anti-rabbit a 488 
Goat anti-rabbit
1:200
1:200
Mashl Mouse BD Pharm 1:200 Goat 3% 1% Goat anti-mouse a  594 1:200
Nestin Mouse BD Pharm 1:400 Goat 3% 1% Goat anti-mouse a 594 1:200
NeuN Mouse Chemicon 1:4000 Horse 3% 1% Horse anti mouse 1:200 2ary rat adsorbed
Nkx2.1 Mouse DAKO 1:100 Goat 3% 1% Goat anti-mouse a 594 1:200
Oct-3/4 Mouse Santa Cruz 1:100 Goat 3% 1% Goat anti-mouse a 594 1:200
Otx2 Rabbit Millipore 1:200 Goat 3% 1% Goat anti-rabbit a 488 1:200
Parvalbumin Mouse Sigma 1:4000 Horse 3% 1% Horse anti mouse 1:200 2ary rat adsorbed
Pax6 Mouse DSHB 1:50 Goat 3% 1% Goat anti-mouse a  594 1:200
(3 -galactosidase Mouse Promega 1:1000 Goat
Horse
3%
3%
3%
1%
Goat anti-mouse a 594 
Horse anti mouse
1:200
1:200 2ary rat adsorbed
(3-II1 tubulin Mouse Sigma 1:1000 Goat 3% 1% Goat anti-mouse a 594 1:200
p-III tubulin Rabbit Sigma 1:500 Goat 3% 1% Goat anti-rabbit a  488 1:200
d
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Appendix 4: QPCR prim er sequences
Primer pairs were generated using:
Mouse Genome Informatics (http: //www. informatics. i ax. orgf)
Ensembl (http: //www. ensembl. org/index.htmO
Primer 3 Input (http: //frodo.wi .mit. edu/c gi-bin/primer3/primer3 www. c gri
QPCR primer sequences (designed for melting at 60°C)
Primer Forward Sequence Reverse Sequence
Axin2 CCAT GACGGACAGTAGCGTA CTGCGATGCATCTCTCTCTG
Dlx2 GT CTCCGGT C AAC AACG AG CAGGGCCAGATACTGGGT
Emx2 T CT GGGTC AT CGCTTCC AAG CT AGCCTT AAAAGCT GGG ACG
Gli3 ATTCCCGT AGC AGCT CTT C A GGGT AGGT G A AGCT C AAT GC
Gsx2 T GGG AGGCTCCG AT ACC AG CGGG AC AGGT AC AT ATT GG AAGA
Mashl CTGGG AATGG ACTTTGG AAG TTTTT CT GCCT CCCC ATTT
Ngn2 AACT CC ACGTCCCC AT AC AG GAGGCGC AT AACGATGCTTCT
Nkx2.1 GTCCTCGG AA AG AC AGC AT C GT GCTTT GG ACT CAT CG AC A
Otx2 CCCGGT ACCC AG AC AT CTT CGGC ACTT AGCT CTT CG ATT
Patched 1 T CTT GCTCTT GGTGTT GGT G CCC AGT CCTGT CCT C AAATG
Pax6 GTGGCGACTCCAGAAGTTGT AGAAAGACCCCCTCGGATAA
Shh CCAATT AC AACCCCGACATC AG AG AT GGCC AAGGC ATTT A
p-actin GCTCTTTTCC AGCCTTCCTT CGG AT GT C AACGT C AC ACTT
e
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Appendix 5: Production o f  Leukaemia Inhibitory Factor (LIF)
Leukaemia Inhibitory Factor (LIF) is necessary for the culture of mouse 
embryonic stem (ES) cell lines in order to maintain pluripotency and to prevent 
differentiation of cells. ES cell lines may be maintained in an undifferentiated state by 
addition of serum and LIF to the culture medium (Ishiwata et al., 2001). Removal of 
LIF has been shown to induce ES cell differentiation, as observed by a reduction in 
Oct 4 expression (Faherty et al., 2005). Addition of LIF to ES cell medium has little 
effect on growth rate of ES cells, but it does influence the decision of cells to self- 
renew or differentiate (Zandstra et al., 2000). The aim here was to produce LIF 
suitable for addition to ES cell medium for maintenance and culture of mouse ES cell 
lines.
(i) Preparation o f  LIF plasm id DNA and Transfection
LIF expression vector was kindly donated by Dr Vladimir Buchman. The 
expression vector (Ampicillin resistant) was transformed into TOP 10 competent 
cells, as described in section 2.2.6. The bacterial suspension was inoculated in LB 
media with ampicillin (150pg/ml). A midi prep was performed following instructions 
from the Qiagen Midi prep kit (section 2.2.7). The DNA was stored at -20°C in TE at 
lpg/pl until use.
For transfection of LIF plasmid DNA, COS cells were used and transfection 
reagent FuGENE 6 was used according to instructions in the kit. After 24 hours, the 
transfection mix was discarded and ES cell culture medium without LIF or PS was 
added and incubated at 37°C overnight. After a further 24 hours, the medium was 
collected into a 50 ml falcon tube, stored at 4°C and another volume of ES cell culture 
medium without LIF or penicillin/streptomycin was added and left at 37°C overnight. 
After 24 hours, the medium was collected, pooled with that collected 24 hours earlier, 
‘LIF-conditioned media’ aliquots were stored at -20°C and COS cells were discarded.
(ii)Testing LIF conditioned medium
For testing of LIF conditioned medium, the mouse ES cell line CGR8.8 
(12901a derived) was used. ES cells were plated in ES cell culture medium without 
LIF, onto gelatin-coated 6-well plates (Costar) at various densities. The cell densities
f
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tested were 1000 cells/well, 2000cells/well and 5000cells/well. Various dilutions of 
LIF conditioned media were added (1:2000, 1:1000, 3:2000 and 1:500), and for 
controls, lOng/ml commercial LIF was added to one well and another well was left 
without any LIF.
Medium was changed daily with replacement of the appropriate concentration 
o f ‘LIF conditioned medium’. Each day the cultures were checked microscopically for 
differences in morphology in order to determine the optimum concentration of LIF 
conditioned media required for maintenance of the ES cell cultures.
g
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Appendix 6: Dorso-ventral gene expression relative to WGE
Gene expression analysis of NEBs following 8 and 16 days in ADF+ neural 
induction culture and treated with the SHH agonist purmorphamine or the SHH 
antagonist cyclopamine is shown relative to expression in E14 mouse WGE.
Nlofi.1 expression following purmorphamine addition Dlx1/2 expression following purmorphamine addition
I  1
•P
WGE
t t
1
t t
i □  Day 8 
| □ Day 16
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Figure 1. Expression o f the ventral markers Nkx2.1 (A), D lxl/2  (B), Mashl (C) and Gsx2 (D) 
were analysed using semi-quantitative RT-PCR on cDNAs prepared from ES cell-derived 
NEBs at day 8 and day 16 of neural induction in ADF+ with 20ng/ml FGF2 and different 
concentrations of the SHH agonist purmorphamine present from day 4. Gene expression is 
shown relative to p-actin. The broken line crossing the y-axis at 1 represents relative 
expression in the E 14 mouse WGE. Each bar on the graphs represents a mean of 3 different 
neural induction cultures and error bars represent SEM. Brackets indicate significance 
between the day 8 and day 16 NEBs at a particular concentration. * = significant difference 
from WGE control, t  = significant difference between NEB groups. (*p<0.05, **p<0.01, 
tp<0.05, ttpO .O l).
h
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Nkx2.1 expression following cyclopam ine addition
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Figure 2. Expression o f the ventral markers Nkx2.1 (A), D lxl/2  (B), Mashl (C) and Gsx2 (D) 
were analysed using semi-quantitative RT-PCR on cDNAs prepared from ES cell-derived 
NEBs at day 8 and day 16 o f neural induction in ADF+ with 20ng/ml FGF2 and different 
concentrations o f the SHH antagonist cyclopamine present from day 4. Gene expression is 
shown relative to fi-actin. The broken line crossing the y-axis at 1 represents relative 
expression in the E14 mouse WGE. Each bar on the graphs represents a mean of 3 different 
neural induction cultures and error bars represent SEM. Brackets indicate significance 
between the day 8 and day 16 NEBs at a particular concentration. * = significant difference to 
untreated NEBs at day 8. t  = significant difference to untreated NEBs at day 16. (**p<0.01, 
tp<0.05).
Appendix 7: A summary o f  the neuronal expression in LG E -derived neurons and day 16 NEBs fo llow in g  in vitro neuronal differentiation.
Neuronal differentiation LGE-derived neurons Day 16 NEBs; untreated Day 16 NEBs; purmorphamine
conditions 7 days 14 days 7 days 14 days 7 days 14 days
U-to PLL/laminin; untreated 71.56 ±2.56% 67.06 ±6.40% 30.71 ±4.89% 15.11 ±2.05% 25.43 ± 1.03% 22.30 ± 1.60%vo Cfl
cj 8 PLL/laminin; BDNF 70.15 ±0.41% - 30.58 ± 0.69% 23.13 ±3.39% 27.01 ±3.97% 21.56 ±1.79%
£ +-W 1/5 PLL/laminin; RA 71.17 ±4.05% - - - - -
a  g> 
3  O
3 £• S
PLL/laminin; BDNF & RA 
LGE glia; untreated
70.32 ± 3.02% -
25.08 ± 7.67% 15.18 ±0.31%
- -
1ca. LGE glia; BDNF - - 28.12 ±3.56% 20.03 ±2.24% - -
aN PLL/laminin; untreated 3.74 ±0.11% 13.38 ±2.37% 4.16 ±1.77% 2.26 ±0.54% 3.82 ±0.89% 2.38 ± 0.49%
** aC/5 ^« .5
G
23 PLL/laminin; BDNF 10.93 ±0.88% 11.68 ±2.30% 3.82 ±0.89% 6.42 ±2.76% 5.60 ±1.24% 3.58 ±1.85%<s a
~cl a
<uc
<u PLL/laminin; RA 2.29 ±0.47% - - - - -
t4H< O
O
*Sooa
PLL/laminin; BDNF & RA 
LGE glia; untreated
5.27 ±0.68% 
7.77 ±0.96% 4.42 ±2.82%
- -
<+H 
£  ° cna
PLL/laminin; untreated 39.59 ±3.80% - 16.89 ±0.81% 21.20 ±2.01% 22.55 ±2.14% 22.03 ±1.60%
M \0 O
®  ^ Oa a PLL/laminin; BDNF 35.10 ± 3.15% - 24.10 ±2.91% 15.94 ±3.42% 21.92 ±4.65% 21.56 ±1.79%
PLL/laminin; untreated 9.51 ±3.16% - 2.04 ±0.80% - 3.19 ±0.58% -
D
A
RP
 
-32
 
as
o' %£ PLL/laminin; BDNF 26.36 ±3.23% - 3.14 ±0.65% - 5.67 ±2.29% -
<<! n© U> PLL/laminin; untreated - - 62.75 ± 7.28% 57.42 ±6.73% 60.18 ±6.95% 54.88 ±7.05%co
<
0  8
o 1oa PLL/laminin; BDNF - - 68.52 ±3.82% 67.24 ±4.51% 67.26 ±7.10% 62.53 ± 5.92%
Appendix 8: A summary o f  graft volumes and cell numbers o f  various phenotypes in graft areas fo llow ing  transplantation into the mouse QA- 
lesioned striatum.
Transplant group Survival
Estimate of 
graft volume
Estimate of number of cells of each phenotype within graft area
(weeks) (mm3) NeuN DARPP-32 FoxPl Parvalbumin Calbindin
Day 16; untreated 6 0.49 ±0.19 2193.06 ±1191.22 178.59 ± 102.30 800.64 ±105.21 240.98 ±92.51 64.01 ±44.81
</>CQ
12 0.58 ±0.27 805.61 ±217.30 65.12 ±21.93 1983.90 ±1001.94 524.60 ±303.99 50.08 ± 29.22
W  " 
£
Day 16; purmorphamine 6 0.45 ± 0.09 364.34 ±192.59 171.23 ±45.25 822.85 ± 326.57 322.69 ± 175.93 23.82 ±23.81
12 0.56 ±0.12 1996.60 ± 1082.13 166.93 ± 73.05 623.63 ±170.76 193.47 ±66.84 75.13 ±49.53
<D
3
LGE 6 0.83 ±0.25 451.38 ±158.03 273.13 ±95.17 639.08 ±493.68 252.12 ±105.09 25.08 ±25.08
in
‘+ 3
■4—>
<D
12 1.52 ±0.53 755.50 ±154.32 476.16 ±135.70 1171.25 ±459.05 291.80 ±81.48 114.47 ±46.12
£
&
MGE 6 1.38 ±0.59 403.97 ± 225.36 200.93 ±73.33 990.63 ± 207.82 301.56 ±155.02 42.52 ±24.76
<S
. §
O h
<D
12 0.86 ±0.07 393.49 ±92.90 312.08 ±54.73 1011.47 ± 160.23 304.89 ± 137.57 120.12 ±52.12
o n
3
O
WGE 6 0.62 ± 0.22 278.17 ±123.35 192.22 ±111.85 993.57 ±499.86 298.81 ±72.34 88.05 ± 88.04
sTT
1— 1w
12 0.74 ±0.26 968.40 ±19.17 856.93 ±496.43 2585.64 ± 1987.24 127.46 ±18.87 45.07 ±45.06
k
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